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The poly(A)-binding proteins (PABPs) are a family of eukaryotic RNA-binding 
proteins with key roles in mRNA translation and stability.  The molecular function of 
PABPs have been largely revealed through study of the prototypical cytoplasmic 
poly(A)-binding protein, PABP1.  Thus, little is known regarding other PABP family 
members.  PABP5 contains four RNA-recognition motifs characteristic of the 
cytoplasmic PABPs yet is structurally distinct as it lacks a portion of the C-terminus.  
This region contains a proline-rich section linked to a globular domain that facilitates 
a number of protein-protein interactions.  To date, little information has been 
presented regarding the expression of PABP5 and there is no data pertaining to the 
function of this protein, despite being mapped to a region of the X-chromosome 
associated with human pathological conditions.   
 
In this thesis, I present the first data documenting the expression of PABP5 within 
mouse tissues, and find it to be expressed at the highest levels within the brain, 
ovary, and testis.  The limited data available suggests that gonads may be the only 
tissue to contain all PABPs therefore I additionally describe the expression of 
PABP1 and PABP4 to ascertain their cellular distribution within these tissues.  This 
revealed that PABPs have overlapping yet distinct expression patterns in mouse 
gonads.   
 
The distinct structure of PABP5 suggested that its function may vary from PABP1.  
Characterisation of its activities in translational regulation was therefore investigated.  
When tethered to a reporter mRNA PABP5 had limited translational stimulatory 
activity, and in addition could not be isolated via m7G cap chromatography and 
failed to interact with translation initiation factors including eIF4G and PAIP-1.  
These factors interact with PABP1 to positively promote translation, implying that 
PABP5 function in translational regulation differs from other PABPs investigated.  
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Examining why PABP5 failed to display translational stimulatory activity also 
revealed an interaction with the negative regulator of translation, PAIP-2.  In 
summary, I present the first description of PABP5 cellular localisation, and have 
gone some way towards elucidating the molecular function of this uncharacterised 
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1.1  Translational Regulation  
 
1.1.1  Translational Regulation and Disease 
The synthesis of a functional gene product from its corresponding gene is a highly 
dynamic and regulated process.  The multiple steps involved are collectively referred 
to as ‘gene expression’ and comprise many complicated molecular events.  For 
protein coding genes messenger ribonucleic acid (mRNA) molecules are transcribed 
from their deoxyribonucleic acid (DNA) templates via the action of RNA 
polymerase, and processed to add an m7GpppN cap and polyadenylate tail, and to 
remove introns via splicing.  Mature mRNAs are exported from the nucleus to the 
cytoplasm whereupon they are decoded by ribosomes to produce proteins in a 
process called translation (see figure 1.1).  
 
Aberrant expression of genes can be associated with a variety of common disorders 
and diseases, underlying the importance of the many layers of control that ensure 
genes are expressed correctly, both spatially, temporally and to an accurate level.  
These tiers of control cover all aspects of the gene expression pathway, including 
epigenetic modifications, transcription, splicing, RNA transport, mRNA translation 
and stability and finally modification and degradation of the protein products. 
 
1.1.2  Translational Control as a Target for Regulation   
Translation of mRNA is far from a constitutive process, and is a highly coordinated 
event, with approximately 1 gene in every 10 known to be strongly regulated at this 
level (Reynolds, 2002) while some estimates place this value considerably higher.  
There are notable advantages to the translational control of mRNAs.  Firstly, is the 
speed and reversibility of many translational control mechanisms (Koritzinsky et al., 
2006; Ling et al., 2005; Teleman et al., 2005).  Secondly, the spatial control of 
mRNA translation permits concentration gradients and regionalised protein synthesis 
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(Huttelmaier et al., 2005; Kwon et al., 1999).  Finally, transcriptional inactivity can 
necessitate translational control, such as before the onset of zygotic transcription in 
developing embryos (Shen-Orr et al., 2010), or during erythropoiesis where the cells 
undergo programmed transcriptional arrest during terminal differentiation (Ostareck 
et al., 1997).  The importance of translational control is further exemplified by the 
growing number of cases where translational deregulation has been shown to result 
in serious human pathophysiological conditions including neurological, metabolic 
and reproductive disorders as well as various cancers (Cazzola and Skoda, 2000; De 





Figure 1.1  Eukaryotic gene expression.  Following transcription by RNA polymerase II, 
pre-mRNAs are spliced to remove introns and have a polyadenylate tail added.  The mRNAs 
are then exported through nuclear pores to the cytoplasm, where they can be translated by 
ribosomes to produce protein, or alternatively they can be repressed and/or degraded.  
Deadenylated messages can be polyadenylated in the cytoplasm to promote translation.      
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Many disease causing mutations affecting mRNA translation have been identified.  
These can take the form of mutations within mRNA cis-acting elements, within the 
trans-acting RNA binding proteins (RNA-BPs) that bind these elements, and within 
translation factors.  Examples include the degenerative neurological condition termed 
vanishing white matter disease for which mutations in the translation factor eIF2B 
are known to be causative, and hereditary hyperferritinemia characterised by 
mutations within the mRNA of the iron storage protein ferritin that abolish binding 
of a translational regulatory protein.  These examples serve to highlight the 
importance of research into the area of translational control.   
 
1.2 Translation: Initiation, Elongation and Termination 
 
1.2.1 Translation Overview 
The process of translation can be divided into three distinct steps; termed initiation, 
elongation and termination.  The most frequently targeted step for translational 
regulation is the initiation step.  Multiple eukaryotic initiation factors (eIFs) are 
involved and these can be regulated, often to control global mRNA translation.  
Manipulating this step also avoids the problems associated with having to deal with 
partially translated protein products that may result from targeting the elongation 
step.  Central to the translational process are the ribosomes which facilitate the 
production of proteins from their constituent amino acids.  Ribosomes are large 
macromolecular structures composed of many proteins (approximately 50 proteins in 
humans), and also ribosomal RNAs (rRNAs).  The eukaryotic ribosomal proteins are 
arranged into a small 40S subunit containing the 18S rRNA and a large 60S subunit 
containing 5S, 5.8S and 28S rRNAs.  The small subunit (SSU) binds mRNA and also 
monitors the fidelity of codon/anticodon interactions within its rRNA composed 
decoding centre.  The decoding centre contains three binding sites for transfer 
ribonucleic acids (tRNAs) – the aminoacyl site (A-site) which binds incoming 
aminoacylated tRNA (aa-tRNA), the peptidyl site (P-site) which binds peptidyl-
tRNA and the exit site (E-site) which binds free tRNAs.   The large subunit (LSU) 
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catalyses the formation of the peptide bond between amino acid moieties of adjacent 
tRNAs and also contains a guanosine-5’-triphosphatase associated centre (GAC). 
 
1.2.2 Translation Initiation 
In eukaryotes, translation initiation is defined as the events leading to the assembly 
of an 80S ribosome (composed of a small 40S subunit bound to a large 60S subunit), 
where the anticodon of the aminoacylated initiator methionyl-transfer RNA (Met-
tRNAi) is base-paired to the mRNA initiation codon in the ribosomal peptidyl site 
(P-site).  The process is mediated by at least 12 eukaryotic initiation factors (eIFs) 
comprising >30 polypeptides (reviewed in Jackson et al., 2010) as well as the 
hydrolysis of adenosine-5’-triphosphate (ATP) and guanosine-5’-triphosphate (GTP).  
In contrast, prokaryotic translation initiation requires only 3 protein factors, IF1, IF2 
and IF3 which share functional and structural similarities to the eukaryotic initiation 
factors eIF1, eIF1A and eIF5B, known to be involved in fidelity of start codon 
recognition and large ribosomal subunit joining (Andreev et al., 2006).  While the 
small ribosomal subunit is recruited to the 5’ terminus of eukaryotic mRNAs, in 
prokaryotes the ribosome appears to be directly recruited to the start codon.  This is 
mediated via two mRNA sequence elements termed the Shine-Dalgarno sequence 
and an AU-rich element.  These elements interact with the ribosomal 16S rRNA and 
ribosomal protein S1 respectively (Boni et al., 1991).  As a result many factors 
required in eukaryotes for the recruitment and scanning of the small ribosomal 
subunit to the start codon are dispensable in prokaryotes explaining the differing 
factor requirements in the 2 systems.  Translation initiation in eukaryotes can be 
subdivided into a number of steps (see figure 1.2), discussed below.   
 
Ternary Complex Formation 
Cap-dependent translation is initiated by the formation of the ternary complex (TC) 
which consists of the heterotrimeric guanosine-5’-triphosphatase (GTPase) protein 
eIF2 bound to GTP and Met-tRNAi.  The TC is responsible for binding of the Met-
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tRNAi to the small ribosomal subunit and possibly also commitment to the 
elongation phase of translation following initiation codon recognition.  eIF2 consists 
of three subunits – α, β, and γ.  eIF2β is responsible for binding to the eIF2 specific 
GTPase activating protein (GAP) eIF5, and also the guanine nucleotide exchange 
factor (GEF) eIF2B (Asano et al., 1999), while eIF2γ appears to bind GTP and the 
Met-tRNAi.  GTP binding domains are present in eIF2β but these sites appear to 
have minimal effect on eIF2 activity (Naranda et al., 1995).  The Met-tRNAi binding 
activity of eIF2γ may be due to the structural similarity to eEF1A, the elongation 
factor responsible for delivering the aa-tRNAs to the ribosomal A-site (Roll-Mecak 
et al., 2004).  The availability of the ternary complex can have profound effects on 
global translation rates and is subject to regulation, primarily through eIF2α 
phosphorylation, as discussed in section 1.3.2.    
 
Formation of 43S Pre-Initiation Complex  
The ternary complex binds to the 40S ribosomal subunit along with large (~800kDa) 
multisubunit factor eIF3, and two small initiation factors, eIF1 and eIF1A.  These 
three eukaryotic initiation factors are probably already associated with the 40S 
ribosome.  Experiments in-vitro have identified eIF3, eIF1 and eIF1A to be required 
for stable quantitative binding of the TC to the 40S ribosome, with eIF3 appearing to 
stabilise the binding of eIF1 and eIF1A (Chaudhuri et al., 1999; Majumdar et al., 
2003).  This complex is referred to as the 43S pre-initiation complex (PIC).  The 
GAP eIF5 may also bind to the PIC prior to mRNA recruitment as an interaction has 
been demonstrated between mammalian eIF5 and the p42 subunit of eIF3 
(Bandyopadhyay and Maitra, 1999).  This interaction has also been documented in 
yeast where eIF3, eIF1, eIF2 and eIF5 can associate in the absence of ribosomes in 
what is termed a multifactor complex (MFC), suggestive of a difference in the 





Figure 1.2 Translation initiation.  The 40S subunit along with eIF1, eIF1A and eIF3 binds 
the ternary complex consisting of eIF2-GTP, met-tRNAi and eIF5 to form the 43S pre-
initiation complex (PIC).  This binds to the mRNA cap structure via an interaction between 
eIF3 and eIF4G which is a component of the eIF4F cap binding complex that also contains 
the cap-binding protein eIF4E and the helicase eIF4A.  The PIC scans the 5’-UTR in a 
process involving eIF1, eIF1A, and eIF4A with its cofactor eIF4B until it reaches an initiation 
codon.  The PIC then binds the mRNA to form a 48S complex, eIF2-GTP is hydrolysed by 
eIF5 and released, and eIF5B-GTP facilitates binding of the 60S subunit.  60S binding 
triggers release of initiation factors and eIF5B-GTP is hydrolysed and released from the 





Binding of the 43S Pre-Initiation Complex to mRNA 
The PIC is recruited to the mRNA to form the 48S complex via an interaction with 
the heterotrimeric eIF4F complex which binds to the 7-methylguanosine cap 
(m7GpppN, where N is any nucleotide) structure found at the extreme 5’-end of all 
nuclear transcribed eukaryotic mRNAs (Shatkin, 1985).  The eIF4F complex consists 
of eIF4E which contains cap binding activity (Sonenberg et al., 1978), eIF4G which 
is a large (~200kDa) scaffolding protein that mediates a number of protein-protein 
interactions and interacts directly with eIF4E, and the ATP-dependent DEAD-box 
RNA helicase eIF4A (Pestova et al., 2001).  One purpose of the eIF4F complex 
appears to be the recruitment of the PIC to the 5’-UTR of mRNA via a direct 
interaction between eIF4G and the eIF3 subunit eIF3e (LeFebvre et al., 2006).  The 
factors eIF1 and eIF1A also facilitate binding to the mRNA by holding the ribosomal 
mRNA entry channel latch in an ‘open’ conformation (Passmore et al., 2007).     
The eIF4F complex is fundamental to the initiation of cap-dependent translation 
(Pestova and Kolupaeva, 2002; Shatkin, 1985) and central to this is the binding of 
eIF4E to the m7GpppN cap (Sonenberg et al., 1980).  The interaction between 
eIF4E/eIF4G has been demonstrated to markedly stimulate the binding of eIF4E to 
the cap and promote ribosome loading in eukaryotes (Friedland et al., 2005; Gross et 
al., 2003; Haghighat and Sonenberg, 1997; von Der Haar et al., 2000), possibly 
through conformational changes that clamp eIF4E onto the cap (Volpon et al., 2006).  
This interaction has functional consequences, with deletion or mutation of eIF4G 
binding residues within eIF4E resulting in reduced size of actively translating 
polysomes (mRNAs containing multiple ribosomes) as determined by sucrose 
gradient centrifugation (Gross et al., 2003; Ptushkina et al., 1998).  In addition, an 
interaction between eIF4G and the polyadenylate-binding protein (PABP1) which 
binds the poly(A) tails of eukaryotic mRNAs has also been shown to increase the 
affinity of eIF4E for the cap (see figure 1.12) (Borman et al., 2000; von Der Haar et 
al., 2000).  While the eIF4F complex promotes recruitment of the PIC through the 
eIF4G/eIF3 interaction, eIF3 may stabilise the interaction through binding to other 
initiation factors located at the 5’-UTR of mRNAs, including eukaryotic initiation 
factor 4B and PABP-interacting protein-1 (PAIP-1) (Martineau et al., 2008; Methot 
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et al., 1996).  Stable binding of the PIC is also thought to require the helicase activity 
of eIF4A to unwind mRNA secondary structure in cap-proximal positions, thereby 
preparing a ‘landing platform’ for the PIC (Pestova et al., 2001).  Thus, it appears 
that many interactions may contribute to the stable binding of the PIC to the mRNA 
cap structure.     
  
Scanning of the 43S Complex 
Once the PIC has bound to the extreme 5’ end of the mRNA, the complex must move 
through the 5’-UTR in a poorly defined process termed scanning.  The initiation 
factors eIF1 and eIF1A are thought to promote scanning by maintaining the 40S 
subunit in a scanning competent ‘open’ conformation (Pestova and Kolupaeva, 
2002).  Although PICs are capable of binding and scanning through unstructured 5’-
UTRs in the absence of eIF4F (Pestova and Kolupaeva, 2002; Sonenberg et al., 
1982), most 5’-UTRs contain secondary structure that requires the mRNA unwinding 
activity of eIF4F.  It is thought that eIF4A is responsible for this helicase activity, as 
dominant negative mutants of eIF4A confer sensitivity to mRNAs with structured 5’-
UTRs (Svitkin et al., 2001b).  The mechanism by which eIF4A, which is an 
intrinsically poor helicase, promotes unwinding of mRNA secondary structure is 
poorly understood but is known to be stimulated by the cofactors eIF4B and eIF4H, 
possibly by increasing the affinity of eIF4A for RNA or ATP or by stabilising 
conformational changes within eIF4A during ATP hydrolysis (Marintchev et al., 
2009; Richter et al., 1999).  eIF4G also stimulates eIF4A activity through a direct 
interaction (Imataka and Sonenberg, 1997) although the mechanism behind this 
stimulatory activity is unclear and structural studies that model the interaction appear 
to differ in their conclusions (Oberer et al., 2005; Schutz et al., 2008).  One model 
suggests a mechanism whereby components of the eIF4F complex and eIF4B/4H 
remain attached to the cap structure, with the 5’-UTR looping out during scanning.  
In this model eIF4B/4H prevent backwards movement of the ribosome during 
eIF4A-ADP to eIF4A-ATP recycling, and promote a 5’ to 3’ unidirectional 
translocation (Spirin, 2009).  However, it is unclear how this model would allow 
more than one PIC to scan at a time.  It has also been postulated that eIF4A may be 
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present on the leading edge of the PIC where its helicase activity would be utilised 
(Marintchev et al., 2009; Spirin, 2009). 
 
Initiation Codon Recognition 
The PIC scans until it encounters an initiation codon (or start codon).  Initiation 
codons are normally the first AUG codon the scanning ribosomal subunit encounters 
in a favourable context.  This context is referred to as the Kozak consensus sequence 
and is annotated GCC(A/G)CCAUGG, with a purine at position -3 (relative to the 
adenine at position +1 in the initiation codon) and a guanine at position +4 (Kozak, 
1987a) being the main determinants.  Initiation codon recognition, GTP hydrolysis, 
and subsequent commitment to the elongation phase of translation requires the 
coordinated activities of a number of initiation factors, of which eIF1 and eIF1A 
appear to be the key moderators (Pestova et al., 1998a).  Together, these two factors 
appear to hold the PIC in an open scanning ‘competent’ form (Passmore et al., 2007).  
During scanning, eIF1 inhibits the GAP activity of eIF5 (Unbehaun et al., 2004) 
preventing premature hydrolysis of eIF2-GTP, and also has a role in rejecting 
incorrectly assembled initiation complexes at non-AUG codons (Pestova and 
Kolupaeva, 2002).  Upon correct initiation codon/anticodon base-pairing the PIC 
undergoes conformational rearrangements that tighten its interaction with eIF1A 
(Maag et al., 2006).  This results in the withdrawal of an unstructured C-terminal tail 
of eIF1A from the ribosomal P-site, allowing the Met-tRNAi to fully enter (Saini et 
al., 2010), and also facilitates the displacement of eIF1 (Maag et al., 2005).  eIF1A 
then contacts eIF5 (possibly linked to the movement of the C-terminal tail out of the 
P-site) and this interaction is thought to transform the PIC from an open form to a 
closed scanning ‘incompetent’ form that locks the PIC onto the mRNA (Maag et al., 
2006).  The expulsion of eIF1 relieves the repression of eIF5 allowing the hydrolysis 
of eIF2-GTP, possibly by repositioning eIF5 relative to eIF2’s GTPase active site 
(Nanda et al., 2009), leading to the release of eIF2-GDP and inorganic phosphate 




60S Ribosome Subunit Joining and Initiation Factor Release 
Following initiation codon recognition, the 60S ribosomal subunit must bind to form 
a translationally competent 80S ribosome.  This is mediated via initiation factor 
release facilitated by eIF1A and eIF5B-GTP.  eIF5B is a ribosome dependent 
GTPase that promotes 60S subunit joining (Pestova et al., 2000) but interestingly the 
GTPase activity of eIF5B is not necessary for subunit joining but rather supports its 
dissociation from the 60S subunit to allow the formation of a functional 80S 
ribosome.  eIF1A interacts with eIF5B, and the hydrolytic activity of eIF5B is greatly 
stimulated in the presence of eIF1A (Acker et al., 2006).  This is thought to provide a 
checkpoint for correct complex assembly.  A further factor, eIF6, binds the 60S 
subunit.  eIF6 interacts with receptor for activated C kinase (RACK1) which binds 
the 40S subunit and interacts with protein kinase C (PKC).  Phosphorylation of eIF6 
via PKC results in its release from the 60S which allows joining of the two ribosomal 
subunits (Ceci et al., 2003).  The involvement of PKC potentially adds a regulatory 
level to subunit joining, although the recapitulation of translation initiation in-vitro in 
the absence of eIF6 (Pestova et al., 1998a) suggests it may not be absolutely 
required.  The 60S subunit joining event is thought to be responsible for the 
dissociation of the remaining initiation factors (Unbehaun et al., 2004).  The 80S 
ribosome is now competent to begin elongation.  
 
1.2.3  Translation Elongation 
Following the formation of a translationally competent 80S ribosome at the mRNA 
initiation codon, the elongation phase of translation begins and the nascent peptide 
chain is synthesised.  This step of translation requires ancillary protein factors and 
these proteins are highly conserved between prokaryotes and eukaryotes (reviewed in 
Noble and Song, 2008).  While the bacterial ribosome is much smaller than that of 
eukaryotes, functionally it is similar to those found in higher organisms, explaining 
the conservation of elongation factors (reviewed in Taylor et al., 2007a).  As a result, 
the deduction of the structure of the eukaryotic ribosome has been largely based on 
structural studies of its bacterial counterpart. 
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aa-tRNA Recruitment and Peptide Bond Formation 
The eukaryotic elongation factor eEF1 is a GTPase that in metazoans consists of 4 
subunits, eEF1A, eEF1Bα, eEF1Bβ, and eEF1Bγ.  eEF1A binds and delivers aa-
tRNA to the ribosomal A-site.  Correct codon/anticodon pairing between the mRNA 
and the tRNA anticodon stem loop results in a tightening of domains in the 
ribosomal small subunit (SSU) around the tRNA (Ogle et al., 2003), and leads to 
GTP hydrolysis of the eEF1A-GTP/aa-tRNA ternary complex.  This is stimulated by 
the GAC of the ribosomal large subunit and promotes dissociation of eEF1A-GDP 
from the ribosome.  Recycling of GDP for GTP is stimulated by the eEF1Bα, β, and 
γ subunits (Taylor et al., 2007a).  The LSU then rapidly catalyses the formation of a 
peptide bond between the amino acid moieties of the tRNAs in the A- and P-sites of 
the decoding centre in the SSU. 
 
Translocation of the mRNA 
To add to the growing peptide chain, the mRNA must translocate through the SSU 
mRNA binding channel to allow decoding of subsequent codons.  This is regulated 
by the action of the GTPase eEF2.  Upon binding to the ribosome eEF2-GTP 
undergoes conformational changes that result in ‘ratcheting’ of the SSU relative to 
the LSU causing partial but not complete movement of the mRNA/tRNA and 
decoding centre of the SSU in the direction of the translocation.  A domain of eEF2-
GTP then enters the A-site of the SSU, and the interactions between the 
mRNA/tRNA complex and the decoding centre of the SSU are severed following 
eEF2-GTP hydrolysis.  This results in complete translocation by a movement of one 
codon (Taylor et al., 2007b).  The free tRNA in the E-site is ejected and replaced by 
the P-site tRNA, and the peptidyl-tRNA in the A-site moves to the P-site, leaving 
behind a vacant A-site, ready to accept the next aa-tRNA.  The severing of the 
connections between the SSU and the mRNA/tRNA complex allow the SSU to back-




1.2.4  Translation Termination and Ribosome Recycling 
The elongation cycle may be repeated hundreds of times for an average protein and 
is terminated upon recognition of a canonical stop codon (UAA, UGA, UAG).  As 
with the translation elongation step, termination requires few factors but is relatively 
poorly understood.  The current model for termination involves eukaryotic release 
factor 1 (eRF1), which is thought to recognise all three stop codons (Konecki et al., 
1977) and acts as a functional mimic of a tRNA.  Binding of eRF1 catalyses the 
hydrolysis of the ester bond linking the peptide chain to the P-site tRNA, but the 
mechanism behind this hydrolysis event remain obscure, although the peptidyl 
transferase centre of the ribosome has been hypothesised to play a role.    
 
A second termination factor, the GTPase eRF3, is also present in eukaryotes.  
Interestingly, eRF3-GTP contains structural similarities to the elongation factor 
eEF1A, and when bound to eRF1 the complex strongly resembles that of the eEF1A-
GTP/aa-tRNA complex (Cheng et al., 2009).  Thus, it has been proposed that eRF3 
helps to deliver and correctly position eRF1 to the ribosomal A-site, much like 
eEF1A delivers cognate aa-tRNAs (Cheng et al., 2009).  Hydrolysis of eIF3-GTP to 
eIF3-GDP has been suggested to facilitate the correct positioning of eRF1 within the 
ribosome, allowing hydrolysis of peptidyl tRNA by eRF1 (Alkalaeva et al., 2006). 
Both the GTPase activity of eRF3 and the hydrolytic activity of eRF1 are stimulated 
when the two factors are present in a complex that also contains the ribosome 
(Frolova et al., 1996).   
 
Dissociation of Ribosomes into 40S and 60S 
The dissociation of post-termination ribosomes involves separation of the 40S and 
60S subunits, followed by release of the deaceytlated tRNA from the P-site of the 
40S and subsequent ejection of the mRNA.  Although the factors eIF3, eIF1 and 
eIF1A have been demonstrated to be capable of promoting ribosomal dissociation, it 
was deemed unlikely that they were the main effectors of subunit separation as they 
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were effective only in a very narrow window of Mg2+ concentrations.  Recently the 
involvement of ABCE1, an ATP-binding cassette protein, has been demonstrated 
(Pisarev et al., 2010).  ABCE1 only associates with post-termination ribosomes 
bound to eRF1, suggesting that eRF1 induces conformational rearrangements in the 
ribosome that facilitate ABCE1 binding (Pisarev et al., 2010).  ABCE1 appears to act 
as a molecular lever, extending from a closed to an open conformation in response to 
ATP hydrolysis and this extension is thought to drive the separation of the two 
ribosomal subunits (Pisarev et al., 2010).  Following subunit dissociation, P-site 
deaceytlated tRNA is released from the 40S by eIF1.  The eIF3 subunit eIF3j which 
is positioned in the decoding centre, decreases the affinity of mRNA for the 40S 
subunit, resulting in its expulsion from the mRNA binding cleft (Fraser et al., 2007).  
This now leaves the 40S subunit with eIF3, eIF1 and eIF1A bound, free to recruit a 
ternary complex and begin another round of initiation. 
 
1.2.5  Cap-Independent Translation 
It is estimated that approximately 10-15% of eukaryotic cellular mRNAs have the 
capability to initiate translation via cap-independent translation pathways (Spriggs et 
al., 2008).  An alternative method of initiation was first identified in the 
picornaviruses, where the 5’-UTRs of poliovirus (PV) and encephalomyocarditis 
virus (EMCV) mRNAs were demonstrated to be capable of promoting translation 
(Jang et al., 1988; Pelletier et al., 1988).  These sites were predicted to recruit the 
ribosome directly in a cap-independent manner via mRNA structural elements which 
were subsequently termed internal ribosome entry sites (IRES’s).  While viral IRES 
function is independent of the cap, many utilise components of the canonical 
initiation factor pathway, such as foot and mouth disease virus (FMDV), while others 
seem to have no requirement for eIFs such as hepatitis C virus (HCV) and cricket 
paralysis virus (CrPV) (Pacheco et al., 2008; Pestova and Hellen, 2003; Pestova et 




In some cases viral IRES’s appear to require endogenous cellular factors for their 
activity, termed IRES trans-acting factors (ITAF’s).  Many have been identified to 
date, including polypyrimidine tract binding protein (PTB), upstream of N-ras 
(UNR), La autoantigen, and a number of heterogeneous nuclear ribonucleoproteins 
(hnRNPs) (Costa-Mattioli et al., 2004; Hunt et al., 1999; Kaminski et al., 1995).  The 
mechanism by which many ITAFs infer translational activity upon viral IRES’s is 
not known but is often linked to remodelling of secondary or tertiary structures of 
IRES’s and/or recruitment of ribosomes (reviewed in Spriggs et al., 2005).  In some 
cases picornaviruses and retroviruses employ viral proteases to cleave initiation 
factors, often eIF4G and PABP (Gradi et al., 1998b; Kerekatte et al., 1999), which 
has the effect of down regulating host cell protein synthesis while promoting 
expression of viral IRES containing transcripts, sometimes through utilisation of the 
cleaved initiation factor fragments (Belsham et al., 2000; Castello et al., 2009; Gradi 
et al., 1998b; Kerekatte et al., 1999; Kuyumcu-Martinez et al., 2004; Ventoso et al., 
2001).     
 
The first human cellular IRES to be identified was that of the immunoglobulin 
heavy-chain binding protein (BiP) mRNA (Macejak and Sarnow, 1991), and there 
are now several dozen identified cellular IRES’s (Elroy-Stein and Merrick, 2007).  
These IRES’s appear to be predominantly active during periods when cap-dependent 
translation is severely compromised, such as apoptosis, cell stress, mitosis and viral 
infection (Marash and Kimchi, 2005; Qin and Sarnow, 2004; Van Eden et al., 2004).  
Cellular IRES’s also utilise ITAF’s, although variation between the primary 
sequences and secondary structure of different IRES’s make binding site predictions 
difficult.  Polypyrimidine tracts are thought to be bound by PTB which has been 
demonstrated to promote translation of a number of cellular IRES’s (Dhar et al., 






1.3  Control of Translation 
 
1.3.1  Global Versus Specific Control 
The accurate spatial, temporal, and magnitudinal expression of proteins is of 
paramount importance.  Control of translation can be global, affecting most cellular 
mRNAs, often through the modification of canonical translation factors.  Global 
control mechanisms are often utilised during cell stress events, and the modification 
of translation factors during these occasions is frequently phosphorylation (Hershey, 
1990).  In contrast specific control only targets individual or subsets of mRNAs, 
through specific mRNA cis-acting elements frequently found in 5’ and 3’-UTRs, or 
via modification of the trans-acting factors that bind these elements (reviewed in 
Gray and Wickens, 1998). 
 
1.3.2 Global Control of Translation 
Phosphorylation of eIF2α 
The translation initiation factor eIF2 is responsible for delivering the Met-tRNAi to 
the 40S ribosomal subunit.  Following initiation codon recognition, eIF2-GTP is 
hydrolysed and released from the 40S as eIF2-GDP.  The GDP moiety is then 
exchanged for GTP by the action of the GEF eIF2B, recycling eIF2 for further 
rounds of translation initiation.  This event appears to be regulated in part through the 
activity of eIF5, which stabilises the binding of GDP to eIF2, therefore acting as a 
GDP dissociation inhibitor (Jennings and Pavitt). Phosphorylation of serine-51 on the 
eIF2α subunit results in the formation of a stable complex between eIF2 and eIF2B 
preventing exchange of GDP for GTP (Kimball et al., 1998).  This stable complex 
depletes the available pool of eIF2B, and therefore the levels of eIF2-GTP, inhibiting 
translation at an early stage of initiation.  eIF2B is limiting, thus phosphorylation of 
small amounts of eIF2 is sufficient to block protein synthesis (Dever, 2002).  In 
eukaryotes four kinases have been identified that phosphorylate serine-51 of eIF2α in 
response to multiple cellular stresses.  Haem-regulated inhibitor kinase (HRI) 
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phosphorylates eIF2α in response to oxidative stress (Lu et al., 2001), protein kinase 
R (PKR) in response to dsRNA frequently associated with viral infection (Vattem et 
al., 2001), PKR-like endoplasmic reticulum kinase (PERK) with ER stress, such as 
the unfolded protein response (UPR) (Harding et al., 2000), and general control non-
repressed 2 (GCN2) in reaction to amino acid starvation and the presence of 
uncharged tRNAs (Dever et al., 1992).  Paradoxically some mRNAs are upregulated 
in response to eIF2α phosphorylation such as the general control non-repressed 4 
(GCN4) mRNA in yeast and the mammalian transcription factors ATF4 and ATF5, 
by a mechanism that will be discussed in section 1.3.5. 
 
Regulation by eIF4E-Binding Proteins (4E-BPs) 
Another commonly employed mechanism to regulate global cap-dependent 
translation is the modification of eIF4F activity.  The main cellular effectors of this 
mechanism of translational inhibition are the 4E-binding proteins (4E-BPs).  In 
humans, there are three 4E-binding proteins, 4E-BP1, 4E-BP2 and 4E-BP3 (Pause et 
al., 1994; Poulin et al., 1998), that associate directly with eIF4E.  This association is 
governed by the level of phosphorylation of 4E-BP, with hyperphosphorylation 
causing dissociation and hypophosphorylation resulting in an interaction (Gingras et 
al., 1998; Pause et al., 1994).  4E-BPs are thought to act as molecular mimics of 
eIF4G, competing for binding to eIF4E (Haghighat et al., 1995) as they contain the 
same eIF4E binding motif (Marcotrigiano et al., 1999).  The binding of these two 
proteins to eIF4E is mutually exclusive, therefore 4E-BP disrupts the formation of an 
active eIF4F complex.  The phosphorylation status of 4E-BP is regulated by a 
number of cellular cues, including cell stress (Patel et al., 2002), and the availability 
of hormones, cytokines and growth factors, such as insulin (Gingras et al., 2001).  
The main pathway responsible for phosphorylation of 4E-BPs appears to be the 
murine target of rapamycin (mTOR) pathway (Burnett et al., 1998; Gingras et al., 
1998), therefore under conditions favourable for cell growth 4E-BP is 
hyperphosphorylated via mTOR and does not associate with eIF4E, allowing cap-
dependent translation to proceed. 
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Modification of eIF4E  
Mammalian eIF4E is phosphorylated on serine-209 by Mnk1 and Mnk2 in response 
to mitogen-activated protein kinase (MAPK) signalling (Joshi et al., 1995; Pyronnet 
et al., 1999; Scheper et al., 2001).  The purpose of this phosphorylation is now 
controversial (reviewed in Scheper and Proud, 2002).  eIF4E has been described as 
an oncogene (reviewed in Zimmer et al., 2000) and phosphorylation of serine-209 is 
linked to its oncogenic activity and role in cellular proliferation (Wendel et al., 
2007).  In addition, eIF4E phosphorylation is also elevated during conditions where 
cellular protein synthesis is stimulated (Flynn and Proud, 1996) implying that the 
translational activity and phosphorylation of eIF4E may be linked.  Conversely, 
Mnk1/2 double knockout mice developed normally, in the absence of any detectable 
eIF4E phosphorylation (Ueda et al., 2004), although phosphorylation has also been 
proposed to reduce eIF4E affinity for the cap by up to 2.5-fold (Scheper et al., 2002). 
 
eIF4G Decoys   
The large scaffolding protein eIF4G plays a central role in translation initiation.  In 
humans there are three family members, eIF4GI, eIF4GII, and p97/death-associated 
protein 5 (DAP5).  eIF4GI and eIF4GII share approximately 46% identity at the 
protein level and appear to be functionally equivalent, as both stimulate translation 
and interact with eIF4E, eIF4A, and eIF3 at least in vitro (Gradi et al., 1998a).  
p97/DAP5 shares homology with approximately two-thirds of the C-terminus of 
eIF4GI and can interact with eIF4A and eIF3, but lacks the N-terminal region 
containing the eIF4E and PABP binding sites (Imataka et al., 1997).  p97 was shown 
to be inhibitory to cap-dependent and cap-independent translation, possibly by 
forming inactive translation complexes excluding eIF4E (Imataka et al., 1997) or by 
titrating initiation factors away from eIF4G.  More recently, a caspase cleavage 
fragment of p97 was proposed to stimulate cap-independent translation during 
apoptosis, including its own translation through a 5’-UTR IRES element within its 
mRNA (Henis-Korenblit et al., 2000), as well as cap-independent translation during 
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the cell-cycle (Marash et al., 2008), when cap-dependent translation is 
downregulated.   
       
1.3.3  Specific Control of Translation 
Translational control at the level of individual mRNAs or subsets of mRNAs is 
usually conferred by cis-acting control elements within the 5’ and 3’-UTRs, and the 
activity of trans-acting factors that bind these elements (reviewed in Gray and 
Wickens, 1998).  These regulatory elements are depicted in figure 1.3.  Proto-
oncogenes, transcription factors and growth factors frequently have long 5’-UTRs 
containing multiple control elements, attesting to their requirement for stringent 
regulation.  Control elements within 3’-UTRs often directly influence the stability, 
localisation and translation of mRNAs and in some cases interact with 5’-UTR 
bound factors to achieve this regulation (Wilkie et al., 2003). 
 
1.3.4  Primary Determinants of Translational Efficiency 
m7GpppN Cap 
The 5’ m7GpppN (m7G) cap structure is a methylated guanosine nucleotide, at the 
extreme 5’ terminus of mRNAs with an unusual 5’ to 5’ triphosphate linkage.  The 
cap must be methylated to promote translation as removal of the methyl group results 
in a loss of translational activity in-vitro (Muthukrishnan et al., 1975).  Cap-
methylation may be subject to differential regulation as two transcription factors, c-
Myc and E2F1, have been demonstrated to specifically induce the cap-methylation of 
their target gene transcripts (Cole and Cowling, 2009), although the mechanism by 
which this occurs is unknown.  Moreover, differential cap-methylation appears to 
occur for certain transcripts such as cyclin D1 which has been found to be largely 
unmethylated in mammary epithelial cells (Cowling, 2010).  Following 
overexpression of the cap-methylation effector protein RNA-guanine-7-
methyltransferase (RNMT), the cyclin D1 transcript is methylated on its cap and 
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cyclin D1 protein expression increases (Cowling, 2010).  Interestingly 
overexpression of RNMT can lead to cellular transformation (Cowling, 2010).  
 
The Poly(A) Tail  
The poly(A) tail is an almost universal feature of eukaryotic mRNAs located at the 
extreme 3’ terminus of transcripts and has fundamental roles in mRNA translation 
and stability (Gallie, 1991; Munroe and Jacobson, 1990).  The function of the 
poly(A) tail in translation is mediated by PABP proteins, the subject of this thesis 
(see section 1.4).  Following transcription a 200-250 nucleotide poly(A) tail is added 
to pre-mRNAs within the nucleus in a process that involves a multifactorial complex 
of cleavage and polyadenylation factors including poly(A) polymerase (PAP) 
(reviewed in Millevoi and Vagner, 2010).  Following nuclear export the poly(A) tail 
is progressively removed eventually signalling the mRNA for degradation (Sheiness 
et al., 1975), However not all mRNAs with short poly(A) tails are degraded, and 
indeed cis-elements within the 3’-UTR of specific transcripts can direct their 
cytoplasmic polyadenylation (Richter, 1999).  Loss of the poly(A) tail is often 
associated with translational silencing, while polyadenylation results in translational 
activation, and this has been demonstrated in a number of biological models (Gray 
and Wickens, 1998).  For example, tissue-type plasminogen activator (tPA) mRNA 
is extensively deadenylated and translationally repressed upon entry into the 
cytoplasm in mouse primary oocytes, and during meiotic maturation is 
polyadenylated and translationally activated (Huarte et al., 1992).  Other oocyte 
mRNAs such as c-mos, β-actin, and cyclin B1 are also regulated in this manner 







Figure 1.3  Translation control elements.  mRNAs can have multiple regulatory elements.  
(1) m7GpppN cap structure,  (2) secondary structure, (3) 5’-UTR protein binding sites, (4) 
upstream ORFs, (5) upstream AUGs, (6) IRES’s, (7) 3’-UTR protein binding sites, (8) 
stability elements, (9) localisation elements, (10) microRNA complementary sites, (11) 
cytoplasmic polyadenylation elements, (12) polyadenylate tail.  Reproduced from Gray and 
Wickens, 1998.  
 
 
The cis-elements responsible for directing the reversible mRNA polyadenylation/ 
deadenylation cycles have been identified in a number of higher organisms but 
studied most extensively in Xenopus laevis oocytes.  Cytoplasmic polyadenylation 
involves two sequence elements within the 3’-UTR; the hexanucleotide AAUAAA 
which is bound by the cleavage and polyadenylation specificity factor (CPSF) and a 
second sequence element of which the best characterised example is the cytoplasmic 
polyadenylation element (CPE) (Mendez and Richter, 2001).  CPEs are uridine-rich 
with a general consensus of U5A1-2U.  The number and position of CPEs relative to 
the hexanucleotide can vary, and may affect the timing and/or extent of 
polyadenylation (Mendez and Richter, 2001).  The CPE is bound by a factor called 
the CPE-binding protein (CPEB) (Hake and Richter, 1994; Stebbins-Boaz et al., 
1996). 
 
The polyadenylation of CPE-containing mRNAs is controlled by the opposing 
activities of a poly(A) polymerase Gld-2 and poly(A) ribonuclease (PARN) which 
both reside in a CPEB containing complex that also contains the scaffolding protein 
symplekin (Richter, 2007).  When PARN is more active than Gld-2 mRNAs are 
maintained with a short poly(A) tail, but following extracellular signalling cues the 
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kinase Aurora A is activated and phosphorylates CPEB on serine-174 (Sarkissian et 
al., 2004) resulting in the expulsion of PARN from the complex, enabling Gld-2 to 
elongate the poly(A) tail (see figure 1.4) (Kim and Richter, 2006).  Interestingly, this 
mechanism of regulation has been suggested to be important in governing synaptic 
plasticity, a key process underlying learning and memory.  Indeed synaptic 
stimulation has been shown to induce the polyadenylation and subsequent translation 
of the α subunit of calcium-calmodulin-dependent protein kinase II (αCaMKII) 





Figure 1.4  Regulation of cytoplasmic polyadenylation.  PARN removes the poly(A) tail 
that Gld-2 is adding.  PARN is more active than Gld-2 so the poly(A) tails remain short.  
Phosphorylation of CPEB by the kinase Aurora A results in the dissociation of PARN from 
the protein complex, allowing Gld-2 to default polyadenylate the mRNA.  Other factors 




1.3.5  5’-UTR Translation Control Elements 
Secondary Structure 
The scanning model of translation initiation posits that the 40S ribosome traverses 
the 5’-UTR until an initiation codon is encountered.  Secondary structures can be 
23 
 
inhibitory to translation initiation, depending on their stability and position within the 
5’-UTR.  Using reporter mRNAs, it has been demonstrated that moderately stable 
stem loops (-30kcal/mol) located in cap-proximal regions can inhibit 43S PIC 
joining, but stem loops in cap-distal positions require more stable secondary 
structures (-61kcal/mol) to abrogate the scanning of ribosomal subunits (Kozak, 
1989).    
 
The translation of endogenous mRNAs appears to be regulated in this manner.  
Ornithine decarboxylase (ODC) is a rate limiting enzyme in polyamine biosynthesis.  
ODC mRNA contains a 160 nucleotide G/C rich region within its 5’-UTR that forms 
a stable stem-loop structure that inhibits translation (Manzella and Blackshear, 
1990).  The stem-loop retains its inhibitory function upon inversion suggesting that it 
is not acting as a platform for the binding of a repressor protein, but rather it is the 
structure itself that is inhibitory (Grens and Scheffler, 1990).  It has been suggested 
that mRNAs containing extensive secondary structure in their 5’-UTRs are more 
sensitive to eIF4E activity (Koromilas et al., 1992).  This would appear to be true for 
ODC mRNA, as reporters containing the ODC 5’-UTR are more efficiently 
translated in a cell line overexpressing eIF4E (Shantz et al., 1996). 
 
Although secondary structure can be inhibitory, the utilisation of initiation codons in 
poor sequence context can be stimulated by the presence of secondary structure in 
vitro.  Positioning of a stem-loop structure 14 nucleotides downstream of non-AUG 
initiation codons (GUG or UUG) in poor sequence context, can increase initiation at 
these codons 3-fold, presumably by stalling the ribosome, allowing more time for 
initiation codon recognition (Kozak, 1990).   
 
RNA-Binding Proteins 
Sequence elements within mRNA 5’-UTRs are often bound by regulatory protein 
factors that can have either a negative or positive influence on translation.  The best 
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characterised 5’-UTR binding proteins are the iron regulatory proteins (IRPs) that 
modulate cellular iron homeostasis.  In response to intracellular iron depletion IRP 
binds to a structural element termed the iron responsive element (IRE) within the 5’-
UTR of mRNAs including the iron storage protein ferritin (Gray and Hentze, 1994) 
strongly inhibiting their translation.  The IREs are positioned cap-proximally, and 
prevent 43S PIC recruitment to the mRNA (Gray and Hentze, 1994).  This steric 
blocking mechanism of repression can be recapitulated with proteins that have no 
role in translational regulation, such as the viral coat protein MS2 and the splicing 
factor U1A, when binding sites for these proteins are present in cap-proximal 
positions within the 5’-UTRs of reporter mRNAs (Stripecke et al., 1994).  
Positioning of the IRE in a cap-distal location in mammalian cells can also modulate 
translation efficiency, by sterically affecting ribosomal scanning (Paraskeva et al., 
1999), showing that protein-mRNA interactions within 5’-UTRs can affect both 
ribosome subunit binding and movement, in a position dependent manner. 
 
Upstream Open Reading Frames and Upstream AUGs  
Upstream AUGs (uAUGs) and upstream open reading frames (uORFs) are cis-acting 
elements within mRNA 5’-UTRs that generally inhibit the ribosomal selection of the 
primary ORF initiation codon (reviewed in Morris and Geballe, 2000).  uORFs are 
characterised by an in-frame initiation and termination codon and generally code for 
very small peptides.  On the contrary, uAUGs do not contain in-frame termination 
codons prior to the initiation codon of the primary ORF.  Up to two-thirds of proto-
oncogenes as well as a number of growth factors and cytokines are thought to 
contain uAUGs/uORFs, highlighting the importance of this mechanism of regulation 
(Kozak, 1991; Morris and Geballe, 2000).    
 
In uORF and uAUG containing transcripts, translation of the main ORF has to occur 
by one of two mechanisms; firstly ‘leaky scanning’, whereupon the ribosome ignores 
the uAUG (a strong determinant being the strength/efficiency of the AUG context 
sequence), or secondly, termination of translation of the uORF and re-initiation at the 
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main AUG.  The process of re-initiation is poorly understood but thought to involve 
recharging of the ribosome with initiation factors (Kozak, 1999).  This is supported 
by evidence that increasing the intercistronic spacing between the uORF termination 
codon and the subsequent AUG eliminates the inhibitory effects of the uORF by 
allowing more time for the ribosome to reacquire necessary factors (Kozak, 1987b).   
 
Much of our understanding of uORF function is a result of studies on the yeast 
GCN4 mRNA which contains four uORFs regulated in response to amino acid 
starvation.  Phophorylation of eIF2α induced by high levels of uncharged tRNAs 
results in limited ternary complex availability, perturbing the re-initiation activity of 
the ribosomes and thus skipping of the highly inhibitory second, third and fourth 
uORFs and promoting initiation at the main AUG (Dever et al., 1992).  Other 
examples are BACE-1 mRNA, involved in amyloid β protein production (a hallmark 
of Alzheimers) which contains six inhibitory uAUGs (De Pietri Tonelli et al., 2004), 
and the potent oncogene MDM2 which utilises alternative promoters to express an 
mRNA with a long 5’-UTR containing a uORF, or a short 5’-UTR that lacks the 
uORF and is efficiently translated (Brown et al., 1999). 
 
Increasingly, ‘sequence specific’ uORFs are being classified where the peptide 
encoded by the uORF participates directly in inhibition of a downstream ORF, such 
as S-adenosylmethionine decarboxylase mRNA (AdoMetDC) (Hill and Morris, 
1993) and arg-2 mRNA (Wang and Sachs, 1997).  AdoMetDC regulates the 
biosynthesis of polyamines, and contains a short uORF coding for the peptide 
sequence MAGDIS.  Mutational analysis showed that the sequence of the uORF was 
important for conferring translational inhibition (Hill and Morris, 1993).  
Mechanisms by which these peptides interfere with translation of downstream ORFs 
is unclear but is thought to involve ribosomal stalling by impeding termination 
(Morris and Geballe, 2000).  Consistent with this, in the presence of high arginine 
concentrations, toeprinting analysis identified stalled ribosomes within the uORF of 
arg-2 transcripts (Wang and Sachs, 1997).   
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1.3.6  3’-UTR Translational Control Elements 
The 3’-UTRs of messages frequently contain cis-elements that are bound by 
multifactor protein complexes.  Protein complexes associated with mRNA 3’-UTRs 
can affect the translation and/or stability of messages in a positive or a negative way, 
and in some cases these effects are linked to mRNA localization.  3’-UTR mediated 
regulation is important in cellular processes as diverse as embryonic patterning, 
differentiation, sex determination, and metabolism (Hentze et al., 2007).  Regulation 
via 3’-UTRs is often intricate and elaborate due to the spatial challenges of 
regulating translation initiation events at the mRNA 5’ terminus (Gray and Wickens, 
1998; Wilkie et al., 2003).  Many of the dissected mechanisms of 3’-UTR mediated 
regulation have been established using the genetically tractable fruit fly model 
Drosophila melanogaster, where mRNA specific translational control in oocytes and 
early embryos is important for axis formation and body patterning.   
 
Regulation of Cap-Binding 
In many cases, the mechanisms involved appear to be conserved in mammals such as 
the regulation of Drosophila oskar mRNA by a 4E-BP-like protein, Cup (Haghighat 
et al., 1995; Nakamura et al., 2004).  CPEB is a well characterised example of a 
translational repressor in Xenopus oocytes.  In translationally repressed mRNAs with 
short poly(A) tails CPEB binds to maskin, which in turn interacts with eIF4E.  This 
binding precludes the interaction of eIF4G with eIF4E (Stebbins-Boaz et al., 1999), 
therefore to promote eIF4F formation and translational activation maskin must be 
displaced from eIF4E.  This is achieved by polyadenylation which facilitates the 
recruitment of PABP to the new poly(A) tail.  PABP in turn binds eIF4G helping it to 
displace maskin from eIF4E (see figure 1.5) (Richter, 2007).  Additionally, a maskin-
like protein (neuroguidin) present in the brain, has been demonstrated to bind CPEB 





Figure 1.5  Regulation of Cytoplasmic Polyadenylation.  Maskin forms a complex with 
eIF4E, that inhibits eIF4F formation.  The newly synthesised poly(A) tail supports PABP 
recruitment which binds eIF4G and helps dissociate maskin, promoting translation.  Other 
factors (CPSF, Gld-2, PARN, and symplekin) have been omitted for clarity.   
 
 
Repression of 43S Recruitment 
In some cases the expression of certain mRNAs has such deleterious consequences 
that multiple mechanisms exist to repress their translation.  MSL proteins function in 
X-chromosome dosage compensation in males, and are responsible for recruiting 
factors important in chromatin remodelling and transcription.  Elevated expression of 
the MSL complex in females is deleterious due to increased transcription from both 
female X-chromosomes, thus expression of the protein is tightly repressed (Kelley et 
al., 1997).   
 
In Drosophila, expression of male-specific lethal 2 (msl-2) mRNA is regulated in an 
unusual fashion by the female specific sex-lethal (SXL) protein which binds both the 
5’ and 3’-UTRs of msl-2 mRNA (Bashaw and Baker, 1997; Kelley et al., 1997), with 
the binding sites in the 5’-UTR and 3’-UTR repressing translation via different 
mechanisms (see figure 1.6).  Both the 5’ and 3’-UTR of msl-2 are necessary for 
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efficient repression, with mutation of either site conferring a partial loss of inhibition 
(Bashaw and Baker, 1997).   
 
The current mechanism for 3’-UTR bound SXL postulates that SXL recruits the 
PABP interacting protein upstream of n-ras (UNR) to the 3’-UTR (Duncan et al., 
2006) (Duncan et al., 2009).  This SXL-UNR complex inhibits 43S PIC recruitment 
(Gebauer et al., 2003) possibly by interfering with PABP function, however the 
effects of SXL appear to be downstream of the eIF4G-PABP interaction and the 






Figure 1.6  3’-UTR mediated repression of msl-2 mRNA translation.  SXL recruits UNR 
to the 3’-UTR of msl-2 mRNA.  UNR in turn interacts with PABP (red double-ended arrow) 
and this interaction does not preclude binding of eIF4E and eIF4G to the mRNA cap. The 
recruitment of the 43S PIC to the mRNA is inhibited by the repressor complex.  PABP 
therefore acts either as a cofactor of the repressor complex enhancing its repressive function 
(red inhibitory bar 1), or PABP may be the effector of the repressive mechanism, with the 
interaction between PABP and UNR interfering with an uncharacterised function of PABP in 
43S recruitment (red inhibitory bar 2).  Reproduced from Duncan et al. 2009. 
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Inhibition of Scanning 
SXL binding sites are found within a 5’-UTR intron of the msl-2 pre-mRNA.  The 
binding of SXL to these intronic sites inhibits splicing by preventing recruitment of 
the nuclear splicing machinery (Forch et al., 2001).  SXL remains associated with 
these sites following nuclear export resulting in translational repression by a 43S PIC 
scanning inhibition mechanism (Forch et al., 2001; Gebauer et al., 1998).  In males, 
the absence of SXL protein facilitates splicing of the 5’-UTR intron and efficient 
translation of msl-2 mRNA.  A simple model of steric inhibition of scanning has 
been ruled out, as binding of a related protein to this site with a similar affinity as 
SXL failed to repress expression (Beckmann et al., 2005).  It has therefore been 
suggested that SXL modulates secondary structure, or facilitates the formation of a 
higher order repressive complex (Beckmann et al., 2005).  Thus, the 3’ and 5’-UTR 
elements appear to function in a bipartite mechanism initially preventing the 
recruitment of 43S PIC complexes, with any ribosomal complexes escaping this 
block subjected to scanning inhibition. 
 
  
Figure 1.7  Regulation of LOX mRNA translation by DICE elements.  hnRNPs K and E1 
bind to the DICE element in the LOX 3’-UTR and inhibit 60S joining.  Whether the inhibition 
is direct is unclear and may involve other factors (denoted by the white ‘X’ in the black box).  
43S PIC binding, scanning, and 48S PIC formation all appear to proceed normally.  
Reproduced from Ostareck et al. 2001.  
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Repression of 60S Joining 
The enzyme 15-lipoxygenase (LOX) is involved in the degradation of mitochondria 
during terminal erythroid differentiation.  LOX mRNA is translationally repressed in 
erythroid precursor cells through heterogeneous nuclear ribonucleoproteins 
(hnRNPs) K and E1 which bind to CT rich sequence elements within the LOX 3’-
UTR called differentiation control elements (DICE) (Ostareck-Lederer et al., 1994; 
Ostareck et al., 1997).  48S complex formation could be observed, but 80S formation 
is inhibited suggesting that 60S joining is impeded (see figure 1.7) (Ostareck et al., 
2001).  This could be due to a direct interference with the ribosomal subunit 
interacting surfaces, but a DICE containing reporter mRNA was not inhibited when 
translation was driven by a CrPV IRES (which does not utilize eIFs) in the 5’-UTR 
suggesting that hnRNPs K and E1/2 are targeting an initiation factor responsible for 
60S joining (Ostareck et al., 2001).  Interestingly, phosphorylation of a tyrosine 
residue in the nucleic acid binding region of hnRNPK by the tyrosine kinase c-Src 
prevents association with DICE, and relieves inhibition of LOX translation, 
suggesting that upstream signalling may play an important role in establishing 
repression (Messias et al., 2006). 
 
MicroRNAs 
MicroRNAs (miRNAs) are nuclear transcribed short non-coding RNA molecules of 
approximately 22 nucleotides with a crucial role in post-transcriptional mRNA 
regulation.  Binding of miRNAs to complementary sequences usually within the 3’-
UTR of their target mRNAs induces inhibition and/or degradation of these 
transcripts.  Computational approaches to identify miRNA binding sites within 
cellular mRNAs have estimated that up to 60% of all mammalian transcripts may be 
regulated in this manner (Friedman et al., 2009).  Mature miRNAs are associated 
with a number of protein factors including GW182 and the endonucleolytic 
argonaute protein Ago2, in a functional complex called the miRNA-containing RNA-
induced silencing complex (miRISC).  The level of complementarity between the 
miRNA and mRNA determines whether the target mRNA will be directed for 
degradation or translational inhibition with a high or perfect level of 
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complementarity signalling cleavage (Pillai et al., 2005).  The mechanism of 
translational inhibition remains controversial.  Some reports indicate that that 
miRNAs target translation initiation, possibly by inhibiting eIF4E binding to the cap 
(Pillai et al., 2005), while other reports suggest that elongation is targeted, causing 
ribosomal dissociation from the mRNA (Petersen et al., 2006).  Furthermore, a small 
number of miRNAs have been demonstrated to increase translation of reporter 
mRNAs in response to cell cycle arrest (Vasudevan et al., 2007).   
 
Stability Elements 
Control of mRNA stability is an irreversible mechanism by which cells can rapidly 
modulate protein output.  Sequence elements that regulate mRNA stability are 
frequently located within 3’-UTRs, and can stabilise mRNA, or prompt 
destabilisation and turnover, often by blocking or recruiting components of the 
cellular degradation machinery (Barreau et al., 2005).  In mammals, bulk mRNA 
turnover proceeds through a deadenylation-dependent pathway (see figure 1.8) 
(Garneau et al., 2007).  Poly(A) tail removal is a biphasic process requiring the 
actions of two deadenylases complexes, PAN2-PAN3 and CCR4-NOT (Garneau et 
al., 2007).  PAN2-PAN3 first removes the poly(A) tail to a length of approximately 
110 nucleotides, which is then subsequently removed via CCR4-NOT (Yamashita et 
al., 2005).  Another deadenylase, poly(A) ribonuclease (PARN), may also be 
involved in poly(A) tail removal in eukaryotes, and is involved in default mRNA 
deadenylation during Xenopus oocyte meiotic maturation and early development 
(Korner et al., 1998).  Following deadenylation, the mRNA can be degraded in a 3’-
5’ manner by a large complex of proteins called the exosome.  The decapping 
scavenger enzyme, DcpS, then hydrolyses the m7GpppN cap (Liu et al., 2002).  
Alternatively, following deadenylation the transcript can be degraded in a 5’-3’ 
manner in a process that involves decapping by the enzymes DCP1 and DCP2, 
followed by degradation of the mRNA body by the exonuclease XRN1 that 
recognises uncapped 5’-monophosphate mRNAs (Garneau et al., 2007).  This 
process is stimulated by the Lsm1-7 complex that binds the 3’ of deadenylated 
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messages and promotes dissociation of the cap complex (eIF4E/eIF4G) and 
recruitment of DCP1 and DCP2 (Tharun and Parker, 2001).  
 
Adenosine and uridine-rich elements (AREs) are the most extensively studied 3’-
UTR cis-acting sequences affecting mRNA stability.  Approximately 5-8% of human 
protein coding genes are predicted to code for ARE containing transcripts, and these 
frequently represent mRNAs encoding oncoproteins, transcription factors and 
cytokines (Barreau et al., 2005; Peng et al., 1998).  ARE sequences vary 
dramatically between mRNAs but appear to be based loosely on the presence of an 
AUUUA pentamer (Barreau et al., 2005).  The activity of AREs in modulating 
mRNA stability is driven by the binding of ARE-binding proteins (ARE-BPs) of 
which a multitude have been identified, including TTP, AUF1, and KSRP (Garneau 
et al., 2007).  ARE-BPs destabilise in a deadenylation-dependent manner, often by 
directly recruiting cellular degradation machinery, such as PARN and the exosome 
directly to the ARE containing mRNA (Chen et al., 2001; Gherzi et al., 2004; 
Moraes et al., 2006; Tran et al., 2004).  It appears that ARE-BPs can also stabilise 
transcripts.  Overexpression of HuR stabilises specific transcripts such as c-fos, p21, 
and cyclin D1 (Lal et al., 2004; Peng et al., 1998).  The stabilising activity of HuR 
may be induced through competition for binding to AREs with destabilising factors 
(Lal et al., 2004), and intriguingly in some cases through inhibiting the function of 
miRNAs (Bhattacharyya et al., 2006). 
 
As discussed above, mRNA turnover can have direct and dramatic effects on gene 
expression by limiting the number of transcripts available for translation.  Indeed, the 
processes of mRNA turnover and translation are intimately linked, although the 
relationship appears to be complex.  In yeast, degradation of cellular mRNAs has 
been shown to require active translation, in experiments using the elongation 
inhibitor cycloheximide (Herrick et al., 1990) and in certain instances, such as c-fos 
mRNA, ribosome translocation is absolutely required for deadenylation and turnover 
(Chang et al., 2004; Grosset et al., 2000).  Conversely, mutations of yeast initiation 
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factors that have inhibitory effects on translation still allowed efficient decapping and 
deadenylation of cellular mRNAs (Schwartz and Parker, 1999). 
 
Localisation Elements 
Many fundamental biological processes require the correct spatial expression of 
mRNAs.  To this end, many mechanisms employed to accurately localise mRNAs to 
a particular cellular compartment frequently also result in repression of translation to 
prevent mis-localised proteins (Gavis et al., 2007).  The 3’-UTR ‘zipcode’ sequence 
element in β-actin mRNA is bound by zipcode-binding protein (ZBP1) which 
promotes transport to the leading edge of fibroblasts (Ross et al., 1997).  ZBP1 
inhibits translation initiation of β-actin mRNA by preventing 60S joining 
(Huttelmaier et al., 2005).  Upon correct localisation of β-actin, ZBP1 is released 
through phosphorylation by the kinase c-Src relieving the repression (Huttelmaier et 
al., 2005).  
 
Some of the best understood mechanisms of localised mRNA translation have arisen 
from the model organism Drosophila melanogaster, where localisation is critically 
important during embryonic axis formation.  Gurken (Grk), oskar (Osk), nanos 
(Nos), and bicoid (Bcd) are all proteins whose mRNAs have to be localised correctly 
to establish the cellular polarity necessary for anterior-posterior and dorsal-ventral 





Figure 1.8  Deadenylation-dependent mRNA turnover.  Following sequential 
deadenylation by PAN2-PAN3 then CCR4-NOT or PARN, degradation can proceed in a 3’-5’ 
or a 5-3’ direction.  5’-3’ degradation requires decapping by the enzymes DCP1/DCP2, which 
is stimulated by the Lsm1-7 complex, followed by destruction of the mRNA body by the 
exonuclease XRN1.  3’-5’ degradation proceeds through the activity of the exosome followed 
by hydrolysis of the cap structure by DcpS.  Reproduced from Garneau et al. 2007. 
 
 
During Drosophila oogenesis oskar (Osk) is localised to the oocyte posterior where it 
directs the assembly of the germ plasm, a cytoplasmic body that is required for germ 
cell determination and localisation of mRNAs important in posterior patterning such 
as nanos (Ephrussi et al., 1991; Kim-Ha et al., 1991).  Osk is transported in a 
translationally repressed state that is alleviated upon correct localisation.  This is 
achieved through the binding of a number of regulatory proteins including staufen, 
cup, and bruno.  Staufen is required for the transport of Osk mRNA along 
microtubules by the motor protein kinesin 1 (Brendza et al., 2000; Micklem et al., 
2000).  The translational repression of Osk mRNA during this localisation is 
mediated by the 3’-UTR binding protein Bruno.  Bruno interacts with a 4E-BP like 
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protein termed cup (Nakamura et al., 2004), and prevents 43S PIC recruitment 
(Chekulaeva et al., 2006) and additionally, promotes the oligermisation of Osk 
mRNAs into silenced mRNP particles, possibly facilitating bulk transport to the 
oocyte posterior (Chekulaeva et al., 2006). 
 
 
1.4  Poly(A)-Binding Proteins (PABPs) 
 
1.4.1  The PABP Family 
The cytoplasmic poly(A)-binding proteins are a family of eukaryotic multi-functional 
RNA binding proteins that are expressed in yeast, plants, and animals but are not 
conserved in prokaryotes (Gorgoni and Gray, 2004).  The PABP family were first 
identified as proteins that bound with high affinity to the polyadenylate region of 
messenger RNAs in mouse L cells and rat hepatocytes (Blobel, 1973).  Subsequent 
experimental work has shown these proteins to be involved in mRNA translation, 
stabilisation, and turnover (reviewed in Gorgoni and Gray, 2004; Mangus et al., 
2003).   
 
Over the course of eukaryotic evolution, there appears to have been a benefit in 
maintaining multiple PABPs with most eukaryotic species containing a minimum of 
one nuclear and one cytoplasmic PABP (see table 1.10).  The division of PABPs into 
two broad classes, nuclear and cytoplasmic, is based mainly on structural differences 
but also intracellular localisation, however PABP1 has been shown to shuttle to the 
nucleus (Afonina et al., 1998).  Also, Drosophila melanogaster nuclear PABP 
(PABP2) has been reported to regulate poly(A) tail length of oskar and cyclin B 




The domain structure of the mammalian nuclear PABPs is strikingly different to that 
of the cytoplasmic PABPs (see figure 1.9 for human PABPN1 structure).  Human 
PABPN1 contains a single RRM with a glutamate-rich N-terminus and an arginine-
rich C-terminus (Kuhn and Wahle, 2004).  PABPN1 is thought to play a role in pre-
mRNA poly(A) tail addition in the nucleus, forming a complex with another pre-
mRNA processing factor, CPSF, to stimulate the processivity of poly(A) polymerase 
(Bienroth et al., 1993; Wahle, 1991).  PABPN1 is a shuttling protein (Calado et al., 
2000) and there is evidence that this shuttling may facilitate the nuclear export of 
poly(A) mRNA (Apponi et al., 2010; Chen et al., 1999).  Influenza A virus NS1 
protein (NS1A) blocks PABPN1 shuttling as determined by heterokaryon assay, but 
additionally results in the retention of mRNAs within the nucleus (Chen et al., 1999).  
In concurrence, short-interfering RNA (siRNA) knockdown of PABPN1 results in 





Figure 1.9  Domain structure of human PABPN1.  Human PABPN1 is a small protein of 
33kDa that contains a single RRM, a glutamate-rich N-terminus (E-rich) and an arginine-rich 
C-terminus (R-rich).  A coiled α-helical domain (HD) might be involved in stimulation of 
poly(A) polymerase as point mutations within this region ablate this function (Kuhn and 
Wahle, 2004).  Reproduced from Kuhn et al. 2004. 
 
 
A protein that shares approximately 50% identity with PABPN1 was identified in 
Xenopus laevis (Cosson et al., 2004).  This protein specifically bound poly(A) and 
was called ePABP2 (Cosson et al., 2004).  Interestingly despite a similar domain 
structure and sequence homology to PABPN1 this protein is predominantly 
cytoplasmic (Cosson et al., 2004) and appears restricted to oocytes and early 
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embryos (Cosson et al., 2004; Good et al., 2004).  More recently human and mouse 
clones of ePABP2 have been identified (Sakugawa et al., 2008).   
 
1.4.2  PABP1  
Expression of PABP1 
Humans are currently known to contain five cytoplasmic PABP genes (PABP1, 
PABP3, PABP4, ePABP, PABP5 - see table 1.10) and a number of pseudogenes.  
Poly(A)-binding protein 1 (PABP1, PABPC1) is the prototypical member of the 
PABP family.  Substantial experimental work has been directed towards 
understanding the molecular functions of PABP1, but surprisingly little is known 
regarding the physiological roles of this protein in metazoans.  Whilst often regarded 
to be ubiquitously expressed due to the poly(A) tail being an almost universal feature 
of mammalian mRNAs, little is known regarding the expression of PABP1 at the 
tissue or cellular level.  Within HeLa cells PABP1 was determined to be an abundant 
protein with an intracellular concentration estimated at 4µM (Gorlach et al., 1994).  
In Xenopus laevis PABP1 is robustly expressed at the protein level in brain, testis, 
heart and muscle tissue (Cosson et al., 2002b; Wilkie et al., 2005), while in humans, 
northern blot analysis revealed a similar expression pattern with strong expression in 
the ovary (Yang et al., 1995).  Expression of PABP1 in mouse tissues has only been 
documented in testis (Gu et al., 1995; Kleene et al., 1994).  It is known that PABP1 
is subject to translational regulation (see section 1.4.6) emphasising the importance 
of analysing protein rather than mRNA levels. 
 
Subcellular Localisation of PABP1 
PABP1 is predominantly cytoplasmic (Gorlach et al., 1994), but has been 
demonstrated to shuttle to the nucleus (Afonina et al., 1998).  The cellular 
mechanisms responsible for this relocalisation are unclear as PABP1 does not 
contain classic nuclear export or import signals (NES/NLS).  Confusingly, inhibition 
of CRM1 which is responsible for the nuclear export of NES containing proteins by 
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treatment with leptomycin B (LMB) results in nuclear accumulation of PABP1 
(Woods et al., 2002), although this result has recently been challenged (Khacho et 
al., 2008)(H. Burgess, unpublished).  Interestingly the export of PABP1 from the 
nucleus appears to be transcription dependent.  Treatment of cells with inhibitors of 
transcription, such as actinomycin D (ActD) and 5,6-dichlororibofuranosyl-
benzimidazole (DRB) results in nuclear localisation of PABP1 (Afonina et al., 1998; 
Khacho et al., 2008) and concurrent with this a transcription-dependent nuclear 
export motif, DXGX2DX2L, was recently identified in PABP1 (Khacho et al., 2008). 
 
The physiological relevance of PABP1 nuclear localisation is ambiguous.  PABP1 
immunopurifies with PAP (Hosoda et al., 2006) and accumulates in nuclear speckles 
containing the splicing factor SC35 (Afonina et al., 1998), leading to suggestions that 
PABP1 may have roles in pre-mRNA processing events.  Additionally, PABP1 
immunoprecipitates with the adaptor protein paxillin (see figure 1.12) (Woods et al., 
2002).  These proteins localise to the rough endoplasmic reticulum (RER) and 
lamellipodia, but upon LMB treatment accumulate in the nucleus, leading to the 
proposition that the PABP1/paxillin complex may promote mRNA nuclear export 
and targeting of mRNA to sites of translation (Woods et al., 2005; Woods et al., 
2002).  
 
Relocalisation of PABP1 to the nucleus may also represent a mechanism by which 
global cellular mRNA translation levels can be controlled.  For instance infection 
with rotavirus (Harb et al., 2008), gammaherpesvirus, alphaherpesvirus and 
bunyamwera virus all result in nuclear accumulation of PABP1, although the 
mechanisms by which this occurs are unclear (reviewed in Smith and Gray, 2010).  
Interestingly, the cytoplasmic distribution of PABP1 also changes in response to cell 
stress events such as heat shock and oxidative stress, localising to cytoplasmic foci 
termed stress granules (Kedersha et al., 1999; Salaun et al., 2010).  Stress granules 
are sites of mRNA storage and contain a multitude of RNA-binding proteins and 
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translation initiation factors but not 60S ribosomal subunits and decapping enzymes 
(reviewed in Anderson and Kedersha, 2006; Anderson and Kedersha, 2009).  
 
 
Organism Poly(A)-Binding Proteins Present 
Saccharomyces cerevisiae Pab1p 
Drosophila melanogaster pAbp, [PABP2] 
Caenorhabditis elegans Pab-1, Pab-2 
Xenopus laevis PABP1, ePABP, PABP4, [ePABP2], 
[PABPN1/nPABP2] 
Mus musculus Pabp1, Pabp2/tPABP, ePabp, Pabp4, Pabp5, 
[Pabpnl1/ePABP2], [Pabpn1]  
Homo sapiens PABP1, PABP3/tPABP, ePABP/PABP1L, 
PABP4/iPABP, PABP5, [ePABP2], 
[PABPN1/ PABP2/PAB II] 
   
Table 1.10 Poly(A)-binding proteins present in various eukaryotic species.  PABP 
proteins are present in yeast, plants and animals but are not conserved in eukaryotes.  
Humans contain several cytoplasmic PABPs, nuclear PABP, and a nuclear PABP-like 
protein.  Although S. cerevisiae does not appear to contain a nuclear poly(A)-binding protein, 
an unrelated protein, Nab2p, appears to perform similar functions to other eukaryotic nuclear 
PABPs.  Square brackets denote nuclear PABPs. 
 
1.4.3  PABP Protein Structure 
With the exception of PABP5, all of the cytoplasmic poly(A)-binding proteins share 
a common protein domain structure consisting of four N-terminal RNA-recognition 
motifs (RRMs) which function in RNA and protein binding, followed by a relatively 
unstructured proline and glutamine-rich ‘linker’ region that is connected to a globular 
C-terminal module termed the PABC domain (Kuhn and Wahle, 2004).  PABP5 also 
contains four RRMs but lacks the linker or PABC domains (see figure 1.11).  The 
structure of RRMs 1-2 bound to RNA has been solved revealing four antiparallel β-
strands backed by two α-helices.  The β-strands form a trough-like orientation 
facilitating mRNA binding, while simultaneously leaving a face free for protein-
40 
 
protein interactions (Deo et al., 1999).  The structure of RRMs 3-4 remains unsolved.  
The primary function of the PABC domain appears to be in promoting protein-
protein interactions (Kozlov et al., 2001) (see figure 1.12 for the binding sites of 
PABP1-interacting proteins).  The structure of the PABC domain shows homology to 
other proteins, namely the E3 ubiquitin ligase hyperplastic discs (HYD) that 
functions in targeting ubiquitination to specific substrate proteins, consistent with 
PABC functioning as a platform for protein-protein interactions (Kozlov et al., 2004; 
Lim et al., 2006).  Proteins that bind to PABC can do so through a conserved amino 
acid sequence called the PABP-interacting motif 2, (PAM2) (Kozlov et al., 2001).    
 
Bioinformatic approaches have identified a plethora of PAM2 containing proteins 
(Albrecht and Lengauer, 2004; Kozlov et al., 2001), although only a small number 
have been demonstrated to bind PABC experimentally including eRF3, PAIP1, and 
PAIP2 (see figure 1.12) (Gray et al., 2000; Kozlov et al., 2004; Kozlov and Gehring, 




Figure 1.11  Cytoplasmic poly(A)-binding protein structure.  PABP proteins share a 
similar protein domain structure.  All human cytoplasmic PABPs contain four RNA 
recognition motifs (RRMs) that instigate binding to mRNA and also proteins.  With the 
exception of PABP5, all cytoplasmic PABPs also contain a proline and glutamine-rich linker 
region bound to a globular C-terminal domain that facilitate protein-protein interactions and 
also PABP self-association.  Reproduced from Gorgoni and Gray. 2004. 
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mRNA Binding Activity 
The main mRNA substrate of PABP1 is poly(A) to which it binds with a nanomolar 
affinity (Gorlach et al., 1994; Sladic et al., 2004) although binding to poly(U) and 
poly(G) sequences has been shown, albeit to a lesser degree (Deardorff and Sachs, 
1997; Kuhn and Pieler, 1996; Nietfeld et al., 1990).  No binding to poly(C) 
sequences has been demonstrated.  When bound to mRNA, PABP1 covers 
approximately 25 nucleotides and requires a minimum of 12 adenosines for maximal 
binding (Baer and Kornberg, 1983; Sachs et al., 1987).  Functionally, the RRMs 
appear to be dissimilar in mRNA binding activity (Kuhn and Wahle, 2004).  
Experiments in-vitro have shown that the individual RRMs bind mRNA with up  to 
100-fold reduced affinity when compared to the wild-type protein and that typically, 
two RRM domains are required to impart specificity and efficient binding (Burd et 
al., 1991; Kuhn and Pieler, 1996).   
 
Poly(A)-binding is largely mediated by RRMs 1-2, with RRMs 3-4 displaying a 
reduced capacity to do so (Burd et al., 1991; Deardorff and Sachs, 1997; Kuhn and 
Pieler, 1996) leading to the hypothesis that RRMs 3-4 may be involved in stabilising 
the binding to poly(A) and/or promoting binding to other mRNA sequences.  Indeed, 
PABP1 mutations in RRMs 3 and 4 confer reduced binding affinity for poly(A) 
(Deardorff and Sachs, 1997), and additionally RRMs 3-4 possess an AU-rich 
sequence binding activity in-vitro and in-vivo that confers binding of PABP1 with 
only a 6-fold reduced affinity compared to poly(A) (Sladic et al., 2004).  In 
concurrence with this, PABP1 has been isolated from HeLa cell lysates by RNA 
affinity chromatography with the ARE of granulocyte-macrophage colony 
stimulating factor (GM-CSF) (Bollig et al., 2003).  The binding of AU-rich 
sequences is likely to be a conserved function of poly(A)-binding proteins as PABP4 
can also bind AREs (Sladic et al., 2004), and ePABP was initially identified as an 
ARE-binding protein by ARE-affinity selection of Xenopus laevis oocyte extracts 





Figure 1.12  Binding sites of PABP1-interacting proteins.  TOB (Ezzeddine et al., 2007), 
PAN3 (Siddiqui et al., 2007), IMP1 (Patel and Bag, 2006), PABP1 (Melo et al., 2003), eIF4G 
(Imataka et al., 1998), paxillin (Woods et al., 2005), UNR (Chang et al., 2004), eIF4B 
(Bushell et al., 2001), eRF3 (Cosson et al., 2002a), PAIP-1 (Roy et al., 2002), PAIP-2 
(Khaleghpour et al., 2001a), and GW182 (Jinek et al., 2010; Zekri et al., 2009) have all been 
demonstrated to interact with PABP1.  Paxillin, PAIP-1, and PAIP-2 all contain two binding 
sites within the PABP1 protein.  The eIF4B binding site has been determined to be C-
terminal but how far the region extends is not known.  There are discrepancies regarding the 
GW182 binding site in PABP1, with data suggesting it could reside within RRMs 1-4 (Zekri et 
al., 2009) or the C-terminus (Jinek et al., 2010). 
 
 
PABP1 is known to bind to poly(A) tails in an ordered repeating fashion (Baer and 
Kornberg, 1983; Kuhn and Pieler, 1996).  Experiments in-vitro have shown that 
PABP1 can self-associate to stimulate ordered binding of multiple PABPs to mRNA 
and that this interaction requires the C-terminus of PABP1 containing the proline-
rich linker region, but not the PABC domain (see figure 1.12) (Melo et al., 2003; 
Wilkie et al., 2005).  Interestingly, the first three RRMs were suggested to be 
inhibitory to PABP1 dimerisation in the absence of poly(A) suggesting a mechanism 
whereby PABP1 cannot self-associate in the absence of a poly(A) tail (Melo et al., 
2003).  PABP1 has also been isolated by immunoprecipitation with antibodies 
directed against ePABP (Wilkie et al., 2005), tPABP (Kimura et al., 2009) and 
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PABP4 (H. Burgess, unpublished) raising the possibility that different PABP 
proteins may bind the same transcripts. 
 
1.4.4  PABP1 Function in Translation 
The Closed Loop Model 
Translation initiation at the 5’ end of mRNAs is strongly enhanced in the presence of 
the m7GpppG cap structure.  The poly(A) tail present at the extreme 3’ terminus of 
nearly all eukaryotic mRNAs is also a primary determinant of translational efficiency 
(reviewed in Jackson and Standart, 1990; Munroe and Jacobson, 1990).  These two 
structures synergistically enhance translation (Gallie, 1991) via a mechanism termed 
the ‘closed loop’ or ‘end-to-end complex’ model (see figure 1.13) which postulates 
that the opposing termini functionally interact (Gallie, 1998; Munroe and Jacobson, 
1990).   
 
This interaction is mediated by PABP1 which binds to poly(A) (Blobel, 1973) and 
simultaneously interacts with factors bound to the 5’ end of mRNA.  PABP1 has 
been demonstrated to interact with eIF4G in-vitro (Gray et al., 2000; Imataka et al., 
1998; Tarun and Sachs, 1996) facilitating an eIF4E-eIF4G-PABP1 chain of 
interactions critical to the closed loop model.  The original mammalian eIF4GI 
(eIF4G) composite cDNA sequence was determined by screening of a human brain 
λ-cDNA library with labelled oligonucleotides probes that had been designed based 
on peptide sequences derived from a purified eIF4F preparation (Yan et al., 1992).  
Following the subsequent publication of the eIF4GII cDNA and protein sequences it 
was noticed that the amino-terminus was 158 amino-acids longer than that of eIF4GI 
(Gradi et al., 1998a).  Analysis of the two cDNAs showed that sequence homology 
between eIF4GI and eIF4GII abruptly ends at a putative splice acceptor site and 
therefore it was deduced that the published eIF4GI cDNA may contain an intron at 
its 5’ end (Gradi et al., 1998a).  5’-RACE was performed using HeLa cell poly(A)+ 
mRNAs and an N-terminal extension of the eIF4GI mRNA was indeed discovered, 
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adding 156 amino-acids to the protein (Gradi et al., 1998a; Imataka et al., 1998).  It 
had previously been demonstrated that yeast PABP1 could bind to the N-terminus of 
eIF4G (Tarun and Sachs, 1996; Tarun et al., 1997) and following the discovery of 
the human eIF4G N-terminal extension, it too was shown to be capable of binding to 
PABP1 (Imataka et al., 1998).     
 
In support of this model, recombinant yeast eIF4E, eIF4G and Pab1p have been 
shown capable of forming ring-like structures with capped polyadenylated mRNAs 
by atomic force microscopy (Wells et al., 1998).  In addition, disruption of the 
PABP1-eIF4G interaction can inhibit translation of reporter mRNAs (Gray et al., 
2000; Imataka et al., 1998; Kahvejian et al., 2005; Tarun et al., 1997) and in yeast 
translation extracts Pab1p mutants deficient in binding to eIF4G conferred a 
sensitivity to cap analogue and an inhibition of translation initiation as measured by 
toeprinting analysis of 48S complexes (Amrani et al., 2008).      
 
The closed loop model is hypothesised to promote 43S PIC recruitment to the cap 
(Kahvejian et al., 2005; Tarun and Sachs, 1995) although how this is achieved is still 
unclear.  In wheat germ extracts the PABP1-eIF4G interaction increases the affinity 
of PABP1 for the poly(A) tail (Le et al., 1997) while simultaneously increasing the 
affinity of eIF4F for the cap structure (Wei et al., 1998).  It has also been suggested 
that the helicase activity of eIF4A doubles in the presence of PABP1 (Bi and Goss, 
2000).  In mammalian systems, translation of polyadenylated mRNAs was 
demonstrated to be more sensitive to the presence of cap analogue when the PABP1-
eIF4G interaction was disrupted.  This was taken to imply that the affinity of eIF4E 
for the cap structure was increased when PABP1 and eIF4G were complexed 
(Borman et al., 2000) (Yanagiya et al., 2009).  Further interactions may also be 
involved in stabilising the closed loop conformation.  In support of this notion, 
sensitivity of mRNA translation to m7G cap analogue was only abolished when a 
poly(A) tail of 57 adenosines was added to the reporter, allowing binding of two 
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PABP1 molecules (Amrani et al., 2008).  This suggests that stability of the closed 
loop may require the activity of multiple PABPs.   
 
PAIP-1 is a PABP1 interacting protein (Craig et al., 1998) that contains two PABP-
interacting motifs (PAM1 and PAM2) and binds PABP1 with a 1:1 stoichiometry 
through two sites in RRMs 1-2 and the C-terminus of PABP1 (Gray et al., 2000; Roy 
et al., 2002).  PAIP-1 has also been shown capable of binding eIF3 through its 
subunit eIF3g (Martineau et al., 2008), as well as interacting with eIF4A (Craig et 
al., 1998).  In addition, pulldown assays have demonstrated that PABP1 can 
simultaneously interact with eIF4G and PAIP-1 (Martineau et al., 2008).  This set of 
interactions is hypothesised to secure the closed loop conformation (Martineau et al., 
2008).  Furthermore PABP1 has been shown to interact with eIF4B in-vitro (see 
figure 1.12), and in wheat germ extracts this interaction increases the affinity of 
PABP1 for poly(A) as well as facilitating an additional contact between the 5’ and 
3’-UTRs (Bushell et al., 2001; Le et al., 1997). 
 
Transcripts unable to form closed loops by means of a PABP1-eIF4G interaction 
often utilise other methods to circularise, highlighting the importance of this 
configuration for stimulating translation.  Histone mRNAs are capped but 
unadenylated, instead containing a conserved stem loop structure within their 3’-
UTRs.  This is bound by the stem-loop binding protein (SLBP) which stimulates 
histone mRNA translation (Sanchez and Marzluff, 2002).  SLBP has been proposed 
interact with SLBP-interacting protein 1 (SLIP1) which in turn binds eIF4G 
(Cakmakci et al., 2008).  The SLBP-SLIP1-eIF4G chain of interactions is purported 
to circularise the transcript, driving the translation of histone mRNA.  Similarly, the 
rotavirus family of double-stranded RNA (dsRNA) viruses produce capped but 
unadenylated transcripts.  The transcripts are thought to circularise through a direct 
interaction between eIF4G and the viral non-structural protein 3 (NSP3) which binds 
to a conserved sequence element at the 3’ end of all rotavirus mRNAs (Piron et al., 
1998).  This interaction evicts PABP1 from the eIF4F complex and contributes to 
46 
 
host cell shut-off of protein synthesis probably through competition with PABP1 for 





Figure 1.13  The closed loop model.  PABP1 binds to the poly(A) tail and stimulates 43S 
PIC recruitment through an interaction with eIF4G which is part of the eIF4F cap-binding 
complex thus forming a ‘closed loop’ mRNP.  The PABP-eIF4G interaction is thought to 
stabilise eIF4F binding to the cap and potentially stimulates the helicase activity of eIF4A.  
Additional interactions between PABP1 and 5’-UTR bound protein factors such as PAIP-1 
and eIF4B may stabilise the closed loop.  Additionally, PABP1 has been demonstrated to 
interact with eRF3, possibly linking translation termination and initiation thereby promoting 
efficient ribosome recycling.  Reproduced from Smith et al. 2010.  
 
 
Although the closed loop model is postulated to stimulate 43S PIC recruitment there 
is evidence that PABP1 may promote 60S ribosomal subunit joining.  In yeast a 
temperature sensitive mutation in Pab1p that displayed a block in translation 
initiation could be rescued by suppressor mutations that restrict the amount of 60S 
subunit available (Sachs and Davis, 1989).  Mutations in eIF5 and eIF5B which are 
involved in 60S subunit joining have also been reported to impair translation of 
poly(A)+ but not poly(A)- mRNAs (Searfoss et al., 2001).  Moreover in RRLs 
treated with edeine which blocks 60S joining, poly(A)+ and poly(A)- mRNAs were 
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equally capable of forming 48S complexes suggesting that the poly(A) tail is 
dispensable for 48S assembly (Munroe and Jacobson, 1990) and yet when treated 
with cycloheximide which inhibits peptide bond formation poly(A)+ mRNAs formed 
80S complexes two and a half times more efficiently than poly(A)- mRNAs (Munroe 
and Jacobson, 1990).  Additionally, PABP1 depleted Krebs-2 cell extracts showed a 
greater reduction in 80S compared to 48S ribosomal complexes implying that 
PABP1 could target both 43S recruitment and 60S joining (Kahvejian et al., 2005)  
 
PABP1 may also be involved in ribosome recycling through an interaction with 
eRF3.  The interaction between the N-terminal region of eRF3 and the C-terminal 
domain of PABP1, has been proposed to result in eviction of PABP1 from mRNA 
and exposure of the poly(A) tail to deadenylases, thereby linking translation 
termination to mRNA turnover (Hoshino et al., 1999; Hosoda et al., 2003).  
Intriguingly, the eRF3/PABP1 interaction has also been proposed to have a 
stimulatory effect on translation, by physically linking the stop codon to the 5’ cap 
complex, facilitating the efficient recycling of terminating ribosomes (Uchida et al., 
2002). 
 
1.4.5  PABP1 Function in mRNA Turnover and Repression 
PABP1 Role in Deadenylation 
As discussed above (1.3.6  3’-UTR Translational Control Elements) deadenylation is 
the first step in bulk mRNA turnover (Yamashita et al., 2005).  PABP, as the major 
effector of poly(A) tail function, binds to the poly(A) tail and is proposed to stabilise 
the transcripts by precluding the access of deadenylases (reviewed in Mangus et al., 
2003).  The finding that mRNA could be degraded 10-times faster in cell extracts 
lacking PABP1 (Bernstein et al., 1989), and visualisation of deadenylation 
intermediates that differ in size by approximately one PABP1 binding site 
(approximately 30 nucleotides) suggested that this might be the case (Korner and 
Wahle, 1997).   
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This simplistic viewpoint was contested by paradoxical in-vivo evidence suggesting 
that the rate of deadenylation is slowed in Pab1p depleted yeast strains indicative of a 
stimulatory role for Pab1p in deadenylation (Caponigro and Parker, 1995; Sachs and 
Davis, 1989).  The explanation for this activity could reside with the discovery that 
PABP1 can interact with, and stimulate the activity of the PAN2-PAN3 deadenylase 
complex (Funakoshi et al., 2007; Siddiqui et al., 2007; Uchida et al., 2004) through a 
direct interaction with the PAN3 subunit (see figure 1.12).  Interestingly the CCR4-
NOT deadenylase complex also interacts with mammalian PABP1 through the anti-
proliferative protein Tob (Funakoshi et al., 2007).  A mechanism has recently been 
proposed whereby PABP1 exchanges eRF3 for deadenylase complexes upon 
translation termination thereby linking termination to deadenylation (Funakoshi et 
al., 2007).  This is supported by evidence that the binding of eRF3, PAN2-PAN3, 
and CCR4-NOT to PABP1 via the PABC domain are all mutually exclusive, and that 
a translation-dependent exchange between eRF3 and PAN2-PAN3 occurs on PABP1 
in cells (Funakoshi et al., 2007). 
 
PABP1 Requirement in miRNA Mediated Translational Repression and Turnover 
PABP1 has also been implicated in miRNA directed translational repression and 
turnover through an interaction with GW182 (see figure 1.12), a component of the 
miRISC complex (Fabian et al., 2009; Jinek et al., 2010; Zekri et al., 2009).  miRNA 
mediated deadenylation of reporter mRNAs by the CCR4-NOT complex required the 
PABP1-GW182 interaction although surprisingly PABP1 recruitment of CCR4-NOT 
to the miRISC does not appear to be required for miRNA target deadenylation 
(Fabian et al., 2009; Zekri et al., 2009).  A mechanism for deadenylase recruitment 
was provided upon the discovery that CAF1, a component of the CCR4-NOT 
complex, could be co-immunoprecipitated with the miRISC proteins Ago1 and Ago2 
(Fabian et al., 2009).  Interestingly, Drosophila GW182 and eIF4G appear to 
compete for binding to PABP1, therefore a PABP1-GW182 interaction could 
possibly inhibit the formation of closed loop complexes by disrupting the PABP1-
eIF4G interaction.  This could result in translational repression and possibly 
exposure of the poly(A) tail to deadenylases (Zekri et al., 2009).  The PABP1-
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GW182 interaction might also function in juxtaposing the poly(A) tail against the 
miRISC deadenylase complex (Fabian et al., 2009). 
 
PABP1 Role in Nonsense-Mediated Decay 
Nonsense-mediated decay (NMD) degrades mRNAs harbouring premature 
termination codons (PTCs) (reviewed in Silva and Romao, 2009) that could produce 
deleterious truncated protein products.  The NMD surveillance machinery appears to 
detect the exon junction complexes (EJCs) deposited at exon-exon junctions 
following splicing (Le Hir et al., 2000).  As most introns are contained within mRNA 
coding regions EJCs are normally displaced by translating ribosomes (Garneau et al., 
2007), therefore retained EJCs can indicate the presence of a PTC and signal the 
mRNA for decay (Nagy and Maquat, 1998; Singh et al., 2007; Zhang et al., 1998).  
The role of PABP1 in NMD appears to be antagonistic to that of EJCs and can 
repress NMD when tethered downstream of PTCs (Amrani et al., 2004; Behm-
Ansmant et al., 2007; Silva et al., 2008).  Moreover increasing the length of the 3’-
UTR is capable of triggering NMD from natural stop codons (Behm-Ansmant et al., 
2007).  This suggests that PABP1 positioning provides information to the NMD 
machinery regarding natural termination events.  Indeed PABP1 competes for 
binding to the translation termination factor eRF3 with UPF1, a core component of 
the NMD machinery (Ivanov et al., 2008; Singh et al., 2008).  The ability to 
discriminate between normal and premature translational termination events 
therefore appears to be the sum of a number of antagonistic signals.   
 
The current model speculates that at natural stop codons PABP1 interacts with eRF3 
promoting normal termination, whereas at a PTC that is spatially distant to PABP1, 
UPF1 successfully competes for binding to eRF3 promoting NMD by a mechanism 
that appears to be stimulated by EJCs (Silva and Romao, 2009; Singh et al., 2008).  
The process of NMD also appears to regulate the expression of non-PTC containing 
transcripts and it has recently been estimated that 5-10% of the human transcriptome 
is regulated in this manner.  Depletion of UPF1 from mammalian cells resulted in the 
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upregulated expression of transposons and endogenous retroviruses.  These mRNAs 
were found to contain introns downstream of their termination codon which would 
normally be sufficient to initiate NMD (Mendell et al., 2004; Silva and Romao, 
2009). 
 
1.4.6 Regulation of PABP1 Expression and Activity 
Terminal  Oligopyrimidine Tracts  
PABP1 mRNA contains a sequence element termed a terminal oligopyrimidine tract 
(TOP) within its 5’-UTR which is known to regulate the expression of a number of 
mRNAs involved in protein synthesis, including ribosomal proteins (RPs), and the 
translation factors eEF1A, eEF2, which are selectively repressed upon growth arrest 
(Hamilton et al., 2006; Meyuhas, 2000).  While most mRNAs have an adenosine 
immediately following the m7G cap structure, TOP mRNAs contain a cytosine 
followed by 4-14 pyrimidine residues (Hamilton et al., 2006).  The mechanism of 
TOP mediated translational repression is controversial.  Initially it was noted that the 
mitogen stimulated phosphorylation of RPS6 (ribosomal protein S6) by the kinase 
S6K correlated with the translation of TOP mRNAs in a manner that was sensitive to 
both mTOR and phosphatidylinositol 3-kinase (PI3K) inhibitors (Caldarola et al., 
2004; Dufner and Thomas, 1999; Meyuhas, 2000).  Subsequent data has ruled out 
phosphorylation of RPS6 as a mediator of TOP regulation, although PI3K and 
mTOR signalling still appears to be important (Barth-Baus et al., 2002; Stolovich et 
al., 2002; Tang et al., 2001).  It has been hypothesised that binding of a trans-acting 
factor to TOP mRNAs may cause the translational repression.  Incubation of cell free 
translation extracts with oligonucleotides composed of the TOP sequence from 
RPS16 was able to relieve the repression.  This could be indicative of the presence of 
one or more titratable trans-acting factors, but while several proteins capable of 
binding TOP sequences have been identified, a credible candidate is yet to emerge 





Autoregulation of PABP1 mRNA Expression 
The 5’-UTR of PABP1 mRNA contains an adenosine-rich sequence element termed 
the autoregulatory sequence (ARS).  PABP1 has been demonstrated to bind the ARS 
(Patel et al., 2005; Sachs et al., 1986) inhibiting the translation of its own mRNA 
providing a feedback loop that limits the expression of PABP1 (Bag, 2001; Bag and 
Wu, 1996; Patel et al., 2005).  The ARS is proposed to inhibit 40S scanning (Bag, 
2001) by acting as a binding site for the formation of a heterotrimeric complex 
composed of PABP1, IMP1 and UNR (Patel and Bag, 2006; Patel et al., 2005).  
PABP1 binds to the ARS with a lower affinity than poly(A) (Patel et al., 2005) and 
the interactions with IMP1 and UNR (see figure 1.12) are thought to be required to 
form a complex that is sufficient to block ribosome translocation (Patel and Bag, 
2006; Patel et al., 2005). 
 
Regulation of PABP1 Activity By PAIP-2 
The activity of PABP1 is also subject to regulation through an interaction with the 
translational inhibitory protein PABP-interacting protein 2 (PAIP-2) (reviewed in 
Derry et al., 2006).  In contrast to PAIP-1 which stimulates translation (Craig et al., 
1998) addition of PAIP-2 to cell-free translation extracts represses the translation of 
a reporter mRNA 14-fold (Khaleghpour et al., 2001b).  PAIP-2 binds PABP1 
through two PAM domains, PAM1 and PAM2 although unlike PAIP-1, binds with a 
2:1 stoichiometry (see figure 1.14A) (Albrecht and Lengauer, 2004; Khaleghpour et 
al., 2001a; Roy et al., 2002).  PAIP-2 represses translation by decreasing the affinity 
of PABP1 for poly(A) (Khaleghpour et al., 2001b) and additionally competes with 
eIF4G and PAIP-1 for binding to PABP1 (see figure 1.14B) (Karim et al., 2006; 
Khaleghpour et al., 2001b).  A second PAIP-2 clone was identified, PAIP-2B, 
leading to the renaming of the original clone PAIP-2A (Berlanga et al., 2006).  
PAIP-2B also inhibits translation in-vitro and in-vivo to the same degree as PAIP-2A 
(Berlanga et al., 2006), although they differ in their tissue distributions with PAIP-
2B being predominantly expressed in the pancreas, while PAIP-2A is expressed 










Figure 1.14  Regulation of PABP1 activity by PAIP-2.  A.  PAIP-1 and PAIP-2 bind 
PABP1 through two conserved elements called PAM1 and PAM2.  PAM1 interacts with 
PABP1 in RRM2 while PAM2 interacts with the PABC domain.  PAIP-2 binds with a 2:1 
stoichiometry while PAIP-1 binds with a 1:1 stoichiometry.  B.  PAIP-2 negatively regulates 
PABP1 activity to repress translation.  PAIP-2 competes for binding to PABP1 with eIF4G 
and PAIP-1, and reduces the affinity of PABP1 for poly(A).  The interaction of PAIP-2 with 
PABP1 is therefore thought to disrupt the formation of a closed loop.  Reproduced from 





PABP1 and PAIP-2 cellular homeostasis is maintained through a feedback system 
(Yoshida et al., 2006).  In response to decreased PABP1 levels PAIP-2 is 
ubiquitinated by EDD, a member of the HECT family of E3-ubiquitin ligases 
(Callaghan et al., 1998) and targeted for degradation by the proteasome (Yoshida et 
al., 2006).  EDD contains a PABC domain in its C-terminus (Deo et al., 2001; 
Kozlov et al., 2001).  The PABC domain in EDD has a 20-fold lower affinity for 
PAIP-2 than the corresponding domain in PABP1, and consequently only Co-IP’s 
with PAIP-2 in the absence of PABP1 (Yoshida et al., 2006).  This suggests that 
upon lowered PABP1 levels, PAIP-2 can interact with EDD and is ubiquitinated and 
degraded allowing increased PABP1 activity.  PAIP-2B is also ubiquitinated 
implying a similar mechanism of regulation (Berlanga et al., 2006).  In addition to 
PABP1, tPABP and ePABP have also been demonstrated to bind PAIP-2 (Kim and 
Richter, 2007; Kimura et al., 2009).   
 
1.4.7  Other PABP Family Members   
The Role of Multiple PABPs  
As discussed in section 1.4.1, humans express multiple PABPs that share a similar 
domain structure and high level of protein sequence identity (see table 1.15).  The 
data available on other cytoplasmic PABP family members will be discussed in the 
following section and indicates that they may also play roles in translational 
regulation.  Why multiple PABPs are required in vertebrates is unclear, and to date 
no vertebrate PABP phenotypes have been described.  In yeast deletion of the Pab1p 
gene is lethal (Sachs et al., 1987), as is deletion of the cytoplasmic Drosophila 
melanogaster pAbp gene (Sigrist et al., 2000).  In an ethyl methanesulphonate 
(EMS) screen in Caenorhabditis elegans, mutation of the Pab-1 gene resulted in a 
fully penetrant severe germline proliferation defect resulting in sterility (Maciejowski 
et al., 2005).  RNA interference (RNAi) of the Pab-1 transcript resulted in a similar 
sterility phenotype with 25% of the progeny also displaying growth defects 
(Maciejowski et al., 2005).  RNAi of the Pab-2 transcript also resulted in a low 
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occurrence of growth defects leading to the conclusion that the Pab-1 and Pab-2 
proteins act redundantly in the soma but that Pab-1 is essential in the germline 
(Maciejowski et al., 2005).  A separate RNAi knockdown of Pab-1 resulted in 50-




 htPABP hePABP hPABP4 hPABP5 
hPABP1 92% 69% 75% 62% 
htPABP  65% 70% 59% 
hePABP   65% 56% 
hPABP4    63% 
 
Table 1.15  Human cytoplasmic PABP protein sequence identity.  The percentage 
protein sequence identity between members of the human cytoplasmic PABP family was 
calculated.  Human PABP5 lacks the proline-rich linker region and the C-terminal region 
conserved in other cytoplasmic PABPs, therefore the sequence identity of this protein was 
calculated against only RRMs 1-4 of the other family members. 
 
ePABP 
Embryonic PABP (ePABP) is probably the most extensively studied PABP apart 
from PABP1 and was initially described as being expressed in the oocytes and early 
embryos of Xenopus laevis where the protein could be detected up to 30 hours post-
fertilisation (Voeltz et al., 2001).  In contrast PABP1 protein was only detectable 
from 1 day post-fertilisation onwards meaning that ePABP is the predominantly 
expressed PABP at these developmental stages when poly(A) tail length changes are 
important.  The oocyte and early embryonic expression is borne out in mouse 
(Wilkie et al., 2005) and human (Guzeloglu-Kayisli et al., 2008) suggesting a 
conserved expression pattern.  In adult mouse, Xenopus and human tissues ePABP 
has been detected in the ovary and testis (Guzeloglu-Kayisli et al., 2008; Seli et al., 
2005; Wilkie et al., 2005). 
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Initially ePABP was purified from Xenopus laevis oocyte extracts as an ARE-binding 
protein (Voeltz et al., 2001).  Subsequently ePABP was shown to inhibit 
deadenylation of ARE and non-ARE containing substrates (Kim and Richter, 2007; 
Voeltz et al., 2001) and was implicated in regulating cytoplasmic polyadenylation 
possibly via a transient interaction with CPEB from where it could be transferred to 
the newly synthesised poly(A) tails (Kim and Richter, 2007).  Given the sequence 
homology to PABP1 a role for ePABP in translational regulation was also examined.  
In Xenopus oocytes a reporter mRNA to which ePABP was tethered was translated 
8-fold more efficiently than controls (Wilkie et al., 2005), and consistent with a role 
in translational regulation ePABP was observed to co-sediment with polysomes from 
oocyte extracts (Wilkie et al., 2005).  Similar to PABP1, ePABP interacts with 
eIF4G (Kim and Richter, 2007; Wilkie et al., 2005), PAIP-1 (Wilkie et al., 2005), 
PAIP-2 (Kim and Richter, 2007) and eRF3 (Cosson et al., 2002b) and accordingly 
can be purified by m7G affinity chromatography from Xenopus oocyte extracts 
(Cosson et al., 2002b).  Interestingly, despite ePABP having the lowest protein 
sequence conservation across the PABP family (see table 1.15), this data is 
concurrent with ePABP being a genuine translation factor that appears to act in a 
manner similar to PABP1.     
 
tPABP 
The expression of testis PABP (tPABP) is restricted to a sub-population of germ cells 
within the testis of mice and humans (Feral et al., 2001; Kimura et al., 2009).  The 
expression of tPABP is discussed in more detail in chapter 3.  tPABP is an intronless 
gene and is hypothesised to have arisen through retroposition of a PABP1 transcript, 
explaining the high degree of sequence homology between the two PABP proteins 
(see table 1.15) (Kleene et al., 1998).  The available data suggests that tPABP may 
also play a role in translational regulation.  It has a mainly cytoplasmic localisation 
and can bind poly(A) (Feral et al., 2001; Kleene et al., 1994), and stimulates 
translation to a similar degree as PABP1 in RRLs (Kimura et al., 2009), although the 
magnitude of stimulation was only approximately 1.6-fold because the assay was 
undertaken in RRLs which are not cap and poly(A) sensitive.  tPABP has also been 
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demonstrated to interact with eIF4G, PAIP-1 and PAIP-2 (Kimura et al., 2009).  
Curiously tPABP was not observed in the polysomes of fractionated mouse testis 
(Kimura et al., 2009), although this might reflect a detection level issue as tPABP is 




PABP4, also called inducible PABP (iPABP) and activated-platelet protein-1 (APP-
1), was originally cloned as an inducible mRNA in activated T-cells (Yang et al., 
1995) and a protein that was upregulated in activated platelets (Houng et al., 1997).  
PABP4 showed a wide expression pattern in different human tissues as determined 
by northern blot with particularly high mRNA levels in testis and ovary (Yang et al., 
1995).  Moreover PABP4 was the predominant PABP mRNA species present in 
heart and skeletal muscle when compared to PABP1 levels (Yang et al., 1995).  As 
with other characterised PABP family members PABP4 displayed poly(A) binding 
affinity as determined by poly(A)-sepharose binding (Houng et al., 1997; Yang et 
al., 1995) and also by electrophoretic mobility shift assay (EMSA) (Sladic et al., 
2004).  Quantitative EMSA experiments established that PABP4 bound poly(A) with 
a marginally lower affinity than PABP1 (Kd 1.1nM vs Kd 0.67nM) but bound a 
poly(AU) probe with higher affinity (Kd 2.4nM vs Kd 3.9nM) (Sladic et al., 2004).  
The physiological relevance of this binding specificity has yet to be determined. 
 
A function for PABP4 in translational regulation has yet to be firmly established 
although initial data appears to support a role.  PABP4 was shown to modestly 
enhance the translation of polyadenylated interleukin-2 (IL-2) mRNA in an in-vitro 
translation system, although only in the presence of the IL-2 mRNA 3’-UTR (Okochi 
et al., 2005).  This stimulation was suppressed by the overexpression of the 
antiproliferative protein Tob which was shown to interact with PABP4 via the PABC 




The least studied PABP family member is PABP5.  Structurally this protein differs 
from the other ‘classical’ PABP proteins.  It lacks the proline-rich linker region and 
the C-terminal domain, but retains four putative RRMs implying that PABP5 is 
capable of RNA and protein binding.  PABP5 was originally identified via an exon-
trapping study directed at finding expressed genes within the Xq21.3/Yp11.2 
homology block of the human sex chromosomes (Blanco et al., 2001).  The PABP5 
gene appears to be mammalian-specific and highly conserved between species (see 
table 1.16), coding for a protein with a predicted molecular weight of 43kDa (Blanco 
et al., 2001).  Intriguingly, like tPABP, PABP5 may have arisen by retroposition, as 
the gene contains a single uninterrupted ORF.  The documented expression data for 
PABP5 is extremely preliminary, consisting of a single reverse transcriptase-
polymerase chain reaction (RT-PCR) experiment on a panel of human cDNAs 
(Blanco et al., 2001).  The data shows PABP5 mRNA expression in human fetal 
brain, adult brain, kidney, testis, and ovary.  The authors indicate that the highest 
expression levels are seen in the ovary, although the ovary RT-PCR is displayed on a 
separate figure with no other tissues for comparison.  To date no functional analysis 
of the protein has been undertaken. 
 
 






Homo sapiens 94% 100% 99% 96% 
Mus musculus  94% 94% 92% 
Pan 
troglodytes 
  99% 96% 
Macaca 
mulatta 
   96% 
 
Table 1.16  PABP5 protein conservation across mammalian species.  The putative 
PABP5 protein sequence identity was compared across a number of mammalian species.  
Homo sapiens = humans, Mus musculus = mouse, Pan troglodytes = chimpanzee, Macaca 




1.5  Thesis Aims 
 
PABP5 is a mammalian specific protein whose physiological function is currently 
unknown.  There is little published data available for PABP5, despite the PABP5 
gene being mapped to a genetic locus associated with well-known human 
pathological conditions such as premature ovarian failure (see chapter 5).  The 
expression pattern of PABP5 within mammalian tissues is poorly understood and 
there is currently no data pertaining to the molecular function, therefore the aim of 
this thesis was to examine the tissue and cellular distribution of PABP5 in mammals, 
and to begin to dissect the molecular role of this protein, with a longer term aim of 



































Unless otherwise stated all tabletop centrifugation was carried out using an 
Eppendorf 5417R centrifuge with a fixed angle rotor (max.13,000 rpm [16,060 rcf]).  
All other centrifugation was carried out with a Sigma-Aldrich 6K15 centrifuge with a 
swing out bucket rotor (max. 4700 rpm [4495 rcf]).     
 
2.1 General Microbiological Techniques 
 
2.1.1  Bacterial Work 
Bacterial Strains 
All plasmids were prepared in the E. coli strain XL-1 Blue (Stratagene), genotype: 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIqZΔM15 Tn10 
(Tetr)].  All recombinant proteins were expressed and purified from the E. coli strain 
BL21(DE3) (Invitrogen), genotype: F- ompT hsdSB (rB-mB-) gal dcm (DE3). 
 
Bacterial Growth 
Bacteria were grown and maintained on Luria Bertani (LB) agar plates or in liquid 
LB medium containing the appropriate antibiotics (kanamycin at 40μg/ml, ampicillin 
at 100μg/ml, or chloramphenicol at 34μg/ml).  LB agar plates and cultures were 
grown at 37oC and stored at 4oC where necessary. 
 
Bacterial Transformations 
Chemically competent XL-1 Blue E. coli cells were thawed on ice for 30 minutes 
prior to transformation.  Approximately 10-100ng of plasmid DNA or 10ng of 
freshly ligated DNA was then added to 50μl of cells.  The mixture was then 
incubated on ice for 30 minutes before heat shocking at 42oC for 45 seconds in a 
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water bath.  200μl of LB medium was added and the mixture was incubated for 60 
minutes at 37oC.  100μl of the mixture was then plated on LB agar containing the 
required antibiotic, and the plates were incubated at 37oC overnight. 
 
2.1.2  Yeast Work 
Yeast Strains 
Yeast two-hybrid analysis was performed with S. cerevisiae strain L40ura- (MATa, 
ura3-52, leu2-3, 112, his3, trpΔ1, ade2, Δgal4, lys::(lexAop)-HIS3, ura3::(lexAop)-
LacZ) as previously described (Zhang et al., 1999). 
 
Yeast Growth 
Yeast were grown in yeast extract peptone dextrose (YPD) media (10g/l bacto-yeast 
extract, 20g/l bacto-peptone, 20g/l dextrose) or on YPD agar plates (10g/l bacto-
yeast extract, 20g/l bacto-peptone, 20g/l dextrose, 20g/l bacto-agar) at 30oC.  For 
yeast 2-hybrid experiments, yeast were transformed with plasmids containing 
selectable markers and so were grown on selective minimal media plates (6.7g/l 
yeast nitrogenous base, 20g/l D-glucose, 20g/l bacto-agar, 1x dropout mix [1x 
dropout mix = 125mg/l of each of the following: adenine, alanine, arginine, 
asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, 
isoleucine, lysine, methionine, phenylalanine, proline, serine, threonine, tyrosine, 
uracil and valine in dH2O]). 
 
Yeast Transformations for Yeast 2-Hybrid Assay 
A single L40ura- yeast colony was used to inoculate 5ml YPD and the culture was 
grown overnight at 30oC.  The following day, 1ml of overnight culture was used to 
inoculate 50ml YPD and the yeast were grown to O.D. 0.6-1.0.  The culture was 
centrifuged at 4700 rpm for 1 minute.  The supernatant was removed and the yeast 
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pellet was washed with 25ml dH2O before being respun as before.  The supernatant 
was removed and the pellet was resuspended in 25ml of buffer (100mM LiOAc, 1x 
TE [10mM Tris-HCl, pH7.5, 1mM EDTA]) and aliquoted into microcentrifuge tubes 
(500μl per reaction).  The yeast were centrifuged at 7,000 rpm (5,200 rcf) for 1 
minute and the supernatant was removed.  The yeast were then resuspended in the 
transformation reaction buffer which contained 50μl 100mM LiOAc/1x TE, 6μl 
herring testis carrier DNA (Clontech), and 1μg of each plasmid to be transformed.  
300ul of 40% PEG (Mr 3350g/mol)/100mM LiOAc/1x TE was then added to each 
sample, and the samples were vortexed for 10 seconds.  The mixture was incubated 
at 30oC for 30 minutes, followed by heat shock at 42oC for 15 minutes.  After 
centrifugation for 2 minutes at 7,000 rpm, the yeast were resuspended in 200μl of 
dH2O and plated on yeast minimal media plates.  The plates were incubated at 30
oC 
for approximately 3 days to obtain colonies. 
 
2.2 General Nucleic Acid Techniques 
 
2.2.1  Plasmid Purification 
Plasmid DNA was prepared from overnight cultures of transformed E. coli strain 
XL-1 Blue using Qiagen Mini, Midi, or Maxi-Prep kits as per the manufacturer’s 
instructions.  Plasmids were eluted and stored in Buffer EB (Qiagen) and the DNA 
concentration was established using a Nanodrop Spectrophotometer ND-1000 
(Thermo Scientific), measuring the absorbance spectra at 260nm.  DNA quality was 
established using agarose gel electrophoresis with the fluorescent nucleic acid dye 
GelRed (Biotium). 
 
2.2.2  Phenol/Chloroform Extraction (DNA) 
A 1:1 ratio of sample to phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma-Aldrich) 
was mixed vigorously in a screw cap tube.  The sample was then centrifuged at 
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13,000 rpm for 3 minutes.  The upper (aqueous) phase was removed to a fresh tube 
and the extraction was repeated.  The DNA was then ethanol precipitated.   
 
2.2.3  Ethanol Precipitation of RNA/DNA 
The volume of the solution containing the RNA/DNA was estimated and 0.1x 
volume of 3M NaOAc pH5.2 was added, followed by 2.5x volume of molecular 
grade ethanol (Sigma-Aldrich).  The mixture was then placed at -20oC for 2 hours to 
overnight before being spun at 13,000 rpm for 30 minutes.  The RNA and DNA were 
then washed in large volumes of 80% and 70% molecular grade ethanol respectively, 
before being resuspended in dH2O. 
 
2.2.4 Restriction Digestion of DNA 
All restriction enzymes used were supplied by New England Biolabs (NEB) or 
Roche.  Digestions were set up as per manufacturer’s instructions, using the supplied 
buffers.  The restriction enzymes were maintained within a glycerol buffer and 
therefore never comprised more than 10% of the total reaction volume to avoid star 
activity.  1 unit of restriction enzyme was defined as the amount of enzyme required 
to cut 1μg of DNA in 1 hour (Roche), therefore the amount of enzyme and reaction 
incubation time were calculated for individual reactions.  When digesting a plasmid 
vector for cloning, shrimp alkaline phosphatase (Roche) was added to the digestion 
reaction as per manufacturer’s instructions and the vectors/inserts were purified 
using a Qiagen PCR Purification Kit as per manufacturer’s instructions, prior to 
ligation. 
 
2.2.5  DNA Ligations 
All ligations were undertaken using T4 DNA Ligase (NEB) as per manufacturer’s 
instructions.  Ligation reactions were incubated overnight at 4oC. 
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2.2.6  Agarose Gel Electrophoresis 
Agarose gels were prepared in the range 0.8-2% (w/v) by dissolving the appropriate 
mass of agarose in 1x TAE buffer (40mM Tris-HCl, 20mM glacial acetic acid, 
1.3mM EDTA, pH8.5) in a microwave for 1 minute.  GelRed was added to the 
molten agarose at a 1/10,000 dilution and the solution was poured and allowed to set.  
6x Gel loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 30% 
glycerol) was added to DNA samples to a final concentration of 1x, and the samples 
were run at 25-100V in an EmbiTech RunOne System gel electrophoresis tank in 1x 
TAE buffer.  The DNA was visualised under a UV light and band sizes were 
estimated using Promega 1kb ladder. 
 
2.2.7  DNA Sequencing  
All sequencing reactions were run on an in-house ABI 3730 DNA Analyzer machine 
(Applied Biosystems).  The reactions were performed using a Big Dye Terminator 
Sequencing Kit (Applied Biosystems) as per manufacturer’s instructions. 
 
2.2.8  RNA Extraction from Tissue Samples 
RNA was extracted from cells and tissue samples with Tri-Reagent (Ambion) as per 
manufacturer’s instructions.  RNA was resuspended in nuclease-free water 
(Ambion). 
 
2.2.9  In-vitro Transcriptions 
In-situ Hybridisation Probes 
The vectors containing the template sequences for the probes were linearised by 
restriction enzyme digestion at a site 3’ to the transcriptional end point.  The 
construct was purified by phenol/chloroform extraction followed by ethanol 
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precipitation and used as a template for preparing the digoxygenin (DIG) labelled 
probes utilising a DIG-labelling kit (Roche) as per manufacturer’s instructions. 
 
Tethered Function Assay mRNAs 
The vectors containing the template sequences for the mRNAs were linearised by 
restriction enzyme digestion at a site 3’ to the transcriptional end point.  The 
construct was purified by phenol/chloroform extraction followed by ethanol 
precipitation prior to transcription.  For T7-RNA polymerase transcriptions the 
reactions were set up as follows:  1x transcription buffer (Stratagene), 30mM DTT, 
1mM ATP, 1mM UTP, 1mM CTP, 7mM m7G cap (New England Biolabs), 100U 
RNasin (Promega), 4U T7-RNA polymerase (Stratagene), 0.1µg/µl linearised DNA 
template.  The reaction was incubated at 37oC for 5 minutes in the absence of GTP to 
promote capping of the transcripts.  Following the incubation 1mM GTP was added 
and the reaction was allowed to proceed at 37oC for 90 minutes.  The template DNA 
was then digested by addition of 2.5U RQ1 RNase-free DNase (Promega) followed 
by incubation at 37oC for 25 minutes.  The RNAs were purified by two acidic 
phenol/chloroform/isoamylalcohol (25:24:1) (Ambion) extractions and passed over a 
Chroma spin-100 DEPC-H2O column (Clontech) to remove unincorporated m
7G cap 
and short partially transcribed RNA products.  The RNA was then ethanol 
precipitated and resuspended in nuclease-free water (Ambion) and subjected to 
agarose gel electrophoresis to check integrity.  
   
 
2.3 Polymerase Chain Reaction (PCR) Techniques 
 
2.3.1  Polymerase Chain Reaction (PCR) 
PCR reactions were set up on ice, using filter tips.  The polymerase enzyme utilised 
for all PCR based techniques was Phusion High-Fidelity DNA polymerase 
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(Finnzymes) with the exception of PCR reactions to produce products for TA cloning 
which were undertaken with Bio-X-Act (Bioline).  A typical PCR reaction contained 
the following components; 1x Phusion Reaction Buffer, 0.2mM dNTPs, 0.5μM sense 
primer, 0.5μM antisense primer, 10-50ng DNA/cDNA template, 1U Phusion DNA 
polymerase enzyme.  The reactions were run on a Dyad DNA Engine (BioRad) with 
the following standard program; (1) 98oC for 30 seconds, (2) 98oC for 10 seconds, 
(3) 55-65oC (dependent on the melting temperature of the oligonucleotide primers) 
for 30 seconds, (4) 72oC for 30 seconds - 1 minute, (5) repeat steps (2) to (4) 29 - 31 
times, (6) 72oC for 5 minutes. 
 
2.3.2  Reverse Trancription PCR (RT-PCR) 
RT-PCR reactions were undertaken with an AMV First Strand cDNA Synthesis Kit 
(Roche) as per manufacturer’s instructions.  cDNA was then subjected to standard 
PCR (as above) using 1-5μl of the cDNA reaction per PCR.  The mouse Pabp5 RT-
PCR oligos were 5’-CGGTCATCTGGCTGTGACCAC-3’ and 5’-
GCGGCTGCCAGTCAGTCC-3’ and the mouse aromatase RT-PCR oligos were 5’-
GTTCCATGTCATGAAGCACAG-3’ and 5’-TCCAGCATGATGTGTCTCATG-3’. 
 
2.3.3  Quantitative PCR (QPCR) on Human Tissue cDNA Array 
Quantitative PCR analysis was performed in a 7900HT Fast Real-Time PCR System 
(Applied Biosystems) using a pre-designed Taqman probe/primer set (Catalogue no. 
Hs01936220_s1; Applied Biosystems) with a Human QPCR Tissue Array (Origene).  
The reaction mix was set up on ice with the following components (per reaction); 
Taqman probe/primer set 2.5μl, 1x Taqman Universal PCR Master Mix (Catalogue 
no. 4304437; Applied Biosystems).  The cycling parameters were; (1) 50oC for 2 
minutes, (2) 95oC for 10 minutes, (3) 95oC for 15 seconds, (4) 60oC for 1 minute, (5) 





2.3.4  Mutagenesis PCR 
All plasmid mutagenesis reactions were carried out with the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene) as per manufacturer’s instructions.  For details 
of the primers and plasmids used see section 2.10. 
 
2.4 General Protein Work 
 
2.4.1  Bradford Assay 
Sample protein concentrations were quantified by Bradford assay using Protein 
Assay Reagent (BioRad) as per manufacturer’s instructions.  A standard curve (0-
20µg) was generated using bovine serum albumin (BSA) dissolved in water and the 
sample concentration was calculated from the values obtained from the standard 
curve.  A Genequant Pro Spectrophotometer (GE Healthcare) was used to determine 
the absorbencies of the samples at 595nm. 
 
2.4.2  Protein Extraction from Tissues and Cells 
Unless stated in text, all protein preparations from tissues and cells were undertaken 
using phospho-RIPA buffer (50mM Tris, 150mM NaCl, 1mM EDTA, 1% NP40, 
0.2% SDS, 10mM sodium pyrophosphate, 25mM β-glycerophosphate, 0.5% sodium 
deoxycholate, 100mM sodium orthovanadate, 5mM sodium fluoride, 2mM DTT, 
protease inhibitor cocktail tablets [Roche], pH7.4 with HCl).  Following suspension 
in phospho-RIPA buffer, samples were incubated on ice for 10 minutes then passed 
3-4 times through a 21-G needle.  Some larger tissue samples required mechanical 
homogenisation with a pestle.  The solution was then cleared by centrifugation at 





2.4.3  Polyacrylamide Gel Electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis (SDS-PAGE) (Shapiro et al., 1967) of protein 
samples was undertaken using Mighty Small II Gel Apparatus (Hoefer) with an HC 
PowerPac (BioRad).  The gel pouring apparatus was ethanol then dH2O cleaned and 
assembled, and the separating gel (0.375M Tris, 3.5mM SDS, 10-12% [v/v] 
acrylamide/bisacrylamide [29:1], 4.4mM APS, 6.7mM TEMED, pH8.8) was poured 
(0.75mm spacers).  The separating gel was overlayed with dH2O and left to set for 30 
minutes.  The water was then poured off and the stacking gel (0.125M Tris, 3.5mM 
SDS, 4% acrylamide/bisacrylamide [29:1], 4.4mM APS, 6.7mM TEMED, pH6.8) 
was poured and the comb inserted.  Samples were heated to 99oC for 5 minutes in 1x 
SDS-PAGE sample loading buffer (125mM Tris-HCl pH6.8, 2% SDS [w/v], 10% 
glycerol [v/v], 100mM DTT, 0.01% bromophenol blue [w/v]).  The gels were run at 
75-150V for 1-2 hours in 1x PAGE running buffer (25mM Tris, 190mM glycine, 
3.5mM SDS, pH8.3).  Benchmark and SeeBlue protein ladders (Invitrogen) were run 
as molecular weight markers.  Some gels were run using the NuPAGE Bis-Tris Pre-
Cast Gel System (Invitrogen) as per manufacturer’s instructions.  Briefly, protein 
samples were heated to 70oC in 1x NuPAGE LDS Sample Buffer (Invitrogen) for 10 
minutes.  Gels were run at 100-200V (constant) for 45-90 minutes in 1x NuPAGE 
MOPS SDS Running Buffer (Invitrogen) with 500μl NuPAGE antioxidant 
(Invitrogen) added to the gel chamber.  To stain the proteins, the gels were first 
washed 3 times in dH2O for 10 minutes each wash.  The gel was then incubated in 
GelCode Blue Stain Reagent (Thermo Scientific) from 1 hour to overnight before 
destaining in water. 
 
2.4.4  Western Blotting 
Transfer 
Protein gels were incubated in 1x transfer buffer (25mM Tris, 200mM glycine, 20% 
methanol, pH7.4) for 5 minutes.  Gels were transferred to Immobilon-P membrane 
(Millipore) using a V20-SBD semi-dry blotter (SCIE-PLAS) in a transfer cassette 
consisting of 3 pieces of blotting paper soaked in transfer buffer placed on the anode 
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plate, followed by the Immobilon membrane (rehydrated through methanol [1 
minute] then 1x transfer buffer [3 minutes with rocking]), then the gel, and a further 
3 pieces of blotting paper.  Proteins were transferred at 75-100mA (constant) for 45-
90 minutes.  NuPAGE gels were transferred in an identical manner, except using 1x 
NuPAGE transfer buffer.   
 
Blocking 
Membranes were blocked in 1x Western Blocking Reagent (Roche) diluted in 1x 
TBS (10mM Tris, 140mM NaCl, pH7.4) or 5% non-fat dried milk powder (w/v) in 
TBST (0.1% Tween-20 [v/v], 1x TBS) depending on the primary antibody, for 2 
hours at room temperature or overnight at 4oC on a rocker.  Primary antibodies were 
then prepared to the appropriate dilution (see table 2.1) in 0.5% Western Blocking 
Reagent or 5% milk TBST and applied to the membrane for 2 hours at room 
temperature or overnight at 4oC on a rocker.  Membranes were washed in TBST 3 
times, for 5 minutes each wash.  Secondary antibodies were applied at the 
appropriate dilution (see table 2.1) in 0.5% Western Blocking Reagent or 5% milk 
TBST and applied to the membrane for 1 hour at room temperature.  Membranes 
were washed in TBST 3 or more times, for 15 minutes each wash and subjected to 
ECL (GE Healthcare) detection, as per manufacturer’s instructions.  The membranes 
were exposed to Hyperfilm ECL chemiluminescent film (GE Healthcare) unless 
otherwise stated and were developed through a Compact X4 Developer (XoGraph 
Imaging Systems). 
 
2.4.5  TCA Precipitation of Proteins 
Equal volumes of sample and 20% (v/v) trichloroacetic acid in water were mixed 
well and incubated on ice for 30 minutes.  Samples were centrifuged at 13,000 rpm 
for 15 minutes then washed twice in acetone for 15 minutes each wash.  Proteins 




2.4.6  Immunoprecipitation (IP) 
1mg of protein lysate was incubated with 50µl of protein G sepharose beads (GE 
Healthcare) which had been washed 3 times in cold phosphor-RIPA buffer (see 
2.4.2) and 1µg of the relevant antibody.  The mixture was incubated for 4 hours at 
4oC then the beads were washed six times in cold phosphor-RIPA buffer containing 
300mM NaCl with centrifugation at 3,000 rpm (857 rcf) between washes.  The beads 
were then were heated to 70oC in twice the bed volume of 2x NuPAGE LDS Sample 
Buffer (Invitrogen) for 10 minutes before being subjected to SDS-PAGE.  Protein 
gels containing proteins labelled with 35S were fixed in 3x 10 minute washes of fix 
solution (40% methanol, 10% acetic acid) followed by incubation in Enlightening 
solution (Perkin-Elmer) + 5% glycerol for 30 mins.  The gels were then dried for 2 
hours at 80oC in a BioRad 583 Gel Drier.  The gel was then exposed to Kodak 
BioMax MR film overnight.   
 
2.5 Recombinant Protein Generation 
 
2.5.1  Recombinant Protein Inductions 
BL21(DE3) E. coli cells were transformed with pET28c+ or pGEX6P1 vectors 
containing the gene of interest.  Following transformation the cells were plated on 
LB agar plates containing an appropriate antibiotic and grown overnight at 37oC.  
Single colonies were picked and used to inoculate 5ml of LB media containing an 
appropriate antibiotic.  The cultures were grown overnight at 37oC and the following 
day 0.5ml was used to inoculate 200ml of fresh LB media containing antibiotic and 
the cells grown to an optical density (O.D.) of 0.3-0.5.  Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was then added to a final concentration of 1mM and 
the cells were grown for 4 hours at 22oC (pET28c+) or 3 hours at 37oC (pGEX6P1).  
The cells were then centrifuged at 4700 rpm for 15 minutes at 4oC and used, or 




Antibody Species Raised In Supplier Western Dil. 
PABP1 Rabbit N. Gray group 1/10,000 
PABP4 Rabbit N. Gray group 1/5,000 
PABP5(164) Rabbit Atlas Antibodies 1/1,000 
PABP5(165) Rabbit Atlas Antibodies 1/250 
PABP5(Abnova) Mouse Abnova 1/1,000 
GST Goat Abcam 1/5,000 
Polyhistidine Mouse Sigma-Aldrich 1/1,000 
T7 Mouse Novagen 1/10,000 
eIF4E Rabbit Cell Signalling Tech 1/1,000 
Tubulin Mouse Sigma-Aldrich 1/5,000 
GAPDH Mouse Abcam 1/1,000 
LexA BD Rabbit Millipore 1/5,000 
Gal4 AD Mouse BD Biosciences 1/10,000 
Chicken α Goat (2o) Chicken Santa Cruz  1/20,000 
Goat α Mouse (2o) Goat Pierce 1/20,000 
Goat α Rabbit (2o) Goat Sigma 1/100,000 
 
Table 2.1  Primary and Secondary Antibodies.  List of antibodies used in thesis, with 
dilutions used for Western blot.   
 
2.5.2  His-PABP1 and His-PABP5 Protein Purification 
Lysis buffer (20mM Tris-HCl pH8, 10mM imidazole, 150mM NaCl, 1mM DTT, 1x       
-EDTA protease inhibitor cocktail tablets [Roche], 1x BugBuster solution 
[Novagen], 25U/ml benzonase, 1KU/ml lysozyme) was added to the pelleted 
BL21(DE3) E. coli cells.  The cells were then incubated on a turnwheel for 15 
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minutes at room temperature.  The lysate was cleared by centrifugation at 4700 rpm 
and added to Ni-NTA agarose beads (Qiagen) which had been washed 3x in lysis 
buffer (centrifuging at 3,000 rpm [857 rcf] between washes).  Following incubation 
on a coldroom turnwheel for 2 hours, the beads mixture was centrifuged at 3,000 rpm 
and the supernatant removed.  The beads were washed 3x in wash buffer (20mM 
Tris-HCl pH8, 10mM imidazole, 300mM NaCl, 1mM DTT, 1x -EDTA protease 
inhibitor cocktail tablets [Roche]) on ice, centifuging at 3,000 rpm between washes, 
and the proteins were eluted in 3x 5 minute incubations in elution buffer (20mM 
Tris-HCl pH8, 250mM imidazole, 150mM NaCl, 1mM DTT, 1x -EDTA protease 
inhibitor cocktail tablets [Roche]) centifuging at 13,000 rpm between elutions.  For 
column purifications, the same protocol was utilised except following the incubation 
of the Ni-NTA beads with the cell lysate, the mixture was transferred to a BioRad 
poly-prep chromatography column.  Once the beads had settled, the column was 
washed 3 times with wash buffer and the proteins were eluted with elution buffer.  
All the washes and elutions were collected.  
 
2.5.3  Quantification of Induced Proteins.   
Serial dilutions of the recombinant proteins were prepared and subjected to SDS-
PAGE alongside BSA standards (0-10µg).  The protein gels were stained with 
SYPRO Ruby protein gel stain (Invitrogen) as per manufacturer’s instructions.  The 
gels were then scanned using a Typhoon Variable Mode Imager with a 488nm 









2.6 Histological Analysis 
 
2.6.1  Sectioning 
Tissue samples were fixed in Bouins fluid (Clintech) overnight.  Large samples such 
as testes were cut in half prior to immersion in Bouins. Samples were then washed in 
70% ethanol followed by dehydration in increasing concentrations of alcohol, 
followed by xylene. The tissues were embedded in hot paraffin wax and 7µm 
sections were cut using a microtome and mounted on glass slides. Slides were 
incubated at 55°C overnight to dry. 
 
2.6.2  Haematoxylin and Eosin Staining Tissues 
The tissues were dewaxed in 3x 5 minute changes of xylene then rehydrated in 2x 5 
minute washes of 100% ethanol, 1x 2 minute washes in each of 90%, 70%, 50%, 
30% ethanol and finally 3x 2 minute washes in tap water.  Slides containing the 
tissue sections were immersed in haematoxylin for 4 minutes then washed in tap 
water followed by acid/alcohol (1% HCl, 70% ethanol) for 5 seconds.  The slides 
were washed again in tap water then immersed in lithium carbonate for 5 seconds 
followed by a 1-5 minute immersion in eosin.  Following a brief immersion in water 
and then 3x 1 minute washes in 100% ethanol the tissue was cleared in 3x 5 minute 
incubations in xylene.  The slides were mounted in Histomount (Invitrogen) 
 
2.6.3  In-situ Hybridisation 
Slides containing paraffin wax embedded tissue sections were placed in baked 
Coplin jars and immersed sequentially in the following: xylene (2x 5 minutes), 100% 
ethanol (2x 5 minutes), 90% ethanol (1x 5 minutes), 70% ethanol (1x 5 minutes), 
0.2M HCl (1x 20 minutes), ddH20 (2x 5 minutes), proteinase K solution (1x 25 
minutes [2µg/ml proteinase K, 100mM Tris-HCl pH8, 50mM EDTA]), 0.2% (w/v) 
glycine precooled to 4oC (1x 10 minutes), 0.1M triethanolamine-HCl (TEA) pH8 (1x 
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5 minutes), 0.1M TEA containing 0.004% (v/v) acetic anhydride (1x 10 minutes), 5x 
SSC (1x 15 minutes [750mM NaCl, 75mM sodium citrate, pH7]).  The slides were 
then removed from the coplin jars and excess liquid removed.  Prehybridisation 
buffer (50% [v/v] formamide, 3x SSC, 1x Denhardts solution) was then applied 
followed by coverslips and the slides were incubated for 2 hours at 50oC in a 
humidified oven (100x Denhardts = 2% [w/v] Ficoll 400 [Pharmacia], 2% [w/v] 
polyvinylpyrrolidone, 2% [w/v] BSA).  The hybridization mix (prehybridisation 
buffer containing 10% dextran sulphate, 100µg/ml yeast RNA [Ambion], 200µg/ml 
herring sperm DNA [Abcam]) was heated at 100oC for 10 minutes to denature, then 
cooled on ice for 10 minutes.  The digoxygenin labeled RNA probe was then added 
to the hybridization mix to a final concentration of 0.1-1ng/µl.  The mixture was then 
heated to 65oC and applied to the slides.  Coverslips were added and the slides 
returned to the humidified oven overnight.  The following day the slides were 
transferred to Coplin jars and incubated sequentially in the following: 2x SSC (1x 1 
minutes), 2x SSC (1x 15 minutes), RNase A wash solution (1x 30 minutes at 37oC 
[0.02mg/ml RNase A, 2x SSC]), 2x SSC (1x 15 minutes at 55oC), 1x SSC (1x 15 
minutes at 55oC), 0.1x SSC (1x 15 minutes at 55oC), buffer 1 (1x 5 minutes [100mM 
maleic acid pH7.4, 150mM NaCl]), 1x blocking solution (1x 30 minutes [buffer 1 
containing 1x Roche blocking solution, 0.04% v/v fetal calf serum]).  The anti-
digoxygenin antibody conjugated to alkaline phosphatase (Roche) was centrifuged at 
13,000 rpm for 5 minutes at 4oC then 1µl was added to 200µl of 1x blocking solution 
and applied to the slides for 1 hour at room temperature.  The slides were washed for 
2x 15 minutes in buffer 1 and then equilibrated in buffer 2 (100mM Tris-HCl pH9.5, 
0.1% v/v Tween-20, 0.5mg/ml levamisole) for 5 minutes.  The BCIP/NBT substrate 
solution (Vector Laboratories) was then prepared in buffer 2 as per manufacturer’s 
instructions and applied to the slides followed by a coverslip.  Following sufficient 
colour development the reaction was terminated by incubating the slides in tap water.  
The tissues were counterstained with Nuclear FastRed Counterstain (Vector 
Laboratories) as per manufacturer’s instructions and mounted in Histomount 




2.6.4  Immunohistochemistry 
The tissue sections were dewaxed and rehydrated as described in the in-situ 
hybridisation protocol.  Following rehydration the slides were incubated in blocking 
solution (3% [v/v] hydrogen peroxide in methanol).  Slides were sequentially washed 
in water then TBS and then incubated in blocking solution 2 (5% [v/v] goat serum, 
5% [w/v] BSA in TBS) for 1 hour.  After washing once in TBS the slides were 
treated with a Streptavidin-Biotin Blocking Kit (Vector Laboratories) as per 
manufacturer’s instructions.  The primary antibodies were diluted in blocking 
solution 2 (anti-PABP1: 1/10,000 and anti-PABP4: 1/500) and incubated overnight 
on the tissue at 4oC.  Slides were subsequently washed twice in TBS and incubated 
with biotin-conjugated secondary antibodies diluted in blocking solution 2 (anti-
mouse: 1/500, anti-rabbit: 1/500).  Slides were then washed twice in TBS, and 
incubated for 15 minutes with streptavidin conjugated to HRP (Vector Laboratories) 
which had been diluted 1/1000 in TBS.  The slides were washed twice in TBS.  The 
diaminobenzidinetrahydrochloride (DAB) was prepared using an ImmPACT DAB 
Kit (Vector Laboratories) and applied to the slides.  The reaction was terminated by 
washing in tap water.  The tissues were counterstained in haematoxylin for 1 minute 
followed by washing in water (1x 5 minutes), acid/alcohol (1x 5 seconds), water (1x 
5 minutes), Scott’s tap water (1x 30 seconds [20mM KHCO3, 81mM 
MgSO4.7H2O]), water (1x 5 minutes), 70% ethanol (1x 20 seconds), 95% ethanol 
(1x 20 seconds), 100% ethanol (2x 20 seconds), then xylene (2x 5 minutes).  The 




2.7 Cell Culture Techniques 
 
2.7.1  Cell Culture 
HeLa (human cervical carcinoma), 3T3 (mouse fibroblast), and L929 (mouse 
fibroblast) cells were maintained in 5% CO2 in Dulbecco’s minimal essential 
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medium (DMEM: Invitrogen) containing 10% fetal calf serum (FCS: Invitrogen) at 
37oC.  KK1 (transformed mouse granulosa) cells were grown in 5% CO2 in DMEM-
F12 media (Invitrogen) containing 10% fetal calf serum and supplemented with 
4mM L-glutamine (Invitrogen) at 37oC.  SK11 (transformed mouse Sertoli) cells 
were a kind gift from Dr Ian Adams (MRC Human Genetics Unit, Edinburgh).  Cell 
passaging was performed by washing the cells twice in PBS that had been pre-
warmed to 37oC and incubating with 10% trypsin in PBS for 2 minutes at 37oC.  
Cells were transferred to a 15ml centrifuge tube and pre-warmed media added.  The 
cells were then centrifuged at 1,200 rpm (290 rcf) and the media aspirated.  
Following resuspension in pre-warmed media the cells were added to flasks 
containing pre-warmed media.  To maintain stocks, cells were frozen down and 
stored in liquid nitrogen.  To prepare the cells for freezing the cells were passaged as 
above, but following centrifugation were resuspended in 1ml of freeze mix (0.7ml 
media, 0.2ml FCS, 0.1ml DMSO) and transferred to a suitable cryovial.  The 
cryovials were then wrapped in tissue, placed in a sealable plastic bag and moved to -
80oC storage.  The following day the cells were transferred to liquid nitrogen storage.  
 
2.7.2  DNA Transfection 
Cells were grown to 50-75% confluence and transfected with plasmid DNA using 
SuperFect transfection reagent (Qiagen) as per manufacturer’s instructions.  All 
transfections were undertaken using OPTIMEM media (Invitrogen). 
 
2.7.3  Fixing and Imaging of Cells 
For imaging cells were grown on 22mm x 22mm coverslips in 6-well plates.  To fix 
the cells the media was aspirated and 4% paraformaldehyde in PBS was added for 15 
minutes at room temperature on a rocker.  The paraformaldehyde solution was 
aspirated and replaced with ice cold methanol for 10 minutes at room temperature, 
again with rocking.  After a final wash in PBS the coverslips were dropped cell-side 
down onto droplets of Vectashield with DAPI (Vector Laboratories) on glass slides 
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to counterstain the cell nuclei.  The coverslips were sealed onto the slides with Pang 
Supersolution (Pang [UK] Ltd).  All fluorescent images were taken on a Coolsnap 
HQ CCD camera (Photometrics) on a Zeiss Axioplan II fluorescence microscope. 
 
2.8 Pulldown Assays 
 
2.8.1  Cap Chromatography 
T75 flasks of cells were scraped in cold PBS containing 2mM benzamidine then 
centrifuged at 1,200 rpm for 5 minutes at 4oC.  The cells were resuspended in 200µl 
of lysis buffer (20mM MOPS.KOH pH7.2, 25mM KCl, 2mM MgCl2, 2mM 
benzamidine, 2mM EGTA, 0.1mM GTP, 0.5mM DTT, 10% [v/v] glycerol, protease 
inhibitor cocktail tablets [Roche], 0.2% [v/v] IgePal [Rhodia Inc.], 0.4% [w/v] 
sodium deoxycholate) per T75 flask and incubated on ice for 20 minutes.  The 
lysates were cleared by centrifugation at 13,000 rpm for 5 minutes at 4oC and 
quantified by Bradford assay.  30µl of m7G-sepharose (Amersham) bead slurry per 
point was washed twice in buffer 1 (20mM MOPS.KOH pH7.2, 20mM KCl, 2mM 
benzamidine, 7mM β-mercaptoethanol, 1mM magnesium acetate, 0.1mM GTP, 
0.25% IgePal, protease inhibitor cocktail tablets) and 120µg of cell lysate was added.  
The volume was made up to approximately 250µl with buffer 1, and the beads were 
incubated on ice for 10 minutes with occasional gentle agitation.  Following the 
incubation the beads were washed 2 times in buffer 1 and the factors were eluted in 
25µl of protein loading buffer. 
 
2.8.2  eIF4G-PABP Pulldowns 
ANTI-FLAG M2 Affinity Resin (Sigma-Aldrich) was washed two times in binding 
buffer (50mM Tris-HCl pH7.5, 150mM NaCl, 1mM DTT, 0.5% [v/v] IgePal).  30µl 
resin slurry was used per point.  The beads were incubated for 5 minutes in 1µg/µl 
BSA then washed a further two times in binding buffer.  200ng of the purified 
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recombinant FLAG-tagged eIF4G proteins were added to the resin along with 100µl 
of BL21 E. coli lysate containing the recombinant PABP proteins.  The mixture was 
then incubated on a coldroom turnwheel for 3 hours then washed six times in binding 
buffer.  The proteins were eluted in protein loading buffer. 
 
2.8.3  PAIP-PABP Pulldowns 
To bind GST-tagged PAIP proteins to glutathione sepharose 4B beads (GE 
Healthcare), 1ml of BL21 E. coli lysate induced to express GST, GST-PAIP-1 or 
GST-PAIP-2 was added to 300µl of bead slurry which had been washed two times in 
binding buffer (50mM Tris-HCl pH7.5, 100mM NaCl, 0.1% IgePal, protease 
inhibitor cocktail tablets).  The mixture was incubated on a coldroom turnwheel for 
3-4 hours.  The beads were then washed five times in binding buffer, and could be 
stored at 4oC in binding buffer containing 33% (v/v) glycerol.  The amount of each 
GST protein bound per µl of beads was quantified as described in section 2.5.3.  For 
the pulldown assay, beads containing equal quantities of the GST proteins were 
washed once in binding buffer, and 100µl of BL21 E. coli lysate induced to express 
PABP1 or PABP5 was added.  The mixture was incubated on a coldroom turnwheel 
for 3 hours and then the beads were washed five times in wash buffer (50mM Tris-
HCl pH7.5, 150mM NaCl, 0.1% [v/v] IgePal).  The proteins were eluted in protein 
loading buffer.    
 
2.9 Xenopus laevis Oocyte Techniques 
 
2.9.1  Oocyte Preparation 
Oocytes were collected from female Xenopus laevis frogs that were euthanised in 
250ml water containing 4g 4-aminobenzoic acid for 20 minutes.  The frogs were 
tested for their inability to 'right' themselves before delivering an intracardiac 
injection of 0.4ml euthatal.  The neck was then dislocated and the heart removed.  
79 
 
The lobes containing oocytes were removed and bathed in 3 washes of 1x MMR 
(100mM NaCl, 2mM KCl, 5mM HEPES, 1mM MgCl2, 2mM CaCl2, 0.1% 
pen/strep).  The lobes containing the oocytes were then gently torn open and 
incubated for 1 ½ hours in 5mg/ml collagenase B (Roche) on a turnwheel, then 
washed 6 times in 1x MMR. 
 
2.9.2  Oocyte Microinjection 
All microinjections were undertaken using a Harvard Apparatus (USA) 
Microinjector and a Narishige (Japan) Micromanipulator.  Oocytes were viewed 
under a Leica MZ6 dissecting microscope.  All microinjections were undertaken on 
stage VI oocytes which were sorted based on size and appearance, and 25 were 
injected per experimental point.  The injection site was always the oocyte midline to 
avoid the nucleus, and each injection delivered approximately 50nl of RNA to the 
oocyte.   
 
2.9.3  Tethered Function Assay 
Oocytes were first injected with RNA encoding the MS2-fusion protein at a 
concentration of 1μg/μl.  Following injection the oocytes were incubated at 18oC for 
6 hours before injection with reporter RNAs.  Luciferase and β-galactosidase 
reporters were injected at 15ng/μl and 30ng/μl respectively.  The oocytes were 
subsequently incubated overnight at 18oC before assaying for luciferase and β-
galactosidase.  Prior to assaying any necrotic oocytes were discarded and the 
remaining oocytes were sorted into groups of 5.  The MMR was removed and the 
oocytes were mechanically homogenised in 40μl lysis buffer (Tropix) per oocyte 
with a pestle.  For the luciferase assay 5μl of oocyte extract was mixed with 100μl of 
Luciferase Assay Reagent (Promega) and the luciferase activity was measured using 
a Monolight 3010 Luminometer (Pharmingen).  For the β-galactosidase assay, 2.5μl 
oocyte extract was added to 100μl of a 1/100 dilution of Galacton-Plus (Tropix) in 
Galacto Reaction Buffer Dilutent (Tropix).  The samples were incubated at room 
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temperature in the dark for 1 hour before mixing in 100μl of Accelerator II Reaction 
Substrate (Tropix) and measuring β-galactosidase activity on the luminometer. 
 
2.9.4  Radiolabelling of Oocytes 
Injected oocytes were directly labelled by incubation in 1x MMR containing 5μl/ml 
of [35S]-methionine (10μCi/ul - MP Biomedical UK) for 6 hours at 18oC.  Oocytes 
were lysed in 1x TE containing protease inhibitor cocktail tablets (Roche) with a 
pestle.  Lysates were centrifuged at 13,000 rpm in a bench top centrifuge for 10 
mins.  The supernatant was removed to a fresh tube and respun for a further 10 mins.  
15μl of the supernatant was mixed with  5μl 4x NuPAGE LDS sample buffer 
(Invitrogen) and heated at 75oC for 10 mins before running on a NuPAGE Novex 4-
12% Bis-Tris gel (Invitrogen).  The gel was fixed in 3x 10 minute washes of fix 
solution (40% methanol, 10% acetic acid) followed by incubation in Enlightening 
solution (Perkin-Elmer) + 5% glycerol for 30 mins.  The gel was then dried for 2 
hours at 80oC in a BioRad 583 Gel Drier.  The gel was then exposed to Kodak 
BioMax MR film overnight. 
 
2.9.5  Oocyte RNA Extraction 
Groups of 10 oocytes were mechanically homogenised in 100μl Tri-Reagent using a 
pestle.  Following homogenisation, the volume of the extract was increased by the 
addition of a further 300μl of Tri-Reagent.  The lysates were centrifuged at 13,000 
rpm in a bench top centrifuge for 10 mins at 4oC and the supernatents were collected.  
100μl of chloroform was added to each sample and vortexed for 15 seconds.  The 
samples were then centrifuged at 13,000 rpm for 15 mins at 4oC, the upper phase was 
collected, and the RNA precipitated by the addition of 250μl of isopropanol at room 
temperature followed by centrifugation at 13,000 rpm for 10 mins at 4oC.  The 




2.9.6  QPCR RNA Stability Assay 
Oocytes were injected as for the tether function assay and harvested at T=0 
(immediately after injection of reporter RNAs) and T=16 (16 hours after injection of 
reporter RNAs).  cDNA was prepared from the oocytes as above and QPCR analysis 
was performed using an ABI 7500 Fast Real-Time PCR System (Applied 
Biosystems) and measuring SYBR green incorporation with primers 5'-
GGCGCGGTCGGTAAAGTT-3' and 5'-AGCGTTTTCCCGGTATCCA-3' for 
luciferase.  The reaction mix was set up on ice with the following components; 
0.5μM sense primer, 0.5μM antisense primer, 1x PowerSybr Mix (Applied 
Biosystems), cDNA 1μl.  Data was presented as Ct scores, representing levels of 
luciferase RNA in the oocytes at time of harvesting. 
 
2.10 Miscellaneous Methods  
 
2.10.1  Cell-Free Translation Extracts 
The cell-free HeLa translation extracts were a kind gift from Christian Thoma 
(University Hospital of Freiberg, Germany).  The extracts had been prepared as 
previously described (Thoma et al., 2004).   
 
2.10.2  Programming the Cell-Free HeLa Extracts with mRNA 
To prepare the cell-free translation extracts for programming with luciferase reporter 
mRNAs 4µl of extract per experimental point was initially centrifuged at 4000 rcf  
for 1 minute and then added to 6µl of reaction mix (0.06mM complete amino acid 
mix [Promega], 0.8mM ATP, 0.1mM GTP, 16mM HEPES pH7.6, 8U RNasin, 
20mM creatine phosphate, 40µg/ml creatine kinase, 0.05mM spermidine, 2.5mM 
magnesium acetate, 40mM potassium acetate, 0-100ng reporter mRNA).  The 
creatine kinase was reconstituted immediately prior to addition into the reaction mix.  
Additionally, once combined the reaction components were gently stirred rather than 
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vigorously pipetted to mix.  The reaction was then incubated for 30 minutes at 37oC 
before being assayed in a luminometer using the same protocol as for oocytes in the 
tethered function assay (see section 2.9.3)   
 
2.10.3  Micrococcal Nuclease Treatment of Extracts 
The cell-free extracts were treated with micrococcal nuclease (0.01U per µl extract) 
and 1mM calcium acetate for 6 minutes at 26oC.  The reaction was terminated by 
addition of EGTA to a final concentration of 2mM. 
 
2.10.4  PABP Depletions from Cell-Free HeLa Extracts 
GST and GST-PAIP-2 proteins were expressed in BL21 E. coli cells as described in 
section 2.5.1, and then lysed as described in section 2.5.2.  300µl of glutathione 
sepharose 4B bead slurry was washed three times in cold PBS and resuspended in 
300µl HeLa cell extract then incubated on a coldroom turnwheel for 1 hour.  The 
beads were then washed three times in cold PBS and resuspended in an equal volume 
of PBS to make a 50% slurry.  Half of the slurry was added to BL21 E. coli lysate 
containing recombinant GST and half was added to lysate containing recombinant 
GST-PAIP-2.  The mixture was incubated on a coldroom turnwheel for 3 hours 
before washing the beads three times in chilled buffer D (25mM HEPES.KOH 
pH7.3, 50mM KCl, 75mM potassium acetate, 2mM MgCl2).  As much buffer D was 
removed as possible following the final wash.  Micrococcal nuclease treated extracts 
(see section 2.10.3) were added to the beads (approximately 3:1 ratio of extract to 
beads) and incubated on a coldroom turnwheel for 2 hours.  The beads were then 
centrifuged at 6,000 rpm (3427 rcf) for 2 minutes at 4oC and the extract was 
removed.  The whole protocol was repeated so the final extract had been subjected to 
two rounds of depletion.  The extract was then Western blotted for the presence of 




2.10.5  Sucrose Gradient Fractionation 
Pouring the Gradients  
20-50% sucrose gradients were poured (20-50% sucrose dissolved in 15mM MgCl2, 
15mM Tris-HCl pH7.4, 300mM NaCl) using a dual chamber manual gradient pourer 
attached to a peristaltic pump.  Following the pouring the gradients were balanced 
and left overnight at 4oC to settle. 
 
Cell Preparation 
T75 flasks of cells (75-90% confluence) were treated with either 0.1mg/ml 
cycloheximide made up in ethanol for 7 minutes at 37oC or 0.1mg/ml puromycin for 
40 minutes at 37oC.  Following treatment the cells were removed to a coldroom and 
placed on a tray of ice, then washed twice in PBS containing 0.1mg/ml 
cycloheximide or puromycin.  Cells were then lysed in 1ml lysis buffer (1% [v/v] 
triton-X-100 [Sigma-Aldrich], 15mM MgCl2, 15mM Tris-HCl pH7.4, 300mM NaCl, 
0.1mg/ml cycloheximide or puromycin, 100U RNasin) and scraped into centrifuge 
tubes.  200µg/ml heparin was added to the lysate followed by incubation on ice for 
10 minutes.  The lysates were cleared by centrifugation at 13,000 rpm for 5 minutes 
at 4oC.  The lysates were then carefully layered onto the surface of the sucrose 
gradients and centrifuged for 90 minutes at 39000 rpm at 4oC in a Sorval TH-641 
rotor.   
 
Fraction Collection 
The gradients were fractionated using a Superfrac fraction collector (Pharmacia) with 
the following settings: 10mV range, 0 zero suppression, 39 second fraction collect.  
The absorbance of RNA was measured at 254nm using an in-line UV monitor 
(Pharmacia) to allow identification of fractions containing mRNPs, 80S monosomes 
and polysomes.  The proteins in each fraction were TCA precipitated and subjected 
to Western blotting.      
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2.10.6  Electrophoretic Mobility Shift Assay 
The native protein gel was poured (1xTBE, 5% [v/v] acrylamide/bisacrylamide 
[60:1], 4.4mM APS, 6.7mM TEMED) between glass gel pouring plates (15cm by 
20cm) using 1.5mm spacers) and allowed to set.  The oligonucleotides 
AAAAAAAAAAAAAAAAAAAAAAAAA and AUUUAUUUAUUUAUUUAUU 
UAUUUA utilised in this assay were 5’-labelled with Cy5 (Eurogentec).  The 
reaction mixture was prepared on ice (10 or 20pmol labelled oligonucleotide, 10mM 
HEPES pH7.6, 5% [v/v] glycerol, 0.02% [v/v] NP40, 1mM DTT, 140mM KCl, 3mM 
MgCl2, 5µg/µl heparin, 40U RNasin, purified recombinant protein) and incubated on 
ice for 30 minutes.  Protein loading buffer was then added and the mixture was 
electrophoresed at a constant 100V at 4oC for 5-6 hours.  Following electrophoresis 
the gel was removed from the glass plates and washed for 5 minutes in ddH2O, then 




All oligonucleotides (oligos) were purchased from Eurogentec unless otherwise 
stated. 
 
2.11.1  IMAGE clones 
IMAGE clone 6816124 (accession number: BC046233) was ordered from 
Geneservice and contains the full length Mus musculus (mouse) Pabp1 open reading 
frame (ORF). 
 
IMAGE clone 40056131 (accession number: BC107362) was ordered from 
Geneservice and contains the full length mouse Pabp5 ORF. 
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IMAGE clone 6452933 (accession number: BC063113) was ordered from 
Geneservice and contains the full length Homo sapiens (human) PABP5 ORF. 
 
2.11.2  Mutagenesis plasmids 
pYXAsc-MmPab1(RRM2mut) was created by two rounds of PCR based site directed 
mutagenesis (see figure 4.17) of IMAGE clone 6816124 to introduce two silent 
restriction sites straddling RRM2.  A BstB1 restriction site was introduced using 
oligos 5'-CGTGATCCATCACTTCGAAAAAGTGGAGTAGGCAA-3' and 5'-
TTGCCTACTCCACTTTTTCGAAGTGATGGATCACG-3'.  An Xma1 restriction 
site was then introduced using oligos 5'-CAGAGCTTGGAGCCCGGG 
CAAAGGAGTTC-3' and 5'-GAACTCCTTTGCCCGGGCTCCAAGCTCTG-3'.  
RRM2 was excised from the plasmid with BstB1 and Xma1 and replaced by the 
BstB1 and Xma1 cut RRM2 from  pCRBluntII-MmPab5(RRM2mut). 
 
pCRBluntII-MmPab5(RRM2mut) was created by two rounds of PCR based site 
directed mutagenesis (see figure 4.17) of IMAGE clone 40056131 to introduce two 
silent restriction sites straddling RRM2.  A BstB1 restriction site was introduced 
using oligos 5'-TGGTCACAGCCAGATGACCGTCTTCGAAAGTCTGGAGTTG 
GAAATA-3' and 5'-TATTTCCAACTCCAGACTTTCGAAGACGGTCATCTG 
GCTGTGACCA-3'.  An Xma1 restriction site was then introduced using oligos 5'-
AGCAGCAGAAGTCAGAACCCGGGAAAGAGCAACATTTACCA -3' and 5'-
TGGTAAATGTTGCTCTTTCCCGGGTTCTGACTTCTGCTGCT -3'.  RRM2 was 
excised from the plasmid with BstB1 and Xma1 and replaced by the BstB1 and 
Xma1 cut RRM2 from  pYXAsc-MmPab1(RRM2mut). 
 
pYXAsc-MmPab1(M161V) was created by PCR based site directed mutagenesis 
(see figure 4.17) of IMAGE clone 6816124 to introduce a single point mutation into 
RRM2 of mouse Pabp1 using oligos 5'-CACTTTACGATCATTTAGAA 
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GCACCCCATTCATTTTTTCAATAG -3' and 5'-GAGCTATTGAAAAAATGAAT 
GGGGTGCTTCTAAATGATCGTAAAGTG-3'.   
 
pCRBluntII-MmPab5(V167M) was created by PCR based site directed mutagenesis 
(see figure 4.17) of IMAGE clone 40056131 to introduce a single point mutation into 
RRM2 of mouse Pabp5 using oligos 5'-GGGCTATCTGGCACATGAAT 
GGAATGCGGCTCAATA-3' and 5'-TATTGAGCCGCATTCCATTCATGTGCC 
AGATAGCCC-3'.   
 
2.11.3  Tethered function plasmids 
pMSPN was supplied by Dr Nicola Gray (MRC Human Reproductive Sciences Unit, 
Edinburgh).  An oligo (5'-GATCGGATCCAATTGACTAGT-3') was inserted into 
the BamHI site in pET-MS2 (described in Coller et al., 1998). 
 
pMSPN-U1A has been previously described (Gray et al., 2000). 
 
pMSPN-HsPab5 was created by PCR generation of a fragment containing the full 
length ORF of human PABP5 using oligos 5'-CAGTCAGCTAGCAT 
GGGGAGCGGGGAGCCTAATCCT-3' and 5'-CAGTCAACTAGTTCAGCACCT 
GCGCCTGGCCTG-3' using IMAGE clone 6452933 as a template.  The PCR 
product was cut with Nhe1 and Spe1 and ligated into pMSPN which was linearised 
with Nhe1 and Spe1. 
 
pMSPN-MmPab5 was created by PCR generation of a fragment containing the full 
length ORF of mouse Pabp5 using oligos 5'-CAGTCAGCTAGCATGAG 
TGGGGAGCCTAATACTGCTGGC -3' and 5'-CAGTCAACTAGTTCACCACCT 
GTGCCTAGCTTGCCC -3' using IMAGE clone 40056131 as a template.  The PCR 
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product was cut with Nhe1 and Spe1 and ligated into pMSPN which was linearised 
with Nhe1 and Spe1. 
 
pMSPN-hPABP1 was supplied by Dr Barbara Gorgoni (MRC Human Reproductive 
Sciences Unit, Edinburgh).  The full length human PABP1 ORF was cloned into the 
Mfe1 and Spe1 sites in pMSPN. 
 
pMSPN-xPABP has been previously described (Gray et al., 2000). 
 
pMSPN-MmPab1 was created by PCR generation of a fragment containing the full 
length ORF of mouse Pabp1 using oligos 5'-CAGTCAGCTAGCATGAACC 
CCAGCGCCCCC -3' and 5'-CAGTCAGGATCCTTAGACAGTTGGAACACC 
AGTGGC -3' using IMAGE clone 6816124 as a template.  The PCR product was cut 
with Nhe1 and BamH1 and ligated into pMSPN which was linearised with Nhe1 and 
BamH1. 
 
pMSPN-MmPab1(1-4) was created by PCR generation of a fragment containing 
RNA recognition motifs (RRMs) 1 - 4 of mouse Pabp1 using oligos 5'-CAGTC 
AGCTAGCATGAACCCCAGCGCCCCC -3' and 5'-CAGTCAGGATCCTCAGCG 
CTCTTCTTTGCGCTGAGC -3' using IMAGE clone 6816124 as a template.  The 
PCR product was cut with Nhe1 and BamH1 and ligated into pMSPN which was 
linearised with Nhe1 and BamH1. 
 




pMSPN-MmPab1(RRM2mut) was created by PCR generation of a fragment 
containing the ORF of mouse Pabp1 with RRM2 of mouse Pabp5 using oligos 5'-
CAGTCAGCTAGCATGAACCCCAGCGCCCCC -3' and 5'-CAGTCAGGATCC 
TTAGACAGTTGGAACACCAGTGGC -3' using pYXAsc-MmPab1(RRM2mut) as 
a template.  The PCR product was cut with Nhe1 and BamH1 and ligated into 
pMSPN which was linearised with Nhe1 and BamH1. 
 
pMSPN-MmPab5(RRM2mut) was created by PCR generation of a fragment 
containing the ORF of mouse Pabp5 with RRM2 of mouse Pabp1 using oligos 5'- 
CAGTCAGCTAGCATGAGTGGGGAGCCTAATACTGCTGGC -3' and 5'- 
CAGTCAACTAGTTCACCACCTGTGCCTAGCTTGCCC -3' using pCRBluntII-
MmPab5(RRM2mut) as a template.  The PCR product was cut with Nhe1 and 
BamH1 and ligated into pMSPN which was linearised with Nhe1 and BamH1. 
 
pMSPN-MmPab1(M161V) was created by PCR generation of a fragment containing 
the ORF of mouse Pabp1 with a single point mutation in RRM2 using oligos 5'-
CAGTCAGCTAGCATGAACCCCAGCGCCCCC -3' and 5'-CAGTCAGGATCC 
TTAGACAGTTGGAACACCAGTGGC -3' using pYXAsc-MmPab1(M161V) as a 
template.  The PCR product was cut with Nhe1 and BamH1 and ligated into pMSPN 
which was linearised with Nhe1 and BamH1. 
 
pMSPN-MmPab5(V167M) was created by PCR generation of a fragment containing 
the ORF of mouse Pabp5 with a single point mutation in RRM2 using oligos 5'- 
CAGTCAGCTAGCATGAGTGGGGAGCCTAATACTGCTGGC -3' and 5'- 
CAGTCAACTAGTTCACCACCTGTGCCTAGCTTGCCC -3' using pCRBluntII-
MmPab5(V167M) as a template.  The PCR product was cut with Nhe1 and BamH1 




pLG-MS2 has been previously described (Gray et al., 2000). 
 
pJK-350 has been previously described (Evans et al., 1994). 
 
2.11.4  Yeast 2-hybrid plasmids 
pBTM was created by Dr David Bernstein.  A kanamycin resistance cassette was 
inserted into the ampillicin gene of pBTM116 by transposition.  
 
pBTM-HsPab5 was created by PCR generation of a fragment containing the ORF of 
human PABP5 using oligos 5'-CAGTCAGAATTCATGGGGAGCGGGGA 
GCCTAATCC-3' and 5'-CAGTCAGGATCCTCAGCACCTGCGCCTGGCCT 
GGCC-3' using pMSPN-HsPab5 as a template.  The PCR product was cut with 
EcoR1 and BamH1 and ligated into pBTM which was linearised with EcoR1 and 
BamH1. 
   
pBTM-MmPab5 was created by PCR generation of a fragment containing the ORF 
of mouse Pabp5 using oligos 5'-CAGTCAGAATTCATGAGTGGGGAGCCT 
AATACT -3' and 5'-CAGTCAGGATCCTCACCACCTGTGCCTAGC -3' using 
pMSPN-MmPab5 as a template.  The PCR product was cut with EcoR1 and BamH1 
and ligated into pBTM which was linearised with EcoR1 and BamH1. 
 
pBTM-MmPab1(1-4) was created by PCR generation of a fragment containing RNA 
recognition motifs (RRMs) 1 - 4 of mouse Pabp1 using oligos 5'-
CAGTCAGAATTCATGAACCCCAGCGCCCCC -3' and 5'-CAGTCAGGATCCT 
CAGCGCTCTTCTTTGCGCTGAGC -3' using IMAGE clone 6816124 as a 
template.  The PCR product was cut with EcoR1 and BamH1 and ligated into pBTM 
which was linearised with EcoR1 and BamH1. 
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pBTM-xPAB1-2 has been previously described (Gray et al., 2000). 
 
pGAD-eIF1A, pGAD-eIF1, pGAD-eIF2α, pGAD-eIF2β, pGAD-eIF3S1, pGAD-
eIF3S2, pGAD-eIF3S3, pGAD-eIF3S4, pGAD-eIF3S5, pGAD-eIF3S6, pGAD-
eIF3S7, pGAD-eIF3S8, pGAD-eIF4AII, pGAD-eIF4H, pACTII-eIF4B, pACT-
eIF4E, pGAD-eIF5, pGAD-eIF5A, and pACT-eIF5B were cloned within the 
laboratory of Dr Nicola K. Gray (MRC Human Reproductive Sciences Unit, 
Edinburgh) by Dr Barbara Gorgoni, Dr Gavin Wilkie, William Richardson and Dr 
Nicola K. Gray.   
 
pACT-IRP has been previously described (SenGupta et al., 1996). 
 
pACT-hPaip1 has been previously described (Gorgoni et al., 2005). 
 
pACT2-hPaip2 was created by PCR generation of a fragment containing the ORF of 
human Paip2 using oligos 5'- CAGTCACCATGGCTATGAAAGATCCAAGTC 
GCAGC-3' and 5'- CAGTCAGGATCCTCAAATATTTCCGTACTTCACCCC-3' 
using pGEX6P1-HsPaip2 as a template.  The PCR product was cut with Nco1 and 
BamH1 and ligated into pACT2 which was linearised with Nco1 and BamH1.  
 
pACT-4GNT has been previously described (Gray et al., 2000). 
pBTM-MmPab1(RRM2mut) was created by PCR generation of a fragment 
containing the ORF of mouse Pabp1 with RRM2 of mouse Pabp5 using oligos 5'-
CAGTCAGAATTCATGAACCCCAGCGCCCCC -3' and 5'-CAGTCAGGATC 
CTTAGACAGTTGGAACACCAGTGGC-3' using pYXAsc-MmPab1(RRM2mut) 
as a template.  The PCR product was cut with EcoR1 and BamH1 and ligated into 
pBTM which was linearised with EcoR1 and BamH1. 
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pBTM-MmPab5(RRM2mut) was created by PCR generation of a fragment 
containing the ORF of mouse Pabp5 with RRM2 of mouse Pabp1 using oligos 5'- 
CAGTCAGAATTCATGAGTGGGGAGCCTAATACT -3' and 5'- CAGTCAGGAT 
CCTCACCACCTGTGCCTAGC -3' using pCRBluntII-MmPab5(RRM2mut) as a 
template.  The PCR product was cut with EcoR1 and BamH1 and ligated into pBTM 
which was linearised with EcoR1 and BamH1. 
 
pBTM-MmPab1(M161V) was created by PCR generation of a fragment containing 
the ORF of mouse Pabp1 with a single point mutation in RRM2 using oligos 5'- 
CAGTCAGAATTCATGAACCCCAGCGCCCCC -3' and 5'- CAGTCAGGAT 
CCTTAGACAGTTGGAACACCAGTGGC -3' using pYXAsc-MmPab1(M161V) as 
a template.  The PCR product was cut with EcoR1 and BamH1 and ligated into 
pBTM which was linearised with EcoR1 and BamH1. 
 
pBTM-MmPab5(V167M) was created by PCR generation of a fragment           
containing the ORF of mouse Pabp5 with a single point mutation in RRM2            
using oligos 5'- CAGTCAGAATTCATGAGTGGGGAGCCTAATACT -3'                 
and 5'- CAGTCAGGATCCTCACCACCTGTGCCTAGC -3' using pCRBluntII-
MmPab5(V167M) as a template.  The PCR product was cut with EcoR1 and BamH1 
and ligated into pBTM which was linearised with EcoR1 and BamH1. 
 
2.11.5  Other plasmids 
pCGN has been previously described (Tanaka and Herr, 1990). 
 
pCGN-MmPab1 was created by PCR generation of a fragment containing the full 
length ORF of mouse Pabp1 using oligos 5'-CAGTCATCTAGAATGAAC 
CCCAGCGCCCCCAGCTAC -3' and 5'-CAGTCAGGATCCTTAGACAGTTGG 
AACACCAGTGGCACTG -3' using pMSPN-MmPab1 as a template.  The PCR 
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product was cut with Xba1 and BamH1 and ligated into pCGN which was linearised 
with Xba1 and BamH1. 
 
pCGN-MmPab5 was created by PCR generation of a fragment containing the full 
length ORF of mouse Pabp5 using oligos 5'-CAGTCATCTAGAATGAGTG 
GGGAGCCTAATACTGCTGGC -3' and 5'-CAGTCAGGATCCTCACCACCTGT 
GCCTAGCTTGC -3' using pMSPN-MmPab5 as a template.  The PCR product was 
cut with Xba1 and BamH1 and ligated into pCGN which was linearised with Xba1 
and BamH1. 
 
pCGN-SF2 was a kind gift from Dr J. Long. 
 
pEGFP-MmPab1 was created by PCR generation of a fragment containing the full 
length ORF of mouse Pabp1 using oligos 5'-CAGTCAGTCGACATGAAC 
CCCAGCGCCCCCAGCTAC -3' and 5'-CAGTCAGGATCCTTAGACAGTTGGA 
ACACCAGTGGCACTG -3' using pMSPN-MmPab1 as a template.  The PCR 
product was cut with Sal1 and BamH1 and ligated into pEGFP-C1 (Clontech) which 
was linearised with Sal1 and BamH1. 
 
pEGFP-MmPab5 was created by PCR generation of a fragment containing the full 
length ORF of mouse Pabp5 using oligos 5'-CAGTCAGTCGACATGAGT 
GGGGAGCCTAATACTGCTGGC -3' and 5'- CAGTCAGGATCCTCACCACCT 
GTGCCTAGCTTGC -3' using pMSPN-MmPab5 as a template.  The PCR product 
was cut with Sal1 and BamH1 and ligated into pEGFP-C1 (Clontech) which was 
linearised with Sal1 and BamH1. 
 
pGEX6P1-HsPAIP-1 was a kind gift from Dr Barbara Gorgoni. 
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pGEX6P1-HsPAIP-2 was a kind gift from Dr Barbara Gorgoni. 
 
pGEM-MmPab1(ISH) contained sequence derived from the 3’-UTR of mouse Pab1.  
The vector was linearised and used as a template for the in-vitro transcription of 
Pabp1 in-situ hybridisation probes.  The construct was a kind gift from Dr Matthew 
Brook. 
 
pGEM-MmPab5(ISH) was created by PCR generation of a fragment containing the 
5’-UTR of mouse Pabp5 using oligos 5’-CGGTCATCTGGCTGTGACCAC-3’ and 
5’-GCGGCTGCCAGTCAGTCC-3’ using mouse brain cDNA as a template.  The 
PCR product was cloned into pGEM-T-easy (as per manufacturer’s instructions) via 
A-overhangs incorporated by the PCR enzyme.  The vector was linearised and used 
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3.1  Introduction and Aims 
Human poly(A)-binding protein 5 (PABP5) was originally identified during an exon 
trapping study.  Subsequent RACE analysis using a fetal brain cDNA library yielded 
an extension product that matched a testis GenBank cDNA clone, as well as brain 
and fetal testis ESTs.  A theoretical mRNA was compiled from available EST and 
RACE data that contained a polyadenylation signal in good context and a 
polyadenylate tail (Blanco et al., 2001) implying that it is an expressed gene.   
Subsequent RT-PCR analysis by Blanco et al. using a human cDNA panel showed 
expression in various compartments of human brain and also within the ovary.  The 
EST information available for human PABP5 partially overlaps with this data, with 6 
out of the 16 existing ESTs being derived from human brain cDNA libraries. While 
this preliminary expression is available for humans, the expression of PABP5 in 
mouse is completely unknown and EST data is not available.   
 
Other murine poly(A)-binding proteins display distinct yet overlapping RNA and 
protein tissue expression patterns.  Western blotting data has shown both mouse 
PABP1 and PABP4 to have wide-ranging yet distinct expression patterns (Hannah 
Burgess, unpublished) with PABP1 expression highest in ovary and testis, and 
PABP4 showing robust expression within the heart.  Interestingly, some tissues such 
as liver express both proteins, and unexpectedly tissues such as kidney appear to 
express neither.  tPABP and ePABP have more limited expression patterns with 
tPABP being restricted to the pachytene spermatocytes and round spermatids of the 
testis (Kimura et al., 2009), and ePABP, the predominant PABP protein prior to the 
onset of zygotic transcription during early development, is restricted to germ cells 
within adult ovary and testis (Seli et al., 2005; Wilkie et al., 2005).  
 
In this chapter I examine the expression of PABP5, primarily in mouse tissues, and 
compare the cellular distribution of PABP5 with that of PABP1 and PABP4 in the 
mouse gonads, as these tissues express multiple PABP proteins.  
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3.2  In-silico Analysis of the PABP5 Gene 
The human PABP5 gene codes for a putative 383 amino acid protein of predicted 
molecular weight 43.3kDa.  The PABP5 gene contains only two exons with an 
uninterrupted ORF suggesting it arose via a retroposition event like tPABP (Kleene 
et al., 1998). Although PABP5 is considered to be a PABP family member based on 
phylogeny (Gorgoni and Gray, 2004; Mangus et al., 2003) the dN/dS ratio of PABP5 
was calculated (see figure 3.1). dN is the non-synonymous nucleotide substitution 
rate and dS is the synonymous rate, therefore dN/dS is a measure of the history of 
selection for change in the gene, with low values indicating a selective pressure to 
maintain the gene sequence.  The dN/dS ratio for the human PABP5 gene versus 
mouse PABP5 is 0.043.  The 30 genes immediately adjacent to PABP5 were also 
analysed with the average calculated to be 0.18, which is slightly higher than the 
genome average (0.17).  The average ratio for all genes on the X-chromosome is 
0.41, implying that PABP5 has been under strong selective constraint in contrast to 
other genes on the X-chromosome.  Upon plotting the distribution of dN/dS ratios in 
a histogram across the entire genome and the X-chromosome, PABP5 falls into the 
top 20% of genes under the strongest conservative pressure (see figure 3.1). 
 
 
Figure 3.1  dN/dS ratios for the PABP5 gene.  A.  dN/dS ratio distribution - human vs. 
mouse genome.  B.  dN/dS ratio distribution - human vs. mouse X-chromosome genes.  Blue 
bar represents location of PABP5 within the distribution.  dN/dS ratios were calculated using 
MEGA2 – Molecular Evolutionary Genetic Analysis Software, Version 2 (2001) by Philippe 




Another useful measure of functionality is the conservation of promoter sequences.  
Distal enhancer, silencer and insulator sequences can be located from 10-50kb 
upstream or downstream of the transcription start site, but eukaryotic core promoter 
elements and any associated binding sites for proximal regulatory factors tend to be 
located within a few hundred base pairs of the transcriptional start site (Levine and 
Tjian, 2003).  The promoter sequences for PABP5 have yet to be established, but 
high conservation within the region immediately upstream of the gene could suggest 
a conservative selective pressure.  A percentage identity plot (PIP) was generated to 
assess whether potential upstream promoter sequences were conserved across 
mammalian species as an indicator of functionality (see figure 3.2).  The baseline 
was set as human, with range of 50%-100% for the plot.  The PIP shows that while 
the conservation is not particularly striking, the 1-2kb immediately upstream and 4-
5kb downstream are relatively well conserved suggesting a selective pressure to 
maintain the sequence.  These data support the assignment of PABP5 as a functional 
PABP family member.   
 
 
Figure 3.2  Percentage identity plot of the PABP5 gene.  The human PABP5 gene was 
set as the baseline with a 50%-100% range.  Colour code: red=coding, light orange=UTR’s, 
light yellow=intron.  Analysis was undertaken with GeneDoc version 2.0.1 (1997) by Philippe 





3.3  Expression Analysis of Human PABP5 mRNA 
Most expression analysis of the mammalian poly(A)-binding proteins to date has 
been undertaken at the level of RNA, due to the high sequence homology at the 
protein level making it difficult to generate specific antibodies.  RT-PCR analysis of 
PABP5 mRNA expression has only been undertaken on a limited panel of human 
tissues (Blanco et al., 2001).  To expand our knowledge of PABP5 expression in 
humans, quantitative PCR (qPCR) using a FAM labelled Taqman primer/probe set 
specific for PABP5 (Applied Biosystems) was undertaken on an Origene Human 
TissueScan Array (see figure 3.3),   prepared from 48 human tissues.  The cDNA is 
pre-normalised to β-actin by first northern blotting the mRNA preparations with 
probes specific for β-actin and adjusting the amount of mRNA added to each reverse-
transcription reaction accordingly.  This method of normalisation does not take into 
account the efficiency of individual reverse-transcriptase reactions.  Following the 
qPCR reaction the tissues were ranked based on the 2(-ΔΔCt) method.  The brain 
ranked 3rd highest for PABP5 expression, correlating with previous data (Blanco et 
al., 2001) but intriguingly the tissues ranked 1st, 2nd, and 4th for PABP5 expression 
were all tissues of secretory nature – the thyroid, adrenal, and pituitary glands 
respectively.  Given the relative high level of PABP5 expression in the pituitary 
gland versus the whole brain, it would seem plausible that it might represent the 
major site of PABP5 expression within the brain.  Unexpectedly, the ovary was one 
of the lowest ranked tissues in the panel, in disagreement with Blanco et al, who 
described the ovary as a major site of PABP5 expression in humans.  Further qPCR 
experiments, utilising cDNA prepared from selected human tissues would need to be 
undertaken to determine if this discrepancy is an artefact of the TissueScan array pre-
normalisation method.  
     
3.4  Expression Analysis of Mouse PABP5 mRNA 
The expression pattern of PABP5 mRNA in mouse tissues has not been addressed.  
The availability of tissue and the tractability of mouse as a model organism make it 
an ideal model in which to study the expression and function of PABP5.  As an 
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initial approach towards determining the expression of PABP5 in mouse tissues 
PABP5 specific oligonucleotide primers were generated to investigate the expression 
of PABP5 mRNA by RT-PCR.  These primers were designed to generate a 517bp 
amplicon and spanned the 5’ intron of PABP5 to allow the identification of any 
contaminating genomic DNA in the RNA preparation.  An additional advantage of 
designing primers against 5’-UTR sequence within the PABP5 transcript is that 
sequence homology between poly(A)-binding protein mRNAs is low within these 
regions.  mRNA was extracted from a panel of adult mouse tissues of CD1 
background and subjected to reverse-transcription followed by PCR (see figure 3.4).  
PABP5 was only detectable after 33 PCR cycles implying that it is a relatively low 
abundance transcript and appears to display a tissue specific expression pattern. The 
highest levels of expression was in the brain of both sexes and the ovary.  Testis, 
heart and lung also display relatively high levels of expression.  Interestingly, the 
relative expression levels between male and female appear to be roughly similar in 
these tissues, implying that PABP5 is subjected to X-inactivation in females.  PABP5 
was beneath detection in male but not female kidney, although this was not always 
observed and likely represents experimental variation due to the low levels of 
PABP5.  Comparison with previous human RT-PCR data (Blanco et al., 2001) would 
imply a partially conserved expression pattern between these species.  Given the 
discrepancy between the PABP5 RT-PCR (Blanco et al., 2001) and qPCR data sets 
(figure 3.3) regarding the expression of PABP5 in the human ovary, the mouse RT-
PCR results would appear to be consistent with the analysis by Blanco et al., (see 



































































































































































































































Figure 3.3  PABP5 qPCR on Origene human TissueScan array.  Data is plotted as relative copy number by the 2(-∆∆Ct) method on the Y-axis.  The 
amount of cDNA in each reaction was pre-normalised to β-actin levels in each tissue, and 2(-∆∆Ct) was calculated using thyroid as a reference standard.  
Results are the mean of two separate TissueScan arrays.  With the exception of optic nerve, pituitary and skin, the 2 (-∆∆Ct) values obtained for each 





Figure 3.4  PABP5 mouse tissue RT-PCR.  Mouse tissue was CD1 background and mice 
were approximately age matched.  RT-PCR was run for 33 cycles and electrophoresed in a 
1.5% TAE agarose gel.  Primers were used to amplify a 350bp product from the Hprt1 
transcript as a loading control.  Sm. muscle = smooth muscle, Sk. muscle = skeletal muscle, 
Sm. intestine = small intestine, Lg. intestine = large intestine.  Relative expression was 
highest in mouse brain and ovary.  The RT-PCR reaction was performed twice with cDNA 
prepared from two separate mice.   
 
3.5  Expression of PABPs in the Mammalian Gonads 
Very little is known regarding the cellular distribution of the PABP family of 
proteins below the whole tissue level.  Determining expression of PABPs at the 
cellular level could give insight into the physiological roles of these proteins and also 
raises interesting questions with respect to their relative functions.  In particular, to 
understand PABP5 function it is important to determine whether the low levels of 
PABP5 represent low ubiquitous expression or high levels of expression in certain 
cell types and whether PABP5 is co-expressed with other PABP proteins.  Gonadal 
tissues were chosen for analysis as they express the greatest number of PABP 
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proteins and represent the only tissues where any cellular expression patterns have 
been delineated (see below). To this end reagents specific to PABP1, PABP4 and 
PABP5 were generated to probe mouse histological tissue sections to determine the 
localisation of these PABP species.   
 
Although limited analysis is available, the cellular distribution of poly(A)-binding 
proteins within mammalian gonads are still poorly understood.  The histological 
information available pertains to the expression of ePABP, tPABP and PABP1 only.  
In the testis, tPABP mRNA has been shown to be present within pachytene 
spermatocytes and round spermatids within the seminiferous tubules by northern blot 
on enriched cell populations from mouse testis (Kleene et al., 1994).  This data 
overlaps with expression of human tPABP mRNA, although it appears to be absent 
or below the detection threshold in pachytene spermatocytes by both northern blot 
and in-situ hybridisation (Feral et al., 2001).  PABP1 mRNA expression in mouse 
testis has been documented in spermatocytes and round spermatids by northern blot 
(Gu et al., 1995; Kleene et al., 1994), and this situation is replicated in human testis 
(Feral et al., 2001) but with the interesting observation that the protein is also present 
in elongating spermatids in the absence of PABP1 mRNA.  In the ovary only the 
distribution of ePABP mRNA has been examined in mouse by in-situ hybridisation 
showing that expression is restricted to oocytes (Seli et al., 2005).   
  
3.6  Expression of PABPs in the Mouse Testes 
The gonads are part of both the reproductive system and the endocrine system, being 
responsible for the production of gametes (via spermatogenesis and oogenesis in the 
testis and ovary respectively) and also sex hormones.  The gonads are therefore 
complex organs composed of both germ cells and somatic cells.   
 
In males, spermatogenesis is the process by which haploid gametes are generated.  It 
occurs within the seminiferous tubules of the testis where spermatogonial stem cells 
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divide to produce diploid primary spermatocytes.  The cellular composition of 
seminiferous tubules is shown in figure 3.5A and 3.5B.  Two meiotic divisions 
results in 4 spermatids which mature through a process called spermiogenesis into 
round spermatids and then elongating spermatids (characterised by the presence of a 
tail, an acrosome and  nuclear protamines).  The germ cells are now referred to as 
spermatozoa.  A process termed spermiation then results in the release of these 
spermatozoa into the lumen of the seminiferous tubule where further maturation 
results in fertilisation competent sperm.  The somatic component of seminiferous 
tubules plays a significant role in germ cell development.  In males, luteinising 
hormone signalling results in the production of the steroid hormone testosterone by 
the somatic Leydig cells of the testis.  Testosterone is important in directing the 
process of spermatogenesis via androgen receptor signalling.  Sertoli cells produce 
androgen binding-protein in response to follicle stimulating hormone signalling, and 
androgen binding-protein functions in concentrating testosterone in the luminal fluid 
of the seminiferous tubules.     
 
To gain a preliminary insight into the distribution of PABP1, PABP4, tPABP and 
PABP5 between the somatic and germ cell components of seminiferous tubules RT-
PCR was performed on cDNA prepared from the testes of wild-type or Dazl -/- mice 
(see figure 3.6A).  Dazl is an RNA binding protein that is expressed in germ cells 
and is essential for gametogenesis.  Dazl knockout mice display defects in 
spermatogenesis (see figure 3.5C), with a severe reduction of germ cells beyond the 
spermatogonial stage in seminiferous tubules (Ruggiu et al., 1997).  Thus, mRNAs 
expressed only in later stages of spermatogenesis will be reduced or absent in Dazl -
/- mouse testes.  Both tPABP and PABP1 mRNAs are essentially absent from the 
Dazl -/- testes cDNA preparations indicating that these mRNAs are present in post-
spermatogonial germ cells, consistent with published data (Feral et al., 2001; Gu et 
al., 1995; Kleene et al., 1994).  Interestingly, PABP4 mRNA appears to be present in 
Dazl -/- testes indicating that PABP4 is partially or wholly contained within the 




Figure 3.5  Haematoxylin and eosin staining of mouse seminiferous tubules.  A.  Schematic of a seminiferous tubule cross section.  Adapted from 
Krawetz, 2005.  B.  7µm sections were cut from wax embedded mouse testis.  Seminiferous tubule cross section.  BM=basal lamina, LC=leydig cell, 
S=spermatogonia, SP=spermatocyte, RS=round spermatid, ES=elongating spermatid, SC=sertoli cell, L=lumen.  C.  Dazl -/- testis phenotype.  Loss of 
post-spermatogonial germ cells (indicated by black arrows).  Dazl-/- tissue was a kind gift from Mary Taggart, MRC Human Genetics Unit, Edinburgh. 106 
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When an RT-PCR reaction was performed using PABP5 specific primers (see figure 
3.6B) a signal was observed in the Dazl -/-testes cDNA suggesting that PABP5 is not 
restricted to germ cells within testes.  Intriguingly there was an apparent enrichment 
of PABP5 within Dazl -/- testis implying that perhaps PABP5 is expressed 
predominantly within somatic testis cells although in-situ hybridisation or 




Figure 3.6  Dazl -/- RT-PCRs.  cDNA was prepared from adult testes and ovaries of wild-
type mice.  cDNA was also prepared from the testis of Dazl -/- mice.  These cDNA 
preparations were subjected to PCR using primers specific to (A) PABP1, PABP4, tPABP 
and Hprt or (B) PABP5 and Hprt.  All mice were MF1 background. 
 
 
3.7(A)  Cellular Distribution of PABP1 and PABP4 in Mouse Testis 
Immunohistochemical analysis of both PABP1 and PABP4 was performed using 
rabbit polyclonal antibodies generated against each protein.  The peptides used to 
immunise the rabbits were conserved between mouse and human so that the 
antibodies could be used in a variety of mammalian species.  In addition, they were 
designed against the C-terminal regions of the proteins where there is significant 
sequence divergence between PABP family members to minimise likelihood of 




Figure 3.7  Location of peptides used to generate antibodies.  Blue text denotes the 
peptides used to generate the PABP4 antibodies and yellow denotes the peptides used to 
generate the PABP1 antibodies. 
 
 
The antibodies were tested by Western blotting against PABP1 and PABP4 
recombinant proteins and no cross reactivity was detected (Hannah Burgess, 
unpublished).  PABP5 does not contain the extreme C-terminal region that the 
peptides were generated against, and so cross-reactivity is very unlikely.  Cross 
reactivity of the PABP1 antibody with tPABP is likely as only 1 amino acid within 
the peptide sequence differs between human proteins and 3 differ between the mouse 
proteins.  This will be an issue in round spermatids, in which both proteins are 
expressed (Kimura et al., 2009), and where determining levels of expression would 
be impossible to deduce as the relative contributions of each protein to the signal is 
unknown.  PABP1 localised to the spermatocytes, round spermatids and early 
elongating spermatids within the seminiferous tubules with no signal detected in 
spermatogonial, Sertoli or Leydig cells (see figure 3.8 part 1).  PABP4 displays a 
more wide ranging expression pattern with the protein detectable in all cell types 
within the tubules, including the Sertoli cells (see figure 3.8 part 2), consistent with 
the RT analysis (figure 3.6A).  This represents the first cellular expression pattern for 
mouse PABP1 and PABP4 proteins and reveals that certain cells contain both 
PABP1 and PABP4.  However, others such as spermatogonial cells which express 




Figure 3.8 Part 1. PABP1 expression in mouse testes.  Testis tissue sections were subjected to immunohistochemical analysis with α-PABP1 or  α-
PABP4 polyclonal antibodies at a 1/10,000 dilution or a 1/500 dilution respectively.  A.  Seminiferous tubule at 20x magnification.  B.  Seminiferous 
tubule at 40x magnification.  Staining was seen in spermatocytes (grey arrow), and round spermatids (white arrow) but was absent in spermatogonial 
cells (black arrow), elongating spermatids (blue arrow), Sertoli cells (red arrow) and Leydig cells (green arrow).  C.  Control slide incubated with normal 





Figure 3.8 Part 2. PABP4 expression in mouse testes.  D.  Seminiferous tubule at 20x magnification.  E.  Seminiferous tubule at 40x magnification.  
Staining was seen in spermatocytes (grey arrow), spermatids (white arrow), and elongating spermatids (blue arrow).  Stronger relative staining was 




  3.7(B)  Cellular Distribution of PABP1 and PABP4 in Mouse Ovaries 
As with the testis, the ovary is responsible for the production of hormones and 
female gametes (ova) and is composed of both somatic tissue as well as germ cells.  
Oogenesis is characterised by cyclical waves of germ cell development, maturation, 
and then release.  Unlike males who can produce sperm for their entire adult life, the 
number of oocytes available for ovulation in mammals is determined during fetal 
development.  By birth, the finite pool of immature primary oocytes are associated 
with granulosa cells and are referred to as primordial follicles.  The oocytes within 
these follicles are arrested in dicytate (meiotic prophase 1) which can last up to 50 
years. Primordial follicles are then selected from the pool to undergo folliculogenesis 
in a poorly understood process and over the course of approximately one year in 
humans (and approximately 20 days in mice) develop through primary, secondary, 
tertiary and up to pre-ovulatory follicle stages (see figure 3.9 for a schematic 
representation of folliculogenesis). Whilst the oocyte grows during these stages of 
folliculogenesis meiosis only resumes shortly before ovulation in a process termed 
oocyte maturation.   
 
From the secondary follicle stage onwards this growth and development is largely 
directed by luteinising hormone and follicle stimulating hormone signalling through 
the somatic thecal cells and granulosa cells associated with the oocytes (see figure 
3.9).  Interestingly the granulosa and thecal cells of the ovary are often described as 
somatic equivalents of Sertoli and Leydig cells respectively.  In females, luteinising 
hormone acts on the thecal cells of ovarian follicles, resulting in the production of 
androstenedione (a testosterone precursor).  This steroid hormone is then converted 
into estradiol (an estrogen hormone) in granulosa cells via the action of the 
cytochrome P450 enzyme aromatase, which is produced in response to follicle 
stimulating hormone signalling to these cells.  Estradiol directs folliculogenesis in 
the ovary via binding to its cognate receptor and initiating signalling events that 





Figure 3.9  Haematoxylin and eosin staining of mouse ovarian tissue.  A.  Schematic of an ovary with follicles at various stages of folliculogenesis.  
Following selection from the primordial follicle pool the primordial follicles undergo cyclical waves of development and atresia progressing through a 
number of characterised stages.  During this period there is a significant expansion in the granulosa and thecal cell populations, the development of an 
antrum and an increase in size of the oocyte arrested in dictyate.  Immediately prior to ovulation the oocyte resumes meiosis.  Following ovulation in 
response to hormonal signalling the remaining granulosa and thecal cells form an endocrine organ called the corpus luteum which releases hormones 
and is required to maintain the endometrium to allow implantation of the fertilised egg.  Adapted from Matzuk et al., 2002.  B. 7µm sections were cut 
from wax embedded mouse ovaries.  GE=germinal epithelium, GC=granulosa cells, TC=thecal cells, A=antral cavity, O=oocyte, GV=germinal vesicle, 





Following ovulation, the thecal and granulosa cells from the ovulated follicle that are 
retained within the ovary form a structure called the corpus luteum (see figure 3.9) 
which continues to release estrogen and progesterone which are necessary for 
successful implantation should the ova be fertilised. 
 
The cellular distribution of PABPs within the mammalian ovary is poorly 
understood.  ePABP has been shown by in-situ hybridisation to localise to germ cells 
within mammalian follicles (Seli et al., 2005) consistent with the presence of ePABP 
in the oocytes of other vertebrate species (Voeltz et al., 2001).  To further investigate 
the distribution of PABP proteins within the mammalian ovaries 
immunohistochemical analysis of PABP1 and PABP4 expression was examined 
using the same antibodies as in figure 3.7.   
 
In the adult mouse ovary PABP1 displays a restricted expression pattern (see figure 
3.10) but unlike in the testis PABP1 is absent from the germ cells and is expressed 
only in somatic cells within the ovary.  It appears to have the highest expression 
levels within the granulosa cells at multiple stages of the folliculogenesis pathway 
from activated primary follicles up to large antral stage follicles (figure 3.10A).  The 
thecal cells associated with the follicles also stain weakly for PABP1 (figure 3.10C).  
The corpus luteum which is derived from the granulosa and thecal cells of ovulated 
follicles also stains for PABP1 (figure 3.10B) albeit weakly, suggesting a decline in 
PABP1 expression following ovulation.  Thus, PABP1 is expressed in multiple cell-
types within the mouse ovary.  As with the testis, the expression of PABP4 in the 
ovary differs significantly from that of PABP1, with notable expression in the 
cytoplasm of developing oocytes in primordial through to antral follicles (see figure 
3.11A and C).  The primary oocytes within the primordial follicles stain strongly 
suggesting that the oocytes express PABP4 during very early stages of 
folliculogenesis (see figure 3.11C).  The granulosa cells of activated follicles also 
stain for PABP4 (see figures 3.11C).  Whether the squamous pregranulosa cells of 
primordial follicles are positive for PABP4 was undetermined due to the resolution 
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limit of the signal.  Interestingly the corpus luteum also shows significant expression 
of PABP4 (see figure 3.11B) suggesting that the granulosa lutein cells continue to 
express PABP4 following ovulation.  While the stroma appears to display low level 
staining it is unclear if this is background, or a result of overdevelopment of the 
signal.  For the same reasons it is also difficult to determine if the thecal cells are 
positively stained (see figure 3.11C).  Thus, PABP1 and PABP4 display overlapping 
yet distinct expression patterns within the mouse gonads.    
 
3.8  PABP5 Antibody Generation 
To investigate the localisation of PABP5 protein in mouse gonads required the 
generation of a PABP5 specific antibody.  Two peptides were selected and each was 
used to immunise a pair of rabbits.  One peptide was N-terminal within the mouse 
PABP5 protein, and the second was an internal peptide (see figure 3.12).  Both were 
chosen to maximise the potential of cross reaction with the human protein, and to 
minimise the likelihood of cross reaction with other PABP proteins.  Peptide A (the 
N-terminal peptide) failed to stimulate an immune response with the antibody titre 
being extremely low, as determined by an enzyme-linked immunosorbant assay 
(ELISA) whereby the immunogenic peptides were tested against serial dilutions of 
the rabbit sera.  The optical density of the ELISA was measured at 450nm and the 
titre was calculated as the highest dilution of sera that gave an optical density reading 
of greater than 1.  All ELISA assays were performed by Covalab.   
 
Peptide B stimulated a moderate immune response as determined by antibody titre 
(rabbit 286 and rabbit 384).   Rabbit 286 had an antibody titre of 16,000 compared to 
4,000 for rabbit 384 and was subject to antibody purification with an immunoaffinity 






Figure 3.10  PABP1 expression in mouse ovary.  Ovary tissue sections were subjected to immunohistochemical analysis with α-PABP1 polyclonal 
antibody at a 1/10,000 dilution.  A.  Ovary at 4x magnification.  Follicles at various stages, containing PABP1 positive granulosa cells are denoted by 
black arrows.  B.  Ovary at 10x magnification.  Corpus luteum is marked with a black star.  C.  Ovary at 20x magnification.  Black arrow indicates thecal 





Figure 3.11  PABP4 expression in mouse ovary.  Ovary tissue sections were subjected to immunohistochemical analysis with α-PABP4 polyclonal 
antibody at a 1/500 dilution.  A.  Ovary at 4x magnification.  Antral follicles containing strongly stained oocytes are denoted by black arrows.  B.  Ovary 
at 10x magnification.  Corpus luteum is marked with a black star.  C.  Ovary at 20x magnification.  Black arrows indicate primary oocytes positive for 





When crude sera from both rabbits and the immunopurified antibody from rabbit 286 
were tested against E. coli lysate containing recombinant polyhistidine-tagged (his-
tagged) PABP5 by Western blotting (see figure 3.13A) neither generated a signal that 
corresponded to the predicted molecular weight for the recombinant protein despite 
recognising a number of E. coli proteins.  The presence of the recombinant protein in 
the extracts was verified by Western blotting with an antibody raised against the his-
tag.  A further two peptides (peptides C and D) were then chosen for immunisation, 
but both failed to stimulate an immune response in the rabbits over the course of the 
immunisation program, as determined by ELISA.  The immunisation program was 
extended but this failed to stimulate an immune response. 
 
During the development of our own antibodies two commercial antibodies became 
available and were tested for reactivity against PABP5.  The first was an affinity 
purified rabbit polyclonal antibody (Atlas Antibodies; cat. # HPA000164).  The 
rabbits were immunised using a human PABP5 recombinant protein epitope 
signature tag (see figure 3.12).  This antibody will herein be referred to as At164.  
The second antibody was a mouse polyclonal antibody (Abnova; cat. # H00140886-
B01).  The mice were immunised with full length recombinant human PABP5.  This 
antibody will herein be referred to as Ab140886.  To test the reactivity of At164 
against PABP5, E. coli lysates containing recombinant His-tagged PABP5 were 
subjected to Western blotting with At164 (see figure 3.13B).  Unlike the antibody 
generated by immunisation with peptide B, At164 recognised a band of 
approximately 44kDa which corresponds to the predicted molecular weight of 
recombinant PABP5.  The specificity of the antibody for PABP5 was then tested to 
determine its value as an immunohistochemistry reagent.  This is particularly 
important for antibodies raised against PABP proteins given the high level of protein 
sequence conservation within this family and also the common occurrence of 
multiple PABPs within the same tissue.  The specificity was tested in two ways.  
Firstly, At164 was tested by Western blotting of E. coli lysate containing 
recombinant PABP1 and PABP4 (see figure 3.13C) and secondly by Western 
blotting of mouse tissue lysates to determine if the antibody cross-reacted with 
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endogenous mouse proteins (see figure 3.13D). Unfortunately At164 cross-reacts 
with recombinant PABP1 limiting the usefulness of the antibody for 
immunohistochemical analysis.  Western blotting of the mouse tissue lysates 
revealed multiple cross reacting bands.  The peptide used to immunise the rabbit 
covers a large proportion of the PABP5 protein and it is therefore likely that the 




mPABP5         -MSGEPNTAGKKKKYLKAALYVGDLDPDVTEDMLYKKFRPAGPLRFTRICRDPVTRSPLG  
hPABP5         MGSGEPNPAGKKKKYLKAALYVGDLDPDVTEDMLYKKFRPAGPLRFTRICRDPVTRSPLG  
mPABP1         -----MNPSAP--SYPMASLYVGDLHPDVTEAMLYEKFSPAGPILSIRVCRDMITRRSLG  
                      
mPABP5         YGYVNFRFPADAEWALNTMNFDLINGKPFRLMWSQPDDRLRKSGVGNIFIKNLDKTIDNR  
hPABP5         YGYVNFRFPADAEWALNTMNFDLINGKPFRLMWSQPDDRLRKSGVGNIFIKNLDKSIDNR  
mPABP1         YAYVNFQQPADAERALDTMNFDVIKGKPVRIMWSQRDPSLRKSGVGNIFIKNLDKSIDNK  
                
mPABP5         ALFYLFSAFGNILSCKVVCDDNGSKGYAYVHFDSLAAANRAIWHMNGVRLNNRQVYVGRF  
hPABP5         ALFYLFSAFGNILSCKVVCDDNGSKGYAYVHFDSLAAANRAIWHMNGVRLNNRQVYVGRF  
mPABP1         ALYDTFSAFGNILSCKVVCDENGSKGYGFVHFETQEAAERAIEKMNGMLLNDRKVFVGRF  
              
mPABP5         KFPEERAAEVRTRERATFTNVFVKNFGDDIDDEKLNKLFSEYGPTESVKVIRDATGKSKG  
hPABP5         KFPEERAAEVRTRDRATFTNVFVKNIGDDIDDEKLKELFCEYGPTESVKVIRDASGKSKG  
mPABP1         KSRKEREAELGARAK-EFTNVYIKNFGEDMDDERLKELFGKFGPALSVKVMTDESGKSKG  
                
mPABP5         FGFVRYETHEAAQKAVLELHGKSIDGKVLCVGRAQKKIERLAELRRRFERLKLKEKNRPS  
hPABP5         FGFVRYETHEAAQKAVLDLHGKSIDGKVLYVGRAQKKIERLAELRRRFERLRLKEKSRPP  
mPABP1         FGFVSFERHEDAQKAVDEMNGKELNGKQIYVGRAQKKVERQTELKRKFEQMKQDRITRYQ  
 
mPABP5         GVPIYIKNLDETINDEKLKEEFSSFGSISRAKVMMEVGQGKGFGVVCFSSFEEACKAVDE  
hPABP5         GVPIYIKNLDETINDEKLKEEFSSFGSISRAKVMMEVGQGKGFGVVCFSSFEEATKAVDE  
mPABP1         GVNLYVKNLDDGIDDERLRKEFSPFGTITSAKVMMEGGRSKGFGFVCFSSPEEATKAVTE  
 
mPABP5         MNGRIIGSKTLHVTLGQARHRW--------------------------------------  
hPABP5         MNGRIVGSKPLHVTLGQARRRC--------------------------------------  
mPABP1         MNGRIVATKPLYVALAQRKEERQAHLTNQYMQRMASVRAVPNPVINPYQPAPPSGYFMAA  
 
Figure 3.12  Location of peptides for immunisation.  Yellow represents peptide A, green 
represents peptide B, and blue represents the PABP5 recombinant protein epitope signature 
tag used to generate At164.  Pink represents peptide C and grey represents peptide D used 
for the failed immunisation protocol.  Full length recombinant PABP5 was used to generate 






Figure 3.13  Antibody test Westerns.  A.  Affinity purified antibody and sera of rabbit 286 
and the sera from rabbit 384 immunised with peptide B were used to Western blot E. coli 
lysates containing recombinant His-PABP5.  α-histidine was used to indicate presence of 
recombinant protein.  Both antibodies and bleeds were used at a 1/1000 dilution.  B.  At164 
tested by Western blot against E. coli lysates containing recombinant His-PABP5.  Antibody 
was used at a 1/250 dilution.  C.  The specificity of At164 was tested by Western blot against 
E. coli lysates containing recombinant His-PABP1 and recombinant His-PABP4.  Antibody 
was used at a 1/250 dilution.  D.  The specificity of At164 was tested by Western blot against 
mouse tissue lysates containing recombinant His-PABP1 and recombinant His-PABP4.  
Antibody was used at a 1/250 dilution.       
 
Of the many proteins detected by At164 in these lysates there are bands that migrate 
at the predicted molecular weight for both PABP1 and PABP5 (~70kDa and 43kDa 
respectively).  Whether any of the bands represent PABP5 protein is unclear.  To 
determine the identity of the proteins migrating at the predicted molecular weight of 
PABP5, immunoprecipitated (IP) protein could be analysed by mass spectroscopy.  
To determine the immunoprecipitating capacity of At164 an in-vitro coupled 
transcription and translation reaction was performed using a vector containing the 




Figure 3.14  At164 can immunoprecipitate recombinant PABP5.  Coupled transcription 
and translation reactions were carried out with empty pET vector, pET-PABP5, or pET-Prrp.  
At164 was then used to immunoprecipitate PABP5 but was not capable of isolating Prrp.  
The inputs represent 25% of the reaction used for each immunoprecipitation. 
 
The recombinant PABP5 was then subjected to IP using At164 (see figure 3.14).  
This assay demonstrated the ability of At164 to recognise in-vitro translated 
recombinant PABP5.  As a specificity control an antibody raised against an unrelated 
RRM containing protein, Prrp, was also used to IP PABP5.  However the subsequent 
IP of mouse tissue lysates with At164 failed to isolate the 43kD protein detected in 
the Western blots (see figure 3.15).  While there were three observable protein bands 
of approximately the predicted molecular weight of PABP5 they were also present in 
the control IgG reaction and so were deemed non-specific.   It is possible that the 
protein bands detected by Western blot (see figure 3.13D) are at such low abundance 
in mouse tissues it is simply not detectable by IP.  Thus the identities of the proteins 
detected by Western blotting with At 164 remain unknown and the antibody was 
deemed to have little experimental value. 
 
The second commercially available antibody, Ab140886, was tested by Western blot 
against HeLa cell lysate that had been transfected with T7-tagged mouse PABP1 and 
PABP5 to determine if this antibody could specifically recognise mouse PABP5 (see 






Figure 3.15  IP of mouse tissue lysate with At164.  Mouse kidney tissue was lysed and 
subjected to immunoprecipitation with At164.  A control IP reaction was set up using mouse 
IgG.  The IP’d proteins were subjected to SDS-PAGE followed by staining with SYPRO Ruby 
protein stain (Invitrogen) as per manufacturer’s instructions and scanned using a Typhoon 
Variable Mode Imager with a 488nm excitation laser.  There were 3 bands of approximately 
the predicted molecular weight of PABP5 (44kDa) isolated by At164 but they were also 
isolated by the control IgG reaction and so were deemed non-specific (see small black 
arrows).  The antibody heavy and light chains are identified. 
 
The antibody detects a band of approximately 44kDa in the T7-PABP5 transfected 
lysate, and also detects a band of approximately 73kDa in the T7-PABP1 transfected 
lysate (PABP1 predicted mass is 71kDa) suggestive of cross reaction of the antibody 
with the PABP1 protein.  This cross reaction appears to be limited to overexpressed 
protein as there is no detectable band in the untransfected and T7-SF2 transfected 
lysates which contain substantial amounts of endogenous PABP1.  As with At164, 
Ab140886 demonstrated an ability to IP recombinant radiolabelled PABP5 in the 
same assay as undertaken in figure 3.13 (see figure 3.17A) but as before failed to 
specifically isolate any proteins of the predicted molecular weight of PABP5 from 
mouse tissue lysates (data not shown) possibly re-emphasising that PABP5 may be a 
low abundance protein, or alternatively is an abundant protein expressed in only a 





Figure 3.16  Ab140886 recognises recombinant PABP5.  Ab140886 was tested against 
HeLa cell lysates containing mouse  T7-PABP1, T7-PABP5 and T7-SF2, an RRM containing 
protein that is unrelated to the PABP family (right panel).  The presence of the recombinant 
T7-tagged proteins was verified by Western blotting with an antibody raised against the T7-
tag (left panel). 
 
Ab140886 was then used to test a mouse tissue panel by Western blotting. A band 
was identified at 54kDa but no detectable signal at the correct mass for PABP5 was 
observed (data not shown) when the blot was developed using enhanced 
chemiluminescent (ECL) reagent (Amersham).  This band could represent a post-
translationally modified version of the PABP5 protein but was observable in all 
tissue lysates including those with negligible levels of PABP5 mRNA such as the 
liver.  Upon development of the blot with Supersignal West Femto substrate (Thermo 
Scientific) which is a higher sensitivity Western blotting detection reagent a band of 
approximately 44kDa, the predicted mass of PABP5, was visible in both male and 
female brain lysates (see figure 3.17B) which  have relatively high levels of PABP5 




PAIP-2 is known to bind PABP1 (Khaleghpour et al., 2001b) and in chapter 4 I 
demonstrate that recombinant PABP5 can also bind to PAIP-2 in-vitro.  This 
interaction was used to test whether either the 54kDa band (upper band) and/or the 
44kDa band (lower band) represent forms of PABP5.  Mouse brain lysates were 
incubated with GST-PAIP-2 bound to glutathione sepharose beads, and the un-bound 
fraction was Western blotted using Ab140886.  PABP1 was depleted from extracts 
incubated with GST-PAIP-2 but not from extracts incubated with GST alone (see 
figure 3.18).  Neither the upper or lower putative PABP5 bands were depleted by 
GST-PAIP-2 incubation, suggesting that they do not represent forms of the PABP5 
protein (see figure 3.18).  If the upper band corresponds to a post-translationally 
modified version of PABP5, these modifications may preclude binding to PAIP-2. 
 
 
Figure 3.17  Ab140886 characterisation.  A.  Ab140886 can immunoprecipitate 
recombinant PABP5.  Coupled transcription and translation reactions were carried out with 
empty pET vector, pET-PABP5, pET-PABP1 or pET-Prrp.  Ab140886 was then used to 
immunoprecipitate PABP5 but was not capable of isolating PABP1 or Prrp.  The inputs 
represent 20% of the reaction used for each immunoprecipitation.  B.  Mouse tissue lysates 
were subjected to Western blotting using Ab140886 at a 1/2000 dilution.  Upper band at 
approximately 54kDa and lower band at approximately 44kDa indicated by black arrows.  





Figure 3.18  PABP depleted mouse brain lysates.  Mouse brain tissue lysates were 
incubated with GST or GST-PAIP-2 bound to glutathione sepharose beads.  The 
supernatant was then Western blotted with the indicated antibodies.      
 
3.9  Localisation of PABP5 mRNA in the Mouse Gonads 
Immunohistochemical analysis of PABP5 cannot be undertaken in the absence of a 
specific antibody.  Therefore, to gain insight into likely PABP5 expressing cell 
populations in-situ hybridisation was employed.  To generate a labelled PABP5 
specific probe the PABP5 RT-PCR amplicon (see section 3.4) was cloned into a 
vector and transcribed to create digoxygenin labelled RNA probes using a DIG-
labelling kit (Roche).  The probe was complementary to the 5’-UTR of the PABP5 
transcript, was intron spanning and was BLAST searched (NCBI) to ensure there 
would be minimal likelihood of cross-reactivity with transcripts containing similar 
sequence.  The digoxygenin labelled RNA was visualised by applying an antibody 
raised against the digoxygenin moiety.  Antibodies are coupled to alkaline 
phosphatase, an enzyme that catalyses the precipitation of an insoluble purple 
product upon addition of substrate.  A corresponding sense probe was used as a 
control and was synthesised by transcription of the same vector but in the opposite 
direction to produce a non-complimentary probe of the same size as the antisense 
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probe.  PABP1 mRNA sense and antisense digoxygenin labelled probes were also 
created by transcription from a vector containing the PABP1 3’-UTR.  The 
localisation of PABP1 mRNA to a subset of male germ cells within the seminiferous 
tubules of mouse testis (Gu et al., 1995; Kleene et al., 1994) allows the PABP1 in-
situ hybridisation to serve as a positive control for the assay and also as a measure of 
the integrity and condition of the tissue.   
 
Two critical parameters that can affect the detection of an mRNA species by in-situ 
hybridisation are the temperature at which probe annealing is performed, and also the 
concentration at which the probe is applied to the tissues.  A standard annealing 
temperature of 55oC and probe concentration of 0.1ng/µl was initially employed.  
Upon performing the assay on mouse testes tissue no signal could be detected for 
PABP5.  PABP5 mRNA remained undetectable despite increasing the probe 
concentration 10-fold to 1ng/µl and dropping the annealing temperature to 50oC (see 
figures 3.19C and D).  At 55oC (data not shown) or 50oC PABP1 localisation was 
observed in the spermatocytes and spermatids consistent with published data (see 
figures 3.19A and B) (Gu et al., 1995; Kleene et al., 1994).  It was considered that 
the PABP1 probe might be binding to its mRNA with a higher affinity than the 
PABP5 probe, although this was deemed unlikely, as both probes were of similar 
length (PABP1; 439bp, PABP5; 517bp) and PABP5 had a significantly greater GC 
content (PABP1; 29%, PABP5; 51%).  It was therefore concluded that PABP5 
mRNA was below the detection threshold of this assay. 
 
If PABP5 was below the detection limit of the assay, then employing the same assay 
using mouse ovarian tissue may prove to be more successful, given that higher levels 
of mRNA were detected in this tissue by RT-PCR (see figure 3.4).  As with testes 
tissue there was no observable PABP5 mRNA signal using a probe annealing 
temperature of 55oC and concentration of 0.1ng/µl, in contrast to PABP1 which 
showed an expression pattern reminiscent of PABP1 protein expression (see 




Figure 3.19  PABP5 mRNA localisation in the mouse testes.  7µm tissue sections were subjected to in-situ hybridisation.  A, C.  Adult mouse testes 
sections incubated with PABP1 and PABP5 antisense probes respectively.  White arrowhead marks a spermatocyte and the black arrowhead marks a 
round spermatid.  No signal could be seen with the PABP5 probe.  PABP1 displayed strong staining in spermatocytes and round spermatids.  B, D.  
Adult mouse testes sections incubated with PABP1 and PABP5 sense probes respectively.  The PABP1 probes were used at a concentration of 
0.1ng/µl and an annealing temperature of 50oC and the PABP5 probe was used at a concentration of 1ng/µl with an annealing temperature of 50oC.  




However, unlike testis when the annealing temperature was dropped to 50oC and the 
probe was applied at a concentration of 1ng/µl a PABP5 signal was observed within 
specific populations of cells (see figure 3.20).  The signal localised to the cumulus 
and mural granulosa cells, and also the thecal cells, and appeared to be absent from 
oocytes, the stroma and ovarian surface epithelium.  Thus, PABP5 would appear to 
be present in sub-populations of cells of somatic origin within the ovary.  The 
resolution of the signal generated by the digoxygenin probe was not sufficient to 
identify the presence of PABP5 in granulosa or thecal cells in follicles below the 
secondary follicle stage.  The corpus luteum was also positive for PABP5 but at 
much lower intensity than the granulosa and thecal cells, and only displayed signal 
with longer probe incubation times.  Care must be taken in interpreting the presence 
of extremely low level staining in the corpus luteum given the lowered annealing 
temperature and higher probe concentrations used as these parameters can directly 
affect probe specificity.     
 
To determine if PABP5 is present in primordial and primary follicles, tissue sections 
of mouse ovaries were collected at 2 days post partum (dpp) and 6 days post partum 
and subjected to in-situ hybridisation with the PABP5 probe.  At 2dpp only 
primordial follicles inhabit the ovary, and by 6dpp there are only primary and early 
secondary follicles present.  This facilitates the analyses of mRNAs expressed in 
these cell types at this developmental stage by making the precipitative staining 
easier to visualise as the follicles are at higher cellular densities within the ovary.  At 
2dpp there appears to be light staining of the squamous pregranulosa cells associated 
with the oocytes (see figure 3.21 part 1).  This staining becomes more apparent in the 
granulosa cells within the primary and secondary follicles in the 6dpp ovary (see 
figure 3.21 part 2).  Staining is also present in the thecal cells in early secondary 
follicles (see figure 3.21 part 2).  PABP5 is therefore expressed within certain 
somatic cells associated with the developing follicle from very early follicular stages 




Figure 3.20  PABP5 mRNA localisation in the mouse ovary.  7µm tissue sections were subjected to in-situ hybridisation. A,B,C.  Adult mouse ovary 
sections incubated with PABP5 antisense probe.  A robust signal could be seen in mural (black arrow) and cumulus granulosa cells (white arrow), and 
also thecal cells (grey arrow).  The corpus luteal cells also had light staining (black star).  No signal could be observed in stromal tissue (green arrow) 
and the ovarian surface epithelium (blue arrow).  The germ cells appeared negative for PABP5 staining (red star).  D.  Adult mouse ovary section 
incubated with PABP5 sense probe.  The probes were used at a concentration of 1ng/µl and with an annealing temperature of 50oC.  Nuclear 





Figure 3.21  Part 1.  PABP5 localisation in 2dpp mouse ovaries.  7µm tissue sections 
were subjected to in-situ hybridisation. A.  2dpp mouse ovary section incubated with PABP5 
antisense probe.  Staining was observed in the pregranulosa cells surrounding the oocyte.  A 
primordial follicle with squamous pregranulosa cells is circled (see black arrow).  B.  2dpp 
mouse ovary sections incubated with PABP5 sense probe.  The probes were used at a 
concentration of 1ng/µl and with an annealing temperature of 50oC.  Nuclear counterstaining 




Figure 3.21  Part 2.  PABP5 localisation in 6dpp mouse ovaries.  7µm tissue sections 
were subjected to in-situ hybridisation. C.  6dpp mouse follicle incubated with PABP5 
antisense probe.  The cuboidal granulosa cells of primary follicles were positively stained for 
PABP5 (see black arrow).  In the early secondary follicles thecal cells also stained positive 
(see white arrow).D.  6dpp mouse ovary sections incubated with PABP5 sense probe.  The 
probes were used at a concentration of 1ng/µl and with an annealing temperature of 50oC.  




3.10  PABP5 Expressing Cell-Lines 
That PABP5 mRNA appears to be predominantly expressed within the granulosa 
cells of the mouse ovary could suggest that this cell type would be a good candidate 
in which to study PABP5 protein.  Indeed antibodies At164 and Ab140886 may be 
able to detect PABP5 in a pure population of granulosa cells or a granulosa cell-line 
compared to whole ovary extracts.  However, as a preliminary line of investigation 
PABP5 mRNA levels were examined in a range of standard laboratory cell-lines by 
RT-PCR with the PABP5 specific oligonucleotide primers documented in section 
3.4.  As a positive control, mouse genomic DNA was also subjected to PCR with the 
primers.  The product of this PCR reaction was expected to be 1052bp which is 
larger than would be generated by PCR of PABP5 cDNA (517bp) as the primers are 
intron spanning.  Of the cell-lines tested none were positive for PABP5 mRNA (see 
figure 3.22A). 
  
Expression of PABP5 mRNA in two specialised cell lines was then investigated – the 
immortalized murine ovarian granulosa tumour cell-line KK1, and the Sertoli cell-
line SK11.  The Sertoli cell-line was examined for PABP5 mRNA expression for 
three reasons, firstly PABP5 mRNA is known to be present within mouse testis (see 
figure 3.4), secondly PABP5 mRNA is still present in Dazl -/- testes suggesting that 
at least a proportion is expressed within somatic testes tissue (see figure 3.6), and 
thirdly Sertoli cells and granulosa cells are often considered functional equivalents in 
male and female gonads.  The SK11 cell line was derived from transgenic mice 
expressing a temperature sensitive form of the Simian virus 40 (SV40) large T 
antigen.  At the permissive temperature (33oC) the cells are mitotically active, but 
when they are grown at the non-permissive temperature (39oC) they stop 
proliferating, start expressing Sertoli cell markers and undergo cytoskeletal changes 
consistent with the changes seen during functional maturation of Sertoli cells during 
the first wave of spermatogenesis (Sneddon et al., 2005).  If PABP5 was expressed in 
these granulosa or Sertoli cell lines they could prove to be useful molecular biology 




Figure 3.22  Expression of PABP5 mRNA in cell-lines.  A.  Various cell-lines were tested 
for the expression of PABP5 mRNA by RT-PCR.  The expected amplicon was 517bp.  
Genomic mouse DNA was subjected to PCR as a control.  The expected amplicon for this 
reaction was 1052bp as the primers are intron spanning.   B.  PABP5 RT-PCR on cDNA 
derived from granulosa and Sertoli cell lines.  HIH/3T3 cells are a mouse fibroblast line that 
are negative for PABP5 expression.  PABP5 expresses at low levels in SK11 cells grown at 
39oC and also in KK1 cells.  C.  Aromatase RT-PCR on cDNA derived from mouse ovary or 
KK1 cell mRNA.  PCR reactions were 32 cycles.    
 
cDNA was prepared from these cell-lines and RT-PCR was performed.  When SK11 
cells were grown at the permissive and non-permissive (Sertoli cell- like) 
temperatures, the latter appeared to induce a slight increase in PABP5 mRNA levels 
but this was relatively low compared to ovary and testis cDNA expression (see figure 
3.22B).  PABP5 levels were also relatively low in the SK11 granulosa cell line. It is 
known that the KK1 cells luteinise in culture, a process in which the granulosa cells 
undergo radical changes in gene expression and endocrine function in preparation for 
implantation.  This often occurs at especially high cell densities or passage numbers 
(Portela et al., 2010).  This could in part explain the low expression of PABP5 in 
these cells, as the in-situ data in mouse ovary implied that there was severely reduced 
expression of PABP5 in corpus luteal tissue.  RT-PCR was performed on RNA 
extracted from KK1 cells using primers against aromatase, a granulosa expressed 
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gene, as a marker of how granulosa cell ‘like’ the cultured KK1 cells are (see figure 
3.22C).  The KK1 cells fail to express aromatase in culture, possibly through a lack 
of FSH signalling, suggesting that they are more luteal than granulosa like and 
indicating that they are not an ideal cellular background in which to perform PABP5 
functional assays. 
 
3.11  Discussion 
The PABP5 gene contains no introns within its ORF. Thus, it is likely to have 
originated through a retroposition event analogous to tPABP, a mammalian testis 
specific poly(A)-binding protein (Feral et al., 2001; Kleene et al., 1998) that appears 
to share many of the functional characteristics of PABP1 (Kimura et al., 2009). The 
high degree of sequence conservation of the PABP5 gene across mammals implies a 
degree of selective pressure acting upon this gene to maintain the sequence.  While 
no promoter sequences have been determined for PABP5, there is conservation of the 
DNA sequence upstream of the gene.  It would be interesting to run the upstream 
sequence through a transcription factor binding site predictor program such as rVista 
to establish if there are any conserved recognisable transcription factor binding sites 
within this genomic region that may account for regulation of its transcription. 
Alternatively, PABP5 mRNA may be expressed then rapidly turned over in cells 
where it appears absent, and interestingly the 3’-UTR of PABP5 contains a number 
of putative stability or AU-rich elements, suggestive of regulation via this 
mechanism although this is purely speculative.   
 
The main sites of expression of PABP5 mRNA appeared to overlap between species.  
In mice a primary site of expression was the brain (see figure 3.4), correlating with 
qPCR analysis of human tissues (see figure 3.3) and published human data (Blanco 
et al., 2001).  Localisation and translation of mRNAs in neurons has been shown to 
be important for a number of processes, particularly synaptic plasticity and axon 
growth cone movement (reviewed in Lin and Holt, 2007; Schuman et al., 2006), 
therefore it is interesting to find expression of poly(A)-binding proteins within the 
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brain.  The human qPCR cDNA arrays suggest relatively high PABP5 mRNA 
expression within the pituitary gland suggesting it is the main site of expression. 
Whether expression in this gland is conserved in mouse remains to be determined. In 
situ hybridisation of mouse brains was undertaken but resulted in destruction of the 
tissue and further optimisation of the protocol would be required to facilitate these 
experiments.  Expression within the pituitary is particularly intriguing given that in 
mouse ovarian tissue PABP5 is expressed in the granulosa cells which are a direct 
downstream target of follicle stimulating hormone which is produced in the anterior 
portion of the pituitary.   The so called hypothalamic-pituitary-gonadal axis is central 
to gonad function.   
 
Also of interest was the implication that PABP5 may be expressed predominantly in 
endocrine organs.  Besides the brain, ovary and testis, other endocrine organs such as 
the thyroid and adrenal glands were ranked highly in the qPCR assay.  Whether 
PABP5 has a particular subset of mRNA targets that are in some way associated with 
sending or receiving signals, such as cellular receptors or factors involved in the 
packaging of secreted signals in these cell types is unclear.  Certainly investigation 
into PABP5 expression within these organs warrants further attention.         
 
There remains a discrepancy between the human RT-PCR data (Blanco et al., 2001) 
and the qPCR data presented in figure 3.3 regarding the expression of PABP5 in 
human ovarian tissue.  Whilst the higher levels of PABP5 observed in mouse ovaries 
would appear consistent with the results of Blanco et al, it is possible that PABP5 
levels may differ significantly in human and mouse ovaries.  Humans are mono-
ovulatory, and generally produce one ova for each menstrual cycle while mice are 
poly-ovulatory resulting in the production of multiple ovulatory follicles each cycle.  
As a result the PABP5 expressing granulosa cells may represent a higher proportion 




In-situ hybridisation of the testis failed to identify the sites of PABP5 mRNA 
expression.  Since PABP5 is expressed in the granulosa cells of the ovary, it is 
possible that PABP5 may be expressed within the Sertoli cells of the seminiferous 
tubules.  Low abundance transcripts are notoriously difficult to visualise in this cell-
type due to the diffuse nature of their cytoplasm.  As a result, a more sensitive assay 
such as tyramide signal amplification (TSA) or fluorescent in-situ hybridisation may 
prove appropriate.  Alternatively, RT-PCR could be undertaken on isolated primary 
Sertoli cells to confirm the presence of PABP5 transcript in this cell type.   
 
As a result of the failure of the antibodies tested to detect endogenous PABP5, the 
localisation of PABP5 protein at both the whole tissue and cellular level remains to 
be characterised.  Both commercial antibodies, At164 and Ab140886 detected 
recombinant PABP5 protein by Western blot, implying that the levels of endogenous 
PABP5 may be below the detection threshold of the antibodies rather than being non-
immunoreactive against PABP5 antigen.  This would correlate with the levels of 
PABP5 mRNA which appears to be a low abundance transcript.   
  
My results extend the existing literature with regard to the expression pattern of 
PABPs revealing that PABP1, PABP4, ePABP, tPABP and PABP5 are all expressed 
in gonadal tissues, as detailed below (see table 3.23).  This suggests that PABP 
proteins may have important roles in mammalian gametogenesis consistent with 
tPABP and ePABP being gonad specific.   
 
Expression of PABPs in the Mouse Testes 
Investigation into the subcellular localisation of PABP proteins is largely hampered 
by the high levels of sequence homology between the proteins making generation of 
specific reagents difficult.  Available data shows that PABP proteins are present 
within both the somatic tissues and germ cells within the testes, although the 
distribution of PABP proteins varies between cell types, with some cells containing 
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multiple PABP proteins, yet others apparently only containing one.  The non-
ubiquitous nature of the PABP proteins within the cells of the seminiferous tubules 
might argue against functional redundancy between these proteins, perhaps 
implicating that within certain cell-types different physiological requirements 
necessitate different functional activities.  It is distinctly possible that within these 
cell-types the PABP proteins have specific mRNA targets, thus requiring cell-type 
specific expression.     
 
The Sertoli cells and Leydig cells of the testis are somatic endocrine and paracrine 
cells.  I have shown that PABP4 is expressed in Sertoli and more weakly in Leydig 
cells. Kimura et al. document weak PABP1 expression in Leydig cells but this may 
represent cross-reaction with PABP4 as PABP1 mRNA is not present in these cells. 
Moreover, a second in-house PABP1 specific antibody also failed to detect PABP1 
in Leydig cells (L. McCracken, unpublished).  RT analysis would suggest that 
PABP5 may be expressed in at least one of these cell types, however this requires 
further verification.  tPABP is restricted to specific germ cell stages and is not 
expressed in these somatic cells.  Within the germ cell population, it was extremely 
interesting to note that the cells expressing the highest levels of PABP4 protein, the 
mitotically dividing spermatogonia, were completely devoid of PABP1 and tPABP.  
Kimura et al report weak PABP1 expression which for the reasons given above is 
likely to be cross-reaction.  PABP4 levels are reduced in later germ cell stages 
concomitant with the initial expression of PABP1 and tPABP in spermatocytes. 
tPABP and PABP1 expression peaks in round spermatids (Gu et al., 1995; Kimura et 
al., 2009; Kleene et al., 1994), however only PABP1 expression persists into early 
elongating spermatids.   
 
The loss of PABP proteins during elongation correlates with an important 
deadenylation event within elongating spermatids, where the mRNAs coding for 
protamines and transition proteins involved in chromatin remodelling and packaging 
within the spermatozoa undergo a loss of their poly(A) tails (Kleene, 1989; Kleene, 
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1993; Kleene et al., 1984).  Counter-intuitively, inhibition of PABP protein activity 
appears to be required to facilitate the translational activation of these mRNAs 
(Yanagiya et al., In press).  ePABP mRNA is weakly expressed in testis and this may 
represent its presence in specific germ cell stages as it is restricted to oocytes within 
the ovary in several species (Seli et al., 2005; Wilkie et al., 2005).  No evidence 
supporting PABP5 expression in germ cells is available.  
 
Expression of PABPs in the Mouse Ovaries  
As with the testes, mouse ovaries display a distinct yet overlapping expression 
pattern of PABPs.  Only tPABP is not expressed within this tissue, underlining the 
importance of the PABP proteins and translational regulation in oogenesis.  While 
PABP5 was hypothesised to be expressed predominantly within the Sertoli and 
Leydig cells of the testes, the functional equivalents within the ovary, the granulosa 
and thecal cells, were positively identified as sites of expression of PABP5 mRNA.  
PABP1 and PABP4 were also documented in these cell-types.  The granulosa and 
thecal cells have both endocrine and paracrine functions in follicular development, 
and additionally undergo an enormous expansion in cell number during 
folliculogenesis, therefore it could be argued that there is a requirement for high 
levels of active translation within these cells. 
 
The oocytes within the follicles also appear to express more than one PABP with 
ePABP mRNA (Seli et al., 2005) and PABP4 protein both expressed within these 
germ cells.  While ePABP expression is independent of the follicular stage PABP4 
appears to be less abundant in late ovulatory follicles (L. McCracken, unpublished). 
The necessity for translational regulation in oocytes is well established, because the 
transcriptionally quiescent oocytes rely on proteins produced from maternally 
derived mRNAs.  In particular, changes in poly(A) tail length are important for 
progression through pachytene, dictyate and oocyte maturation in mouse (Gebauer et 
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Spermatogonia x x         
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          
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Sertoli cells 
x x         
          
 
Leydig cells 
x x         
 Kimura         
 
Primary oocyte 
x x     x    
  Seli        
 
Granulosa cell 
          
          
 
Thecal cell 
     /x     
          
 
Stroma 
x x    /x x    
          
 
OSE 
x x     x    
          
 
Corpus luteum 
          
          
 
Table 3.23  PABP distributions within mouse gonads.  Ticks and crosses represent 
expression levels documented within thesis.   = strong expression observed,  = 
moderate expression observed,  = weak expression observed, X = no expression 
observed.  Blank boxes represent cell types in which expression levels remain to be 
determined.  Gu = expression in this cell type reported by Gu et al. 1995, Kimura = 
expression in this cell type reported by Kimura et al. 2009, Seli = expression in this cell type 
reported by Seli et al. 2005, Kleene = expression in this cell type reported by Kleene et al. 
1994. 
 
Following ovulation the remaining granulosa and thecal cells of the follicle form an 
endocrine structure called the corpus luteum.  PABP1 and PABP4 protein, as well as 
PABP5 mRNA was documented in this tissue with PABP1 and PABP5 being at 
lower levels than other positively staining cell types.  Whether this is residual 
expression from follicles that have recently undergone ovulation or is physiologically 




PABP Gametogenesis Phenotypes 
Unfortunately, there are no published mouse models for any of the PABP proteins, 
and therefore no attributable mammalian phenotypes.  In the available invertebrate 
models, roles in gametogenesis have been suggested based on the phenotypes.  In 
Caenorhabditis elegans for example ethyl methanesulphonate (EMS) screens and 
RNAi knock-downs of the Pab-1 and Pab-2 genes suggest that the proteins may have 
a redundant function within the soma but that Pab-1 is essential in the germline 
(Maciejowski et al., 2005).  P-element insertions that disrupt pAbp function in 
Drosophila can also lead to meiotic defects during spermatogenesis (Fasulo et al., 
1999). The data described here suggest that loss of PABP function in mammals is 
also likely to result in gametogenesis defects. In support of this loss of function of 
the PABP regulatory protein PAIP2 disrupts spermatogenesis in mouse (Yanagiya et 
al., In press). 
 
In this chapter I have described the expression of a novel mammalian poly(A)-
binding protein, PABP5, and characterised its mRNA distribution within mouse 
ovarian tissue.  I have shown that the mRNA localises to somatic cells within the 
ovary that also contains the PABP proteins PABP1 and PABP4.  The requirement for 
multiple PABP proteins in single cells is unclear, although interestingly, recently 
submitted data from within our laboratory (B. Gorgoni, submitted) suggests that 
despite a high degree of protein sequence conservation PABP1, PABP4 and ePABP 
only have partially redundant roles.  The difference in domain structure between 
PABP5 and the other PABP proteins raises interesting questions pertaining to its 




























4.1  Introduction and Aims 
Most functional data pertaining to the poly(A)-binding proteins is derived from 
studies of the prototypical family member, PABP1.  While little is known regarding 
the functions of the other PABP proteins, a conserved role in the regulation of 
mRNA translation and stability appears likely from the limited experimental 
evidence available.  There is currently no data pertaining to the physiological or 
molecular functions of PABP5.     
 
PABP5 is frequently referred to as a cytoplasmic PABP (Gorgoni and Gray, 2004; 
Mangus et al., 2003), although there is no published evidence of its subcellular 
distribution.  The classification of PABP5 as a cytoplasmic protein is based on 
phylogeny, as PABP5 shares a common RRM domain structure with other 
cytoplasmic PABPs, and bears little structural homology to the nuclear PABPs (see 
figure 1.9 and figure 1.11).  PABP5 lacks both the proline-rich linker region and the 
C-terminal domain present within other cytoplasmic poly(A)-binding proteins, and  
the functional implications of this are unknown.  Given that these domains facilitate 
a number of interactions with protein factors promoting PABP1 activity (Mangus et 
al., 2003) PABP5 could be envisaged to have a function that differs from that of 
PABP1.  In opposition to this, there is data suggesting that PABP5 might share a 
degree of functional similarity to PABP1 even in the absence of a C-terminal 
domain.  Firstly, yeast growth was completely unaffected by the removal of the 
entire yeast Pab-1 C-terminus (Sachs et al., 1987) and secondly, a truncation mutant 
of Xenopus PABP1 that contains only RRMs 1-4 was capable of stimulating 
translation in-vivo when tethered to a reporter mRNA (Gray et al., 2000).  Indeed the 
closed loop model facilitated by the PABP1-eIF4G interaction occurs within PABP1 
RRM2 (Imataka et al., 1998; Kessler and Sachs, 1998) which could feasibly still 




Within this chapter I begin to dissect the molecular functions and interactions of 
PABP5 with regards to a potential role in translational regulation by direct 
comparison with PABP1.  
 
4.2  EGFP-tagged PABP5 is Localised to the Cytoplasm 
While PABP1 is localised predominantly to the cytoplasm the subcellular 
localisation of PABP5 is unknown.  A predominantly cytoplasmic localisation would 
be consistent with a role in translational regulation or mRNA stability.  Since lack of 
a functional antibody prohibits the determination of the subcellular localisation by 
immunofluoresence it was decided to clone mouse PABP5 into a mammalian 
expression vector.  HeLa cells were transiently transfected with the resulting vector 
which expressed PABP5 as an N-terminally tagged fusion with enhanced green 
fluorescent protein (EGFP).  A vector expressing only EGFP was also transfected.  
GFP is known to localise to both the nucleus and cytoplasm in transfected vertebrate 
cells (Ogawa et al., 1995).  Mouse PABP1 was also cloned into the same vector to 
establish any effects of overexpression on subcellular localisation.  It has previously 
been reported that overexpressing GFP-PABP1 in a HeLa cell-line can result in a 
homogeneous cellular distribution of the protein (Afonina et al., 1998), but that cells 
expressing low levels of GFP-PABP1 display a predominantly cytoplasmic 
localisation, mirroring the endogenous protein (Afonina et al., 1998).  It was 
therefore decided to transfect 100ng of the EGFP-PABP constructs rather than 3µg 
which was sufficient to drive nuclear accumulation of the GFP-PABP1 protein 
(Afonina et al., 1998).  Upon transfection EGFP-PABP5 predominantly localised to 
the cytoplasm, as did EGFP-PABP1 (see figure 4.1).  EGFP had a homogeneous 
cellular distribution as was expected.  A number of cells (approximately 10%) 
contained nuclear localised EGFP-PABP1 and EGFP-PABP5.  Whether this is 
physiologically relevant is unclear.  These cells could simply represent cells with 
higher levels of expression, but quantification of the signal intensity to score cells 





Figure 4.1  Localisation of EGFP-PABP proteins.  HeLa cells were transiently transfected 
with 100ng of EGFP, EGFP-mouse PABP1, or EGFP-mouse PABP5 mixed with 1.9µg of 
carrier DNA.  Cells were counterstained with DAPI (blue) to mark the nucleus.  Single 
channel images in grayscale are shown. 
 
The cytoplasmic distribution of EGFP-PABP5 was then determined in two further 
cell lines – the mouse fibroblast cell-lines 3T3 and L929.  As with HeLa cells, 
PABP5 localised predominantly to the cytoplasm suggesting that the localisation is 






4.3  Overexpressed PABP5 Co-Localises with Polysomes 
Cellular translation occurs within the cytoplasm, therefore the localisation of PABP5 
to the cytoplasm is in agreement with a potential role in translational regulation.  If 
PABP5 is a stimulator of translation it could be expected to associate with 
polysomes.  Sucrose gradient fractionation of cell and tissue lysates is a widely 
utilised tool, used to establish if proteins co-sediment with polysomes, and indeed 
PABP1, PABP4 and ePABP are present in the polysomal fractions (Gu et al., 1995; 
Proweller and Butler, 1996; Wilkie et al., 2005) (H.Burgess, unpublished).  HeLa 
cells transfected with T7-tagged PABP1 and PABP5 were treated with 
cycloheximide prior to extracts being resolved on 20-50% sucrose gradients.   
 
Cycloheximide affects the translocation step during translation elongation to ‘freeze’ 
translating ribosomes on the mRNAs.  As a control untransfected HeLa cells were 
also subjected to fractionation.  As expected a proportion of PABP1 (both 
endogenous and overexpressed) localised to the polysomal regions of the sucrose 
gradient as determined by Western blotting (see figure 4.3).  Interestingly a similar 
proportion of PABP5 also co-sedimented with the polysomal fractions.  
 
To determine if this co-sedimentation was likely to represent bona fide polysomal 
association a puromycin ‘release’ experiment was performed in tandem.  Puromycin 
is an aminonucleoside antibiotic that causes premature chain termination during 
translation by entering the ribosomal A-site and joining the growing peptide causing 
premature release and dissociation of the ribosome.  Thus, factors associated with 
polysomes will shift towards free messenger ribonucleoprotein (mRNP) fractions.  
Investigators frequently utilise ethylenediamine-tetraacetic acid (EDTA) as a similar 
control, but this treatment is not specific to ribosomes and can lead to erroneous 
conclusions regarding whether factors are truly polysome associated.  While all the 
PABP proteins appeared to release with puromycin treatment, and this corresponded 
to a resulting increase in ‘free’ 80S monoribosomes, the release was far from 
satisfactory.  This could reflect only some of the PABP proteins in these fractions 
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associating with polysomes, as previous puromycin release experiments have 
demonstrated that some PABP1 remains in polysomal fractions (Kozak et al., 2006).  
Alternatively, this may reflect the effectiveness of puromycin which functions best in 
salt concentrations greater than  300mM, higher than in our assays (Blobel and 




Figure 4.2  Localisation of EGFP-PABP proteins in different cell types.  HeLa, 3T3, or 
L929 cells were transiently transfected with 100ng of EGFP, EGFP-PABP1, or EGFP-PABP5 
mixed with 1.9µg of carrier DNA.  Cells were counterstained with DAPI (blue) to mark the 





Of interest was the observation that ectopically expressed PABP5 appeared to have 
little effect on the polysome profile when compared to the untransfected cells (see 
figure 4.3).  If PABP5 was a potent general translational repressor or stimulator 
overexpression might be expected to promote or inhibit the formation of polysomes.  
Overexpression of PABP1 also appeared to have little effect on mRNA distribution 
perhaps suggesting that the HeLa cells are unresponsive to overexpression of 
PABP1.  Perhaps a more likely explanation is that overexpression of PABP1 results 
in downregulation of endogenous PABP1 via the ARS in the 5’-UTR of PABP1 
mRNA, thus maintaining similar levels of the protein. 
 
It was concluded from the polysome analysis that at least a proportion of the 
overexpressed PABP5 protein was possibly associated with polysomes, although 
care must be taken when interpreting these experiments as a polysomal association 
does not imply a direct role in translation and it is possible that PABP5 could be 
performing a function that requires association with mRNA in a non-translational 
capacity, such as that of a stability factor.  Thus, the translational stimulatory activity 






Figure 4.3  Polysome association of PABP proteins.  (A) Untransfected (B), T7-PABP1 
transfected or (C) T7-PABP5 transfected HeLa cells were lysed in buffer containing 
cycloheximide or puromycin and subjected to sucrose gradient fractionation.  Absorbance of 
the collected fractions was measured at 254nm and plotted.  Red line = cycloheximide 
treatment, black line = puromycin treatment.  The protein was extracted from the fractions by 
trichloroacetic acid precipitation and was subjected to Western blotting with relevant 






4.4  PABP5 Has Little Activity in The Tether Function Assay 
The Tethered Function Assay 
The finding that PABP5 was possibly polysomal fitted with the hypothesis that 
PABP5 may indeed be a translational regulatory protein.  To investigate the 
translational stimulatory activity of PABP5 directly the tethered function assay was 
utilised (depicted in figure 4.4).  The tethered function assay has the advantage of 
being able to test the function of a protein without needing to know the endogenous 
target binding sequence as the ability of PABP5 to bind poly(A) has not been 
determined.  Additionally, tethering avoids the complications of other endogenous 
PABP proteins which would otherwise need to be depleted (Kahvejian et al., 2005).  
A number of tethering approaches have been described, each of which revolves 
around the generation of a fusion protein containing the protein of interest fused to a 
second peptide or protein that binds with high affinity to a known sequence element 
inserted into a reporter mRNA.  The most common tethered function assays utilise 
the RNA-binding domain of the λ phage antiterminator protein N with its specific λ-
N binding site (called a boxB site) (Baron-Benhamou et al., 2004; De Gregorio et al., 
2001) or conversely the bacteriophage coat protein, MS2, which recognises a 
structural stem loop termed an MS2-binding site.  This assay has been utilised to 
investigate the translational activity of other PABPs (Gray et al., 2000; Wilkie et al., 
2005).    
 
All tethered function assays performed within this thesis were undertaken in 
microinjected stage VI oocytes derived from Xenopus laevis frogs.  While translation 
assays could be performed in cultured cell-lines, reporter mRNAs with no poly(A) 
tail would not be efficiently exported from the nucleus and so RNA transfections 
would be required.  Additionally, the lack of a poly(A) tail would render the reporter 
mRNAs vulnerable to degradation.  In contrast mRNAs can be injected directly into 
the cytoplasm of Xenopus oocytes, and have been demonstrated to be highly stable 
within these cells (see figure 1D in Gray et al., 2000).   
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Oocytes were injected with in-vitro transcribed mRNAs coding for the test and 
control proteins fused to an N-terminal MS2 tag.  MS2-U1A mRNA serves as a 
negative control (Gray et al., 2000).  U1A is an RRM containing protein that forms 
part of the U1 small nuclear ribonucleoprotein (snRNP) complex that is essential in 
pre-mRNA splicing, but does not regulate translation (Jovine et al., 1996).   
 
Following a six hour incubation to allow expression of the fusion protein two mRNA 
reporters were simultaneously co-injected, a m7G capped unadenylated luciferase 
reporter mRNA and an internal control β-galactosidase (β-gal) mRNA (see figure 
4.4).  The luciferase reporter contains three MS2-binding sites within its 3’-UTR that 
serve as tethering sites for the fusion protein.  The translational effects of tethering 
the fusion protein to the reporter mRNA can then be directly measured by luciferase 
protein production.  The β-gal reporter is incapable of binding the fusion protein as it 
contains no MS2 sites within its 3’-UTR.  Therefore, variability in injection volumes 
and also the translational capacities of different oocytes can be corrected for by 
normalising the luciferase units to the β-gal light units.  The β-gal reporter mRNA 
was unadenylated and contained an artificial ApppG (ApG) cap and a CSFV IRES 
within the 5’-UTR rather than a physiological m7G cap.  The utilisation of a β-gal 
reporter that lacks a functional cap and a poly(A) tail decouples translation of this 
reporter from the effects of overexpressing PABP proteins.  After reporter mRNA 
injections the oocytes were incubated overnight before assaying.  
 
Oocytes were assayed in batches of five, with a minimum of twenty oocytes per 
experimental point.  The value obtained from the MS2-U1A fusion protein was 
always set to one.  All other values were then corrected relative to MS2-U1A.  
Multiple experiments were undertaken to generate a data set, using oocytes collected 
from different female Xenopus frogs.  The stimulation values were averaged to give a 






Figure 4.4  The tethered function assay.  A.  Oocytes collected from Xenopus laevis are 
injected with mRNA encoding a fusion protein (depicted in B) consisting of the protein to be 
tested fused to bacteriophage MS2 coat protein.  Following incubation the oocytes are 
simultaneously injected with a luciferase reporter containing MS2-binding sites within its 3’-
UTR, and a control β-galactosidase mRNA (depicted in C).  The fusion protein MS2-proteinX 
then binds the MS2-binding sites within the luciferase reporter mRNA 3’-UTR (depicted in D).  
Following a further incubation, the effect of tethering protein X on the translation of the 
reporter can be assessed by directly measuring luciferase protein production.  Luciferase 
units are normalised to β-galactosidase units to correct for small variations in the amount of 





Human PABP5 Activity in the Tethered Function Assay 
To investigate the ability of human PABP1 and PABP5 to stimulate translation 
tethered function assays were performed as described above, with mRNAs coding for 
MS2-PABP5, MS2-U1A and MS2-PABP1 (see figure 4.5A).  MS2-PABP1 
stimulated translation approximately 6-fold over MS2-U1A.  In contrast, MS2-
PABP5 only stimulated translation approximately 2-fold (see figure 4.5A), with a 
lowest stimulation value of 0.66-fold over MS2-U1A and a highest of 3.1-fold.  The 
average stimulation value for PABP5 represents the lowest value reported for a 
PABP protein using this assay, as various Xenopus PABP proteins have been 
demonstrated to stimulate translation up to 7-fold over the control injected protein 
(Gray et al., 2000; Wilkie et al., 2005).  To demonstrate the specificity of the fusion 
protein activity on the reporter mRNAs the raw luciferase and β-gal values from five 
different experiments were plotted (see figure 4.5B).  The β-gal values appeared to 
be largely consistent between different experiments, suggesting that the β-gal 
reporter values were unaffected by the overexpressed fusion protein, and that the 
translational stimulation was through stimulatory effects on the luciferase reporter.  
 
Mouse PABP5 Activity in the Tethered Function Assay 
Previously published data has shown that PABP1 proteins from different species 
have differing capacities to stimulate translation in the tethered function assay.  For 
example Saccharomyces cerevisiae Pab-1 stimulates translation 35-fold over a 
control protein, compared to 7-fold for Xenopus laevis PABP1 (Gray et al., 2000).  
To determine if the reduced translational activity observed by human PABP5 is a 
species specific effect, mouse PABP5 and mouse PABP1 were also tested by 
tethered function assay (see figure 4.6A).  As with the human protein, mouse PABP5 
had a reduced capacity to stimulate translation compared to mouse PABP1, with an 
average stimulation value of approximately 1.5-fold over MS2-U1A.  Thus, in a 
tethered function assay mammalian PABP5 appears to have limited translational 










































































Figure 4.5  Human PABP5 has a reduced capacity to stimulate translation compared 
to human PABP1.  A.  The translational stimulatory activity of human PABP1 (Hs PABP1) 
and human PABP5 (Hs PABP5) on a luciferase reporter mRNA was tested by tethered 
function assay in Xenopus oocytes.  Relative luciferase units (RLU) were calculated by 
normalising luciferase reporter units to the β-galactosidase internal control units.  The 
stimulation values for five separate experiments were averaged and the standard error 
calculated.  MS2-U1A was set to one and all other values were corrected to MS2-U1A.   
While PABP1 stimulated translation approximately 6-fold over U1A, PABP5 only stimulated 
approximately 2-fold.  B.  The raw luciferase and β-galactosidase values generated by the 
tether function assay. 





To determine the extent to which this result reflects a translational effect, effects on 
luciferase reporter mRNA stability must be formally ruled out.  Indeed, the levels of 
luciferase protein may be the net effect of a large increase in reporter translation 
combined with a simultaneous increase in mRNA degradation.  Conversely, the 
stimulatory activity seen by PABP1 could be a result of the tethered PABP1 protein 
stabilising the reporter mRNAs.  As mentioned previously, exogenously introduced 
mRNAs are remarkably stable within Xenopus oocytes and therefore stabilisation is 
unlikely to result in the 5- to 6-fold stimulation visualised by tethering PABP1 to the 
reporter.  Previously,  Xenopus laevis PABP1 and ePABP and Saccharomyces 
cerevisiae Pab-1 have been demonstrated to have minimal effects on reporter mRNA 
stability in a tethered function assay (Collier et al., 2005; Gray et al., 2000; Wilkie et 
al., 2005).   
 
Effects on stability were determined by harvesting oocytes immediately (t=0) or 16 
hours (t=16) following the luciferase reporter injection.  Total mRNA from the 
oocytes was extracted and cDNA was prepared.  The cDNA was then subjected to 
quantitative real-time PCR (QPCR) using primers specific for the luciferase reporter.  
This assay was chosen to circumvent the need to use radioactive material, and also 
due to the high sensitivity offered by using a PCR based assay. SYBR green QPCR 
assays have been used previously in the laboratory to determine mRNA stability 
(Wilkie et al., 2005).  SYBR green fluorescence increases dramatically upon binding 
the minor-groove of DNA and can therefore be used as a direct readout of the level 
of PCR product present within a reaction.   
 
Oocytes were injected with MS2-U1A, MS2-PABP1 (mouse), MS2-PABP5 (mouse) 
and MS2-PABP5 (human) and harvested as described above.  The mRNA was 
harvested from batches of five oocytes and 1µg of total mRNA was added to each 
reverse-transcriptase reaction to produce cDNA.  Following cDNA production, the 
equivalent of 0.1µl from each reverse-transcriptase reaction was added to each 
QPCR reaction.  The data was subsequently plotted as a measure of cycle threshold 
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(CT) number, that is the number of PCR cycles required for the fluorescent signal to 
cross a defined threshold value (i.e. exceeds the background level).  The results of 
two separate experiments were averaged and standard error calculated.  The data is 
plotted in figure 4.6B.  There appeared to be little difference between the luciferase 
reporter CT scores at t=0 and t=16 for all the fusion proteins injected.  Two-tailed 
Student’s t-tests were performed and differences between the paired time-points were 
deemed not statistically significant for all samples (p>0.05).  This shows that the 
differences in expression levels of luciferase protein are true translational effects and 
are not a function of altered luciferase reporter mRNA stability within oocytes as a 
result of tethering the MS2-fusion proteins. 
 
PABP1 Truncation Mutant Activity in the Tethered Function Assay 
Why PABP5 has a markedly reduced translational stimulatory activity is unclear.  
PABP5 lacks the proline-rich linker region and PABC domain important for 
facilitating a number of protein-protein interactions.  It was therefore hypothesised 
that these missing regions may be partially or wholly responsible for the lack of 
translational activity.  To test this hypothesis, full-length and truncation mutants of 
Xenopus laevis and mouse PABP1 were cloned and transcribed as MS2-fusion 
mRNAs for tethered function assay (see figure 4.7A).  Interestingly, mouse PABP1 
RRMs 1-4 was capable of stimulating translation of the luciferase reporter 4-fold 






















































































Figure 4.6  The low translational stimulatory activity of PABP5 is conserved between 
species.  A.  The translational activities of mouse PABP1 (Mm PABP1) and mouse PABP5 
(Mm PABP5) were tested by tethered function assay.  The stimulation values for four 
separate experiments were averaged and the standard error calculated.  RLU = relative 
luciferase units.  B.  Oocytes expressing MS2-U1A, MS2-PABP1 (mouse), MS2-PABP5 
(mouse) and MS2-PABP5 (human) were injected with luciferase reporter mRNA.  Total 
mRNA was extracted from the oocytes immediately following reporter injection (t=0) or 
following a 16 hour incubation (t=16).  cDNA was prepared from the mRNA and used for 
SYBR green QPCR.  The variability between time points for each MS2-fusion protein 
injection was calculated as not significant by two-tailed Student’s t-test (p>0.05). 
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This result mirrored that of Xenopus PABP1 RRMs 1-4 against the full-length 
protein (5-fold and 7-fold respectively).  Of all the full-length PABP1 proteins tested, 
Xenopus laevis PABP1 stimulated translation of the luciferase reporter to the highest 
degree.  This could be a result of the tethered function assays being performed in a 
Xenopus oocyte background, with endogenous factors perhaps having a lower 
functional affinity for the mammalian fusion proteins.  These data imply that lacking 
the C-terminus is not the sole reason for a lack of translational activity, although both 
the Xenopus and mouse PABP1 RRM 1-4 truncation mutants stimulate translation to 
a lesser degree than the full-length wild-type protein suggesting that the C-terminus 
of PABP1 does contribute to the translational activity.  Indeed the previously 
published data showed that both the ePABP and PABP1 C-termini could stimulate 
translation 2-fold over MS2-U1A in a tethered function assay, although the 
mechanism of this stimulation was unclear and the authors warn that it may be a 
result of endogenous PABP recruitment to the luciferase reporter mRNA (Gray et al., 
2000). 
 
Lack of translational activity shown by PABP5 in this assay might be the poor 
expression of the MS2-PABP5 fusion protein.  To determine that the fusion proteins 
were being efficiently expressed, oocytes were injected with mRNAs coding for the 
fusion proteins and were metabolically labelled by incubation in a buffer containing 
35S-methionine for six hours.  Following the incubation the oocytes were collected, 
lysed and subjected to SDS-PAGE, then the labelled proteins were visualised by 
autoradiography.  All newly synthesised proteins were visible including the fusion 
proteins (see figure 4.7B).  The signals for the mouse and human PABP5 fusion 
proteins were visibly weaker than their corresponding PABP1 counterparts.  
However, this is largely a reflection of the number of methionines within the proteins 
as mouse and human PABP5 only contain 8 methionines whereas mouse PABP1 
RRMs 1-4 contains 15 methionines.  These data suggest that the lack of translational 
activity is not as a result of the MS2-PABP5 mRNA failing to express the MS2-








































































Figure 4.7  PABP1 C-terminal truncation mutants have translational stimulatory 
activity.  A.  The translational activities of U1A, PABP1, PABP5 and PABP1 truncation 
mutants were tested by tethered function assay as described above.  The stimulation values 
for four separate experiments were averaged and the standard error calculated.  RLU = 
relative luciferase units.  Mm = mouse, Hs = human, Xl = Xenopus laevis.  B.  The fusion 
proteins are expressed.  Oocytes were injected with mRNA coding for the fusion proteins 
then incubated in buffer containing 35S methioine to label new proteins.  After incubating for 6 
hours oocyte lysates were prepared and run on an SDS-PAGE gel before being subjected to 




4.5  PABP5 Fails to Interact with Translation Initiation Factors 
Data in the previous section suggest that PABP5 has a severely reduced capacity to 
stimulate translation of a reporter mRNA compared to PABP1.  The reasons behind 
the lack of translational activity are unclear.  A number of PABP1 protein 
interactions are thought to promote mRNA circularisation in the closed loop model 
of translational stimulation, including eIF4G (Gray et al., 2000; Imataka et al., 1998; 
Kessler and Sachs, 1998), PAIP-1 (Craig et al., 1998; Roy et al., 2002) and eIF4B 
(Bushell et al., 2001; Cheng and Gallie, 2007).  These interactions have been 
demonstrated to be important for stimulating translation (Bushell et al., 2001; Craig 
et al., 1998; Imataka et al., 1998; Kahvejian et al., 2005).  In addition, other PABP1 
interacting proteins such as PAIP-2, can directly affect PABP1 activity (reviewed in 
Derry et al., 2006).  Thus, interacting proteins play a key role in moderating PABP1 
translational activity.  In the following section I address the possibility that the lack 
of PABP5 activity in the translational assay may be in part due to failure of PABP5 
to bind proteins central to the closed loop mechanism of translational stimulation.  
 
4.6  The Yeast 2-Hybrid Assay 
The yeast 2-hybrid (Y2H) assay is a yeast-based genetic assay utilised to identify 
protein-protein interactions, by taking advantage of the modular nature of 
transcription factors (Fields and Song, 1989).  The reconstitution of a functional 
transcription factor through interacting proteins is exploited in the Y2H assay to 
drive transcription of a reporter gene, often LacZ, allowing quick identification of 
positive yeast colonies by treatment with the β-galactosidase substrate X-gal (see 






Figure 4.8  The yeast 2-hybrid assay.  Fusions consisting of ‘bait’ and ‘prey’ proteins fused 
to the DNA-binding domain (BD) or activating domain (AD) of a transcription factor are 
expressed in yeast.  Upon interaction between bait and prey the transcription factor is 
reconstituted, resulting in the transcription of a reporter gene, LacZ. 
 
 
4.7  PABP5 Fails to Interact with Translation Factors by Y2H Assay 
The Y2H assay was chosen to identify any potential interactions between PABP5 
and known translation factors.  An in-house library of translation factors cloned into 
suitable Y2H GAL4-AD vectors was utilised.  This library has been pre-validated for 
yeast expression within the laboratory (B. Richardson and B. Gorgoni, unpublished).  
Mouse and human PABP5 were therefore cloned into a corresponding Y2H BD 
vector.  The controls used in this assay were Xenopus laevis PABP1 RRMs 1-2 tested 
against IRP (negative control) and the N-terminus of human eIF4G (positive 
control).  Both these interactions have been tested by Y2H previously, in the yeast 
strain used here (Gray et al., 2000).  
 
Mouse PABP5 failed to interact with any of the human translation factors tested by 
Y2H (see figure 4.9A).  In particular, the lack of an interaction with eIF4G could be 
considered unusual as this interaction has been demonstrated for Xenopus ePABP 
(Wilkie et al., 2005) and mouse tPABP (Kimura et al., 2009) in addition to PABP1 





1996), suggesting that it may be a conserved interaction of all the other cytoplasmic 
PABPs.  However, the lack of interaction could be due to PABP5-BD not being 
expressed correctly.  Also, the lexA-BD is approximately 24 kDa therefore 
represents a large peptide which could affect the folding or protein interacting 
capacity of a relatively small protein such as PABP5.  The lack of a positive control 
for PABP5 also makes validation of the expression of PABP5-BD in yeast a 
necessity.  To this end yeast were transformed with mouse PABP5-BD and following 
growth were lysed and subjected to SDS-PAGE followed by Western blotting with a 
primary antibody directed against the LexA-BD.  The PABP5 fusion protein was 
present in all the yeast transformations and was also expressed to a similar degree 
(see figure 4.9B).  In addition, the PABP1 RRMs 1-2 also showed robust expression.        
   
The absence of interaction with eIF4G would reconcile with a lack of translational 
activity in the tethered function assay.  Human PABP5 also failed to interact with 
eIF4G (see figure 4.9C) suggesting that this may be a conserved property of PABP5 
proteins.  Confirmation of this lack of interaction in a second assay is required such 
as a pulldown assay utilising recombinant proteins, or an immunoprecipitation (IP) 






Figure 4.9  Yeast 2-hybrid PABP5 versus translation initiation factors.   A,C.  Mouse 
and human PABP5 respectively were expressed in yeast as fusion proteins with the LexA-
BD.  The translation initiation factors were expressed in the same yeast as fusion proteins 
with the GAL4-AD.  Positive colonies were identified by incubation with X-gal resulting in a 
blue colouration.  Positive control (+ve) = Xenopus laevis PABP1 RRMs 1-2 versus N-
terminus of human eIF4G, negative control (-ve) = Xenopus laevis PABP1 RRMs 1-2 versus 
IRP.  B.  Expression of mouse PABP5-BD fusion protein in yeast.  Antibody was directed 
against the LexA-BD.  PABP5 fusion protein = 67 kDa, PABP1 RRMs 1-2 fusion protein = 43 
kDa.   
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4.8  The eIF4G Residue Responsible for PABP1 Binding is Not 
Conserved in PABP5 
It is known that disruption of the mammalian PABP1-eIF4G interaction is sufficient 
to inhibit translation of reporter mRNAs in-vitro and in-vivo (see chapter 1, section 
1.4.4) (Imataka et al., 1998; Kahvejian et al., 2005), therefore failure of PABP5 and 
eIF4G to interact by Y2H could explain the low levels of translational stimulation 
observed with PABP5 in the tethered function assay.   
 
The eIF4G binding site in PABP1 has been previously mapped to RRM2 (Gray et 
al., 2000; Imataka et al., 1998; Kessler and Sachs, 1998; Otero et al., 1999).  Further 
investigations using isothermal titration calorimetry (ITC) narrowed the binding site 
to a handful of conserved residues (Groft and Burley, 2002).  ITC is a technique that 
is used to determine the thermodynamic parameters of chemical reactions and 
directly measures the heat taken up or evolved upon addition of a ligand to its 
binding molecule.  Thus, binding curves can be determined by plotting heat changes 
in response to increasing amounts of ligand.  Two residues within PABP1 RRM2 
were described as critical for eIF4G binding, methionine 161 (M161) and leucine 
162 (L162).  Mutation of these residues to alanine resulted in complete abolition of 
the interaction (Groft and Burley, 2002).  An additional residue, lysine 157 (K157), 
resulted in significantly decreased eIF4G binding affinity (Kd of 170µM compared to 
the 27µM calculated for wild-type PABP1 RRMs 1-2) (Groft and Burley, 2002).   
 
The M161 to alanine (M161A) PABP1 mutant has been demonstrated to be 
functionally compromised.  In Krebs-2 cell extracts depleted of PABP1, translation 
of a reporter was inhibited 7-fold.  Addition of recombinant wild-type PABP1 but 
not the M161A PABP1 mutant restored translation to levels comparable to 
undepleted extracts (Kahvejian et al., 2005).  Crucially it was demonstrated that the 
M161A mutation does not affect poly(A)-binding activity of PABP1, therefore a 
deficit in translational activity was likely due to inhibition of the PABP1-eIF4G 
interaction (Groft and Burley, 2002). 
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The critical residues M161 and L162 have been described as being conserved 
between PABP1 species from yeast to man (Groft and Burley, 2002).  Upon 
sequence alignment of RRM2 across all the cytoplasmic PABPs in mouse and human 
(see figure 4.10) it was apparent that PABP5 was the only cytoplasmic PABP species 
in which these residues were not conserved, with a valine residue replacing M161 
and an arginine residue replacing L162.  In addition K157 which was described as 
being important for eIF4G binding was substituted with a histidine residue.  
Interestingly K157 is replaced with a threonine in ePABP although this appears to be 
insufficient to prevent binding of Xenopus laevis ePABP to eIF4G (Wilkie et al., 
2005).  In addition to these substitutions in PABP5 which may have functional 
implications, the region around M161 and L162 is not particularly well conserved as 
highlighted by the sequence alignment (see figure 4.10).  This observation could 




Figure 4.10  PABP RRM2 sequence homology.  Mouse and human cytoplasmic PABP 
RRM2 sequence conservation.  Blue shading represents conserved sequence.  The position 
of three amino acids, K157, M161, and L162, are indicated.  These amino acids have been 






4.9  Recombinant Protein Generation 
The sequence alignment mapping the critical eIF4G binding residues would appear 
to correlate with the Y2H data.  Therefore, to confirm that PABP5 and eIF4G fail to 
interact a pulldown assay was performed.  This required generation of recombinant 
proteins.  Both human PABP1 and PABP5 were cloned into the pET28(c)+ bacterial 
expression vector which is based on a T7 promoter driven system.  These clones 
were used to transform E. coli cells expressing the bacteriophage T7-RNA 
polymerase under the control of the lac promoter.  Thus, supplementing the growth 
media with the allolactose analogue isopropyl β-D-1-thiogalactopyranoside (IPTG) 
results in inhibition of the lac repressor and strong expression of T7-RNA 
polymerase.  This in turn induces the rapid expression of the target gene within the 
vector.  The vector contains sequence coding for six consecutive histidine (his) 
residues immediately upstream of the cloning site that forms a tag incorporated into 
the extreme N-terminus of the recombinant protein.  This allows identification of the 
recombinant proteins by Western blotting with a primary antibody raised against the 
his-tag, and additionally can be used to purify the proteins by affinity 
chromatography using a nickel column. 
 
Protocols for T7-promoter driven expression of recombinant PABP5 in E. coli cells 
have previously never been detailed but have been described for the generation of 
recombinant PABP1.  These protocols suggest growth of the transformed E. coli to 
an optical density (O.D.) of 0.3 at 37oC then induction with 0.5mM IPTG at 22oC 
(Woods et al., 2002).  These conditions were used to set up the initial inductions, and 
subsequent optimisation was based around these parameters.  See table 4.11 for all 
induction conditions used.  It was determined that the optimal induction conditions 
differed for the two recombinant proteins with optimal PABP1 induction occurring at 
22oC with 0.5mM IPTG as previously described (Woods et al., 2002).  PABP5 
inductions were more robust at higher temperature and IPTG concentrations (22-
30oC, with 1mM IPTG).  All subsequent inductions post-optimisation were 
undertaken at 22oC with 1mM IPTG.  The recombinant proteins were clearly visible 
after IPTG induction followed by lysis and analysis by SDS-PAGE (see figure 
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4.12A).  The his-tag and the associated vector polylinker region were estimated to 
add approximately 3kDa to the mass of the protein, giving his-PABP1 an estimated 
mass of 75kDa (72kDa + 3kDa) and his-PABP5 a mass of 47kDa (44kDa + 3kDa).  
The induced proteins appeared to migrate in a manner consistent with these 
predictions suggesting that the majority of the recombinant protein produced was 













16oC 4 0.5  - 
22 oC 4 0.5   
22 oC 4 1   
22 oC 4 1.5   
6 oC Overnight 1 ND - 
30 oC 4 1 ND  
 
Table 4.11  E. coli induction conditions.  E. coli cells were transformed with pET28-
PABP1 or pET28-PABP5 and grown to an optical density of 0.3-0.5 before being induced 
using one of the above induction protocols.  ND = not determined.  A hyphen (-) indicates 
that no expression was detectable.  The ticks represent the level of induction as determined 
by SDS-PAGE analysis with one tick indicating a poor induction, two ticks indicating 
moderate induction, and three ticks indicating robust induction.  All inductions post-
optimisation were undertaken at the highlighted parameters. 
 
To confirm that the induced proteins were indeed his-tagged, lysates were subjected 
to SDS-PAGE followed by Western blotting with a primary antibody directed against 
the his-tag (see figure 4.12B).  The majority of the detectable signal for each of the 
proteins corresponded to molecular masses consistent with full-length PABP1 and 
PABP5 proteins.  However, in the PABP1 lysate there was an additional signal 
running at approximately 47kDa. 
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Figure 4.12  Recombinant protein inductions.  A.  E. coli cells were transformed with 
pET28-PABP1 or pET28-PABP5 and induced to express the recombinant proteins.  The 
cells were then lysed and 10µg of the lysate was subjected to SDS-PAGE.  The gel was then 
stained with GelCode Blue (Thermo Scientific).  The PABP1 and PABP5 histidine-tagged 
proteins had predicted molecular masses of 75kDa and 47kDa respectively.  The black stars 
indicate the induced proteins.  B.  Lysate containing recombinant Histidine-tagged PABP1 or 
PABP5 was subjected to SDS-PAGE followed by Western blotting with an anti-polyhistidine 
antibody.  The his-PABP1 and his-PABP5 signals are indicated by black arrows. 
 
 
The fact that it is detectable implies that it contains a his-tag, therefore this was 
considered a breakdown product of the full-length protein.  Given that the his-tag is 
N-terminal and that the signal is of very similar mass to PABP5, it is possible that 
this signal represents RRMs 1-4 of PABP1.  The flexible proline-rich linker region is 
known to be vulnerable to protease attack (Joachims et al., 1999; Kuyumcu-Martinez 
et al., 2002; Kuyumcu-Martinez et al., 2004).  The PABP5 Western also picks up an 
additional signal running immediately underneath the full-length protein at 
approximately 43kDa.  Again this protein must represent a C-terminal truncation as 




Figure 4.13  Recombinant PABP1 purification.  A.  His-PABP1 was purified from E. coli 
lysate by affinity chromatography using nickel agarose.  15µl of the two final bead washes 
(W2 and W3) and the elutions from the beads (E1, E2, and E3) were subjected to SDS-
PAGE followed by staining with GelCode Blue (Thermo Scientific).  The arrow indicates full-
length PABP1 protein.  In lane E1 the possible his-tagged RRM 1-4 breakdown product is 
visible.  B.  0.1µl of purified recombinant PABP1 from E2 and E3 was subjected to Western 
blotting with an anti-PABP1 antibody raised against a peptide derived from the extreme C-
terminus of the human PABP1 protein.  The arrow indicates the presence of the full-length 
protein.       
 
E. coli cell lysates containing recombinant PABP1 and PABP5 were subsequently 
subjected to affinity chromatography with a nickel column to purify the his-tagged 
proteins.  While PABP1 purified in significant quantity and to relative homogeneity 
(see figure 4.13A) PABP5 could not be purified in quantity under the conditions used 
(figure 4.14A).  The presence of recombinant PABP5 within the unbound fraction 
(flow-through) of the purification procedure implied that the protein was not binding 
the nickel-agarose beads with high affinity (see figure 4.14A).  A possible 
explanation could be that the his-tag was partially buried within the protein so as not 
to be accessible to the nickel-agarose.   
 
Following purification both PABP1 and PABP5 were subjected to Western blotting 
(figures 4.13B and 4.14B respectively).  To test for the presence of PABP1 N-
terminal truncations which would not be detectable by Western blot against the N-
terminal his-tag, Western blotting was performed with an antibody raised against an 
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extreme C-terminal peptide of the PABP1 protein (see figure 3.7; Chapter 3).  The 
resulting signal corresponded only to the full length protein (see figure 4.13B) 
therefore it was concluded there were no N-terminal truncations suggesting that 
PABP1 was not subject to breakdown following purification.  The only available 
antibodies for PABP5 were raised against full-length PABP5 protein, therefore the 
epitopes are unknown and the same conclusions could not be drawn regarding 




Figure 4.14  Recombinant PABP5 purification.  A.  his-PABP5 was purified from E. coli 
lysate by affinity chromatography using nickel agarose.  10µl of the flow-through (FT) bead 
washes (W1, W2, and W3) and elutions from the beads (E1, E2, E3, and E4) were subjected 
to SDS-PAGE followed by staining with Coomassie protein stain.  The arrow indicates full-
length PABP5 protein.  The star indicates the recombinant PABP5 protein in the flow-
through.  B.  1µl of purified recombinant PABP5 from E4 was subjected to Western blotting 
with two antibodies raised against PABP5 (HPA000164 and HPA000165).  The arrow 
indicates the presence of the full-length protein.       
 
 
The quantities of PABP5 recombinant protein retrieved by affinity chromatography 
were below the detection threshold for quantification by Bradford assay, therefore it 
was decided to quantify the proteins using SYPRO Ruby protein stain (Invitrogen).  
SYPRO Ruby is a sensitive luminescent stain that is not amino acid biased therefore 
is suitable for quantitation of proteins.  The proteins were subjected to SDS-PAGE 
along with BSA standards.  The gel was then stained with SYPRO Ruby protein stain 
as per manufacturer’s instructions and scanned using a Typhoon Variable Mode 
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Imager with a 488nm excitation laser.  The PABP5 protein was calculated to be at a 
concentration of 15.44ng/µl (0.357µM) while PABP1 was calculated to be at a 




Figure 4.15  Recombinant eIF4G proteins.  A.  Schematic representation of the eIF4G 
recombinant proteins.  Both proteins are C-terminally FLAG-tagged.  FR4G lacks the N-
terminal PABP1 binding site that is retained in the full-length protein (FL4G).  The binding 
sites of other eukaryotic initiation factors are depicted (eIF4E, eIF4A, and eIF3).  B.  200ng 
of each recombinant eIF4G protein was subjected to SDS-PAGE and the gel was stained 
with GelCode Blue.  C.  E. coli cells containing recombinant PABP1 or recombinant PABP5 
were lysed in a buffer containing 25 units of benzonase per ml of buffer.  As a control un-
induced E. coli lysate was lysed in the same buffer but lacking benzonase.  The RNA was 
extracted from the samples using Tri-Reagent (Ambion) and was subjected to agarose gel 





4.10  PABP5 Does Not Interact With eIF4G By Pulldown Assay 
The importance of the PABP1-eIF4G interaction in facilitating closed loop or end-to-
end complex formation is documented in chapter 1, section 1.4.4.  A schematic of the 
full-length eIF4G protein with key binding sites is depicted in figure 4.15A.  To 
further substantiate the finding that PABP5 and eIF4G do not interact in a Y2H assay 
pulldown experiments using recombinant proteins were performed.  Two 
recombinant human FLAG-tagged-eIF4G proteins were utilised for this experiment, 
one containing the N-terminal PABP1 binding site (FL4G) and one lacking this site 
(FR4G).  The FL4G and FR4G samples were estimated to be ≥95% pure and ≥75% 
pure respectively.  These proteins were a kind gift from Dr Simon Morley 
(University of Sussex) and are schematically depicted in figure 4.15A and visualised 
on a protein gel in figure 4.15B.  These proteins could be bound to anti-FLAG 
antibodies conjugated to an agarose affinity resin (Sigma-Aldrich) and tested for 
binding to recombinant PABP5.  Given the problems in purifying significant 
quantities of PABP5 protein, it was decided to undertake the assay using E. coli 
lysate containing either recombinant PABP1 or recombinant PABP5, as the proteins 
could both be expressed to a significant and similar degree within these cells (see 
figure 4.12B).  The E. coli lysates were prepared with a lysis solution containing 
benzonase which has both RNA and DNA endonuclease activity to avoid indirect 
interactions mediated by mRNA-binding.  The activity of the benzonase in the lysis 
solution was sufficient to promote degradation of the bacterial RNAs to small 
oligonucleotide fragments which can be visualised in 4.15C.   
 
FLAG-tagged eIF4G was bound to the anti-FLAG antibody agarose affinity resin 
and was subsequently incubated with E. coli lysate containing either recombinant 
PABP1 or recombinant PABP5.  Following the incubation the beads were washed 
and the proteins eluted into protein loading buffer for analysis by SDS-PAGE 
followed by Western blotting with an anti-his antibody.  PABP1 could be pulled 
down using full-length eIF4G, and as expected could not be isolated using the eIF4G 
truncated protein lacking the PABP1 binding site (see figure 4.16A).  Interestingly in 
the same pulldown assay recombinant PABP5 could not be pulled down with the 
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full-length or truncated eIF4G proteins.  This is in agreement with the Y2H assay and 
the PABP5 protein sequence data.   
 
It is known that PABP1 can also interact with eIF4GII in-vivo (Imataka et al., 1998).  
The binding site for PABP1 within eIF4GI was determined and found to be 
remarkably well conserved in eIF4GII (see figure 4.16B) (Imataka et al., 1998), thus 
while any interaction between PABP5 and eIF4GII has yet to be investigated, it is 





Figure 4.16  Pulldown of PABP proteins with eIF4G.  A.  FLAG-tagged full-length eIF4G 
(FL4G) or truncated eIF4G lacking the PABP1 binding site (FR4G) were bound to anti-FLAG 
affinity resin and incubated with E. coli lysate containing his- tagged PABP1 or PABP5.  
Resin containing no bound eIF4G protein was included as a control pulldown.  The inputs 
represent 3% of the lysate added to the eIF4G resin.  Proteins were eluted and subjected to 
SDS-PAGE followed by Western blotting with an anti-polyhistidine antibody.  B.  Sequence 




4.11  PABP5 is Poorly Isolated by m7G-cap Chromatography 
The binding of PABP1 and eIF4G is one of the core interactions responsible for the 
formation of the closed loop conformation of mRNAs that promotes their translation.  
PABP1 has also been demonstrated to interact with other proteins associated with the 
cap-binding complex to stabilise the closed loop conformation, such as eIF4B and 
PAIP-1.  As a result of these interactions PABP1 can be isolated as part of the eIF4F 
complex by m7G-cap affinity chromatography (Bradrick and Gromeier, 2009; Gallie 
et al., 2000; Willett et al., 2006).  Whether the lack of an observable interaction 
between PABP5 and eIF4G would preclude an association of PABP5 with the cap 
complex is unknown. 
 
To investigate whether PABP5 can associate with the cap-binding complex m7G-cap 
affinity chromatography was performed using lysate derived from HeLa cells that 
had been transiently transfected with T7-tagged PABP5.  As a positive control 
untransfected HeLa cell lysate was also assayed for the association of endogenous 
PABP1 with the cap-complex, as well as lysate derived from HeLa cells transiently 
transfected with T7-tagged PABP1.  Western blotting with an antibody directed 
against the T7-tag allows for the levels of T7-PABP1 and T7-PABP5 isolated in this 
assay to be determined, and assuming equal expression levels allows their relative 
affinities for the cap-complex to be directly compared.  Western blotting with 
antibodies against eIF4E and tubulin was also undertaken to determine the specificity 
of the assay as tubulin is not predicted to bind cap complexes, while it could be 
predicted that eIF4E would be enriched.  The results of the m7G-cap chromatography 
assay are depicted in figure 4.17. 
 
The inputs represent 7.5% of the amount of lysate subjected to cap-chromatography.  
Interestingly, eIF4E was undetectable in the input lysate lanes.  This was attributed to 
two factors.  Firstly was the detection level of the antibody, as the signal for eIF4E 
was only observable upon extended film development times compared to the other 
blots which were developed simultaneously and with shorter development times, and 
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secondly was the level of eIF4E which is frequently described as being a limiting 
initiation factor and rate limiting in eIF4F complex formation (Duncan et al., 1987; 
Goss et al., 1990; Hiremath et al., 1985).   
 
In the untransfected cell lysates a small amount of PABP1 can be isolated by cap-
chromatography.  In the T7-PABP1 overexpressed lysates PABP1 is expressed to a 
markedly higher degree than the endogenous protein and this is reflected in the 
greater amount of PABP1 in the pulldowns.  Thus, the more PABP1 present, the 
more can be isolated by cap-chromatography.  This suggests that not all cap 
complexes associated with the m7G-sepharose in the untransfected lysates are bound 
by PABP1, although whether this is physiologically relevant or simply represents the 
transient nature of the interaction between PABP1 and the cap complex in this assay 
is unclear. 
 
Importantly PABP1 and PABP5 appear to be overexpressed to the same degree in the 
HeLa cells (see input lanes) allowing a more direct comparison of the amount of 
each that is isolated by cap-chromatography.  Interestingly, there is a significant 
difference between PABP1 and PABP5 pulldowns with less PABP5 appearing to 
associate with the cap-complex.  This suggests that PABP5 has reduced affinity for 
the cap-complex, consistent with an unobservable interaction with eIF4G.  There is a 
small amount of PABP5 present in the pulldown lane and this may represent an 
association with the cap-complex via a protein other than eIF4G, or residual eIF4G 
binding activity.  Alternatively this signal could represent background contamination 
as there is a faint tubulin signal detectable in the pulldown lanes suggesting that there 




Figure 4.17  m7G-cap affinity chromatography.  Untransfected, T7-PABP1 or T7-PABP5 
transfected HeLa cell lysates were subjected to m7G-cap affinity chromatography by 
incubating the lysates in the presence of m7G-sepharose resin, followed by washing and 
elution of bound proteins into SDS-PAGE loading buffer.  Western blotting was performed 




Taken together the results thus far provide a speculative model whereby PABP5 
failing to interact with eIF4G precludes its association with the cap-binding complex 
and as a result has little translational activity.  In keeping with this model it is 
interesting to note that the presence of overexpressed T7-PABP5 protein does not 
appear to affect the level of endogenous PABP1 protein associating with the cap-
binding complex.  Assuming PABP5 did interact with eIF4G it could be expected 
that overexpression of PABP5 might result in a competition with PABP1 for binding 
to eIF4G. 
 
4.12  Mutagenesis of PABP5 
The suggested model would imply that ‘rescuing’ the ability of PABP5 to interact 
with eIF4G may promote PABP5 translational activity.  To test this hypothesis a 
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mutagenesis approach was undertaken.  In section 4.8 amino-acids in PABP1 critical 
for the eIF4G interaction were discussed.  These amino-acids are not conserved in 
the PABP5 protein.  In the mouse PABPs these residues are methionine-161 (M161) 
and leucine-162 (L162) which are substituted for valine (V167) and arginine (R168) 
respectively in PABP5.  Since M161 ablates the activity of PABP1 (Kahvejian et al., 
2005; Karim et al., 2006) a PABP5 point mutant, in which V167 of the MS2-PABP5 
construct was mutated to a methionine (V167M) to resemble M161 in PABP1, was 
created.  In contrast, M161 in PABP1 was mutated to a valine (M161V) to determine 
whether this would inhibit the translational activity of PABP1 in a tethered function 
assay.   
 
The mutagenesis strategy was based upon the Stratagene QuikChange XL site 
directed mutagenesis kit in which the mutations are incorporated in a PCR based 
approach (see figure 4.18 for a schematic of the mutagenesis protocol).  In abridged 
form the strategy involves designing two oligonucleotide primers containing the 
desired mutation that are complementary to opposite strands of the DNA.  The 
primers are then extended by PCR.  The PCR reaction is then treated with the Dpn1 
endonuclease which is specific for hemimethylated and methylated DNA.  As most 
DNA isolated from E. coli is methylated Dpn1 treatment results in removal of the 
parental vector.  The PCR product is then transformed into E. coli where the 
staggered nicked ends generated by the PCR reaction are repaired and the vector is 
replicated. 
 
4.13  PABP Point Mutants Have Little Translational Activity 
Following cloning of the mouse PABP1 and PABP5 point mutants (M161V and 
V167M respectively), in-vitro transcribed mRNA was prepared and injected into 






Figure 4.18  Mutagenesis strategy.  Oligonucleotide primers are designed that contain the 
desired mutation (represented by a red dot).  The vector contains the insert with the target 
site for mutation (represented by a black dot).  (1) The primers are annealed to the vector 
and (2) are extended by PCR.  (3) The methylated parental vector is digested by Dpn1 
endonuclease treatment and (4) the remaining PCR product is transformed into E. coli where 







The M161V mutation was sufficient to reduce the translational activity of PABP1 
from approximately 8-fold to approximately 4-fold over MS2-U1A (see figure 4.19).  
While this represents a significant loss in activity of PABP1 it is clearly not 
translationally inactive.  In contrast, previous data has indicated that mutation of 
PABP1 M161 to alanine is sufficient to abolish binding of eIF4G (Groft and Burley, 
2002) resulting in an almost complete loss of translational activity (Kahvejian et al., 
2005).  The reason for the discrepancy is unclear, but raises the possibility that the 
mutation also affects RNA-binding, although this possibility was addressed in the 
original study.   
 
Alternatively, the M161V mutation may not be adequate to completely abolish 
eIF4G binding but instead results in a reduced affinity, or conversely other factors 
that still interact with PABP1 may be sufficient to promote PABP1 activity.  It 
should be noted that the original binding assay that determined a PABP1 M161 to 
alanine mutation was sufficient to eliminate a PABP1-eIF4G interaction was 
undertaken using only RRMs 1-2 of PABP1 rather than full-length protein (Groft and 
Burley, 2002).  As a result issues regarding whether the protein folds correctly and 
supports binding of eIF4G in a manner consistent with full-length protein must be 
considered.   
 
Importantly, the corresponding V167M PABP5 mutation failed to stimulate the 
translational activity of PABP5, with both the wild-type and mutant proteins 
stimulating translation about 3-fold over MS2-U1A (see figure 4.19).  This could 
imply that either the V167M PABP5 mutant still does not interact with eIF4G, or 
conversely V167M PABP5 interacts with eIF4G but that this interaction is 
insufficient to stimulate translation.  As discussed with the M161V PABP1 point 
mutant, it is possible that a single residue swap is not adequate to alter the activity of 
these proteins and that efficient binding of eIF4G is an additive effect of multiple 














































Figure 4.19  Translational activity of mouse PABP point mutants.  The translational 
activities of U1A, PABP1, PABP5, PABP1 M161V and PABP5 V167M were tested by 
tethered function assay.  The stimulation values of two separate experiments were averaged 




4.14  PABP RRM2 Domain Swap Mutants Have Little Translational 
Activity 
As the V167M PABP5 mutation appears to be inadequate in promoting eIF4G 
binding, a PABP5 mutant in which RRM2 is substituted for the RRM2 of PABP1 
was produced.  This approach allows relocation of the mapped eIF4G binding region 
of PABP1 into the corresponding region of PABP5.  As with the point mutations, the 
reciprocal domain swap was undertaken in PABP1 with RRM2 being replaced by the 
corresponding domain in PABP5.   
 
As there were no appropriate endogenous restriction sites in the wild-type sequences 
to facilitate the domain swap a mutagenesis approach was undertaken.  Two rounds 
of mutagenesis were performed on each clone to create novel BstB1 and Xma1 
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restriction sites at opposite ends of the RRM2 regions.  These sites were incorporated 
into both the PABP1 and PABP5 sequences allowing a direct transfer of the regions 
between the two clones.  Importantly these mutations were silent, not altering the 
amino-acids incorporated at these sites in the translated proteins. 
 
The RRM2 domain swap mutant constructs were subjected to tethered function assay 
(see figure 4.20A).  In a result consistent with abolishment of eIF4G binding, the 
PABP1 RRM2 mutant only stimulates translation 2-fold over MS2-U1A compared to 
the wild-type protein (approximately 7-fold).  Comparison of the results from the 
point mutant and RRM2 mutant injections it would appear that the RRM2 mutant has 
less activity in the tethered function assay (4-fold versus 2-fold respectively) 
although the wild-type PABP1 protein also stimulates to a lesser degree in the RRM2 
domain swap experiment.  A tethered function assay in which all the mutants were 
injected simultaneously revealed a slight difference between the PABP1 point and 
RRM2 domain swap mutants (4-fold stimulation versus 3-fold stimulation).  This 
analysis was only undertaken once.  Therefore, to determine if this difference is 
statistically significant, more repeats would be required (see figure 4.20B). 
 
The PABP5 domain swap mutant containing the RRM2 of PABP1 also failed to 
stimulate translation (see figure 4.20A).  As with the PABP5 point mutant, this could 
be due to a failure of PABP5 and eIF4G to interact or alternatively might represent 
an interaction between the two proteins that is not stimulatory to translation.  In the 
case of both RRM2 mutants it is possible that the swapping of the large RRM2 






Figure 4.20  Translational activity of mouse PABP RRM2 domain swap mutants.  A.  
The translational activities of U1A, PABP1, PABP5, PABP1 RRM2 mutant and PABP5 
RRM2 mutant were tested by tethered function assay.  The stimulation values of four 
separate experiments were averaged and the standard error calculated.  RLU = relative 
luciferase units.  B.  The translational activities of all the mutant PABPs were tested in 
parallel by tethered function assay.  The results are representative of one experiment.   
 
4.15  PABP Mutants Fail To Interact With eIF4G 
The ability of the mutant PABP proteins to interact with eIF4G was investigated by 
Y2H.  This would identify whether the PABP5 mutants fail to support eIF4G binding 
or simply that an interaction between PABP5 and eIF4G is insufficient to promote 
translation.  To this end the V167M and RRM2 domain swap mutants were 
subcloned into Y2H bait vectors to be tested against the N-terminus of eIF4G 
(eIF4GNT).  As a positive control PABP1 RRMs 1-4 was tested against eIF4GNT, 
and all the clones were tested against IRP as a negative control.  None of the PABP 
mutant proteins interacted with eIF4G by Y2H (see figure 4.21A).  This is consistent 
with a loss of translational activity in the PABP1 mutant proteins and offers a 
possible explanation as to the lack of increased activity of the PABP5 mutants.  
Expression of the mutant constructs in yeast was confirmed by Western blotting with 
an antibody raised against the LexA-BD region of the fusion proteins (see figure 
4.21B).  Since the PABP5 RRM2 domain swap mutant failed to interact with eIF4G 
despite containing PABP1 RRM2 which is capable of binding eIF4G (Groft and 
Burley, 2002; Imataka et al., 1998) this raised the possibility that interchanging such 




Figure 4.21  The PABP mutants fail to interact with eIF4G by Y2H.  A.  The PABP 
mutants were expressed in yeast as fusion proteins with the LexA-BD.  eIF4G and IRP were 
expressed as fusion proteins with the GAL4-AD.  Positive colonies were identified by 
incubation with X-gal resulting in a blue colouration.  The positive control is mouse PABP1 
RRMs 1-4 tested against the N-terminus of human eIF4G, and the negative control is mouse 
PABP1 RRMs 1-4 tested against IRP.  B.  Yeast expressing the mutant-LexA fusion proteins 
were lysed and subjected to SDS-PAGE followed by Western blotting with an antibody 
raised against the LexA-BD.  LexA-BD is approximately 24 kDa therefore PABP1 RRMs 1-4 
and the PABP5 proteins were predicted to run at approximately 67 kDa (24 kDa LexA-BD + 
43kDa) and the full-length PABP1 proteins were predicted to run at approximately 94 kDa 
(24 kDa + 70 kDa).    
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The X-ray crystal structure of human PABP1 RRMs 1-2 complexed with poly(A) is 
available at a 2.6 Angstrom resolution (Deo et al., 1999).  To assess whether the 
PABP5 RRM2 mutant fails to interact with eIF4G because the chimeric protein is 
significantly unstructured across RRMs 1-2 it was decided to use this PABP1 model 
as a template to predict the structure of PABP5 RRMs 1-2, and the subsequent effect 
of introducing PABP1 RRM2.  Given the high level of sequence identity between 
PABP1 and PABP5 RRMs 1-2 (69%) the prediction was likely to be accurate.  Also, 
given the high level of sequence homology between mouse and human PABP5 
proteins (95%) the results were deemed applicable to both species.  An algorithm 
designed to find the most probable structure for a given amino-acid sequence based 
on alignments with related structures was utilised (Sali and Blundell, 1993).  The 
analysis was undertaken by Dr Jonathan Manning (Bioinformatics, Queens Medical 
Research Institute, University of Edinburgh).   
 
Within the PABP1 RRMs 1-2 model structure 8 amino-acid residues serve to 
mediate inter-domain contacts between RRM1 and RRM2 and were predicted to be 
important for maintenance of the RRM 1-2 structure (Deo et al., 1999).  Two of 
these residues are not conserved in RRMs 1-2 of PABP5, an aspartate at position 70 
(Asp-70) is substituted with an asparagine (Asn-77), and a tyrosine at position 116 
(Tyr-116) is substituted with a phenylalanine (Phe-123).  Interestingly these 
substitutions can be considered conservative as tyrosine and phenylalanine are of 
similar size and contain aromatic side-chain moieties, whereas aspartate and 
asparagine both represent polar hydrophilic amino-acids of similar size.  
 
The Tyr-116 and Asp-70 residues do not interact within PABP1 RRMs 1-2 (Deo et 
al., 1999) presumably due to the spatial distance between them (5.4 Angstroms) as 
was similarly predicted for their conservative substitutions Phe-123 and Asn-77 
within PABP5 RRMs 1-2.  As these substituted residues do not interact but mediate 
contacts between the two RRMs via conserved residues it was predicted that loss of 
structure within RRMs 1-2 of the domain swap proteins was unlikely.  
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4.16  PABP5 Interaction with the PAIP Proteins 
Within the closed loop model of translational stimulation the PABP1-eIF4G 
interaction is implied to be the key contact that facilitates 5’- and 3’-UTR 
communication, however several other factors may also be important for PABP1 
mediated translational stimulation. 
 
The translational enhancer PAIP-1 interacts with PABP1 both in-vitro and in-vivo via 
two binding motifs termed PAM-1 and PAM-2 which interact with RRMs 1-2 and 
the C-terminus of PABP1 respectively (Craig et al., 1998; Roy et al., 2002)(see 
figure 1.14A).  PAIP-1 contains homology to the central domain of eIF4G and can 
also interact with eIF3 and eIF4A in addition to PABP1 (Craig et al., 1998; 
Martineau et al., 2008).  This is suggested to offer an alternative mechanism for the 
circularisation and translational activation of mRNAs (Derry et al., 2006).  Given 
that the PAM-1 domains bind to the RRMs region of PABP1 it is feasible that these 
interactions may be conserved within PABP5 contributing to its residual ability to 
stimulate translation.  Indeed, although PAIP-1 binds PABP1 RRMs 2-3 and C-
terminus with a 1:1 stoichiometry it would appear that the PAM-1 and PAM-2 motifs 
can interact with PABP1 independently as truncation mutants of Xenopus laevis 
PABP1 consisting of either RRMs 1-2 or the C-terminus alone can support binding 
of PAIP-1 (Gray et al., 2000).  Similarly, the negative regulator of PABP1 activity, 
PAIP-2, also contains a PAM-1 and PAM-2 motif which bind a region within RRMs 
2-3 and also the C-terminus of PABP1 respectively.  In distinction to PAIP-1, PAIP-
2 binds PABP1 with a 2:1 stoichiometry (Khaleghpour et al., 2001a). 
 
To investigate the ability of PABP5 to interact with PAIP-1 and PAIP-2 a Y2H 
approach was taken.  The mouse and human PABP5 Y2H LexA-BD constructs 
utilised in figure 4.9, and mouse PABP1 RRMs 1-4 cloned into the same vector (as a 













Figure 4.22  PABP5 interacts with PAIP-2.  The PABP proteins were expressed in yeast 
as fusion proteins with the LexA-BD.  eIF4GNT, IRP, PAIP1 and PAIP-2 were expressed as 
fusion proteins with the GAL4-AD.  Positive colonies were identified by incubation with X-gal 
resulting in a blue colouration.  The controls are Mm PABP1 RRMs 1-4 and Xl PABP1 RRMs 
1-2 tested against eIF4G and PAIP-1 (+ve), and IRP (-ve).  Mm = Mus musculus, Hs = Homo 
sapiens, Xl = Xenopus laevis.     
 
The results of the Y2H are presented in figure 4.22.  As was anticipated, the 
reactions containing the Xenopus and mouse PABP1 proteins were positive for an 
eIF4GNT interaction and negative for an interaction with IRP.  Additionally these 
proteins also interacted with PAIP-1 as has been previously shown (Gray et al., 
2000; Kimura et al., 2009).  Interestingly, both PABP1 proteins interacted with 
PAIP-2.  While this has been documented for the mouse protein (Kimura et al., 
2009) Xenopus laevis PABP1 has never been previously been demonstrated to 
interact with PAIP-2 and therefore represents a conserved interaction. 
 
Remarkably the mouse and human PABP5 proteins interacted with PAIP-2 yet failed 
to bind PAIP-1.  The inability of PABP5 to bind the translational enhancer protein 
PAIP-1 is consistent with its relative inability to stimulate translation.  The 
interaction of PABP5 with PAIP-2 is interesting.  Available evidence demonstrates 
that the association of PAIP-2 is sufficient to down-regulate the activity of PABP1 
via multiple mechanisms (reviewed in Derry et al., 2006), including competition for 
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eIF4G binding.  Therefore, the interaction between PABP5 and PAIP-2 could be 
construed as further evidence supporting the lack of translational activity of PABP5.   
 
4.17  PABP5 Interacts with PAIP-2 
To verify the Y2H results and confirm an interaction of PABP5 with PAIP-2 a 
pulldown experiment using recombinant proteins was performed.  To this end human 
PABP1 and PABP5 were expressed as described in section 4.9 and cell lysates were 
prepared.  Human PAIP-1 and PAIP-2 were cloned into the pGEX-6P-1 bacterial 
expression vector which produces recombinant proteins N-terminally tagged with 
glutathione S-transferase (GST).  The GST-PAIP proteins were produced in E. coli 
cells, using 1mM IPTG and inducing for 3 hours at 37oC.  Lysates were passed over 
glutathione sepharose beads which bind the GST proteins.  The beads were washed 
and the presence of the GST-PAIP proteins was verified by incubating the beads in 
protein loading buffer and subjecting the eluted proteins to SDS-PAGE followed by 
staining of the gel with GelCode Blue.  Three distinct proteins were observed that 
corresponded to the predicted masses for GST, GST-PAIP-1, and GST-PAIP-2 (see 
figure 4.23A).  To verify that these protein bands represented the induced GST 
proteins the samples were subjected to Western blotting with an antibody raised 
against GST.  Again three distinct signals were observed that corresponded to the 
predicted masses of the recombinant proteins (see figure 4.23B).      
 
As with the PABP1 and PABP5 inductions in figure 4.12B, some lower molecular 
weight proteins co-purified with GST-PAIP-1 and GST-PAIP-2.  Western blotting 
revealed that the majority of these were breakdown products of the recombinant 






      
 
 
Figure 4.23  GST proteins induction.  A.  E. coli cells were transformed with the pGEX-6P-
1 constructs and induced to express recombinant proteins.  The cells were lysed and the 
lysate added to glutathione sepharose.  Following washing the bound proteins were eluted in 
protein loading buffer and subjected to SDS-PAGE.  The gel was then stained with GelCode 
Blue (Thermo Scientific).  GST = 26kDa, GST-PAIP-1 = 79kDa, GST-PAIP-2 = 41kDa.  B.  
The same protein samples were subjected to Western blotting using an anti-GST antibody.  
 
For the purposes of the pulldown assay, GST proteins (GST, GST-PAIP-1, and GST-
PAIP-2) were induced in E. coli cells, bound to glutathione sepharose and washed as 
before.  Prior to undertaking the assay the amount of each protein bound per µl of 
beads was quantified to ensure similar levels of the proteins were utilised in each 
pulldown experiment.  To this end the proteins were eluted from various quantities of 
the beads and subjected to SDS-PAGE alongside BSA standards.  The protein gel 
was then stained with SYPRO Ruby (Invitrogen) and the proteins imaged and 
quantified as described in section 4.9.  The results of this quantification are shown in 
appendix 2. 
 
Three different quantities of glutathione-sepharose beads corresponding to 5µg, 
2.5µg, and 0.5µg of each GST-protein were added to E. coli lysates containing 
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PABP1 or PABP5.  Following incubation the beads were washed and the bound 
proteins were eluted in protein loading buffer.  The proteins were subjected to SDS-
PAGE followed by Western blotting with an anti-his antibody directed against the N-
terminal his-tag present on the PABP proteins (see figure 4.24).  The pulldowns 
indicate that PABP1 can interact with both GST-PAIP-1 and GST-PAIP-2 but does 
not cross-react with GST alone.  That the PABP1 signal decreases in response to 
decreasing amounts of the GST-PAIP proteins could suggest that the GST proteins 
are limiting.  Interestingly, the amount of PABP1 isolated with GST-PAIP-1 and 
GST-PAIP-2 is comparable.  PABP5 on the other hand appears to bind PAIP-2 with 
a significantly higher affinity than PAIP-1 based on the amount of PABP5 pulled 
down with each of the proteins (see figure 4.24).  Thus, the pulldown corroborates 
with the Y2H data indicating that in these assay systems PABP5 interacts with PAIP-
2 but fails to show significant binding to PAIP-1.  Whether the inability to interact 
with PAIP-1 is because PABP5 lacks the C-terminal binding site present in the 
PABP1 protein, or rather the RRM 1-2 binding site is not conserved within PABP5 is 
not known.  In support of the latter PABP1 RRMs 1-2 can sustain binding of PAIP-1 
in the absence of the C-terminus (Gray et al., 2000). 
 
 
    
Figure 4.24  PABP5 interacts with PAIP-2 by pulldown assay.  GST, GST-PAIP-1, and 
GST-PAIP-2 were bound to glutathione-sepharose beads.  A volume of beads corresponding 
to 5µg, 2.5µg, 0.5µg, and 0µg of the bound GST-proteins was incubated with E. coli lysate 
containing either his-tagged PABP1 or PABP5.  Following the incubation the beads were 
washed and the bound proteins were eluted in protein loading buffer.  The proteins were 




4.18  Discussion 
Within this chapter I have examined the molecular function of a novel 
uncharacterised poly(A)-binding protein, PABP5.  Ectopically expressed PABP5 
protein appears to be predominantly cytoplasmic in accord with other PABP family 
members.  Interestingly in-vitro and in-vivo analysis suggests that PABP5 may have 
a molecular role that is distinct from the other characterised PABP family members. 
 
PABP5 Localisation 
The cytoplasmic localisation of GFP-PABP5 is consistent with a role in the 
regulation of mRNA translation or stability as this cellular compartment contains the 
protein synthesis machinery.  However it remains to be determined whether 
endogenous PABP5 exhibits a similar predominantly cytoplasmic distribution.  In the 
absence of an antibody that can detect endogenous PABP5 protein, construction of a 
stably expressing PABP5 granulosa cell-line would permit PABP5 subcellular 
localisation to be examined in a cell-type in which it is endogenously expressed.  
This would also allow other in-vivo assays to be performed in an appropriate cellular 
background, although the ability to maintain a ‘granulosa like’ pattern of gene 
expression could be problematic given their propensity to luteinise in culture.   
 
The presence of PABP5 within the nucleus of some of the transfected cells is 
interesting.  Whether this is linked to PABP5 function, or is simply an artefact of 
overexpressing PABP5 is unclear, as overexpressing PABP1 can result in nuclear 
accumulation (Afonina et al., 1998).  However, nuclear import of PABP1 is an 
energy dependent process requiring ATP (Afonina et al., 1998) and endogenous 
PABP1 can also localise to the nucleus (Afonina et al., 1998; Woods et al., 2002).  
Thus PABP5 may also be a true shuttling protein.  The TD-NEM motif recently 
implied to be responsible for nuclear export of PABP1 (Khacho et al., 2008) does not 
appear to be conserved in PABP5 suggesting an alternative mechanism for nuclear 
export of PABP5.  Interestingly, a PABP1-paxillin interaction has also been 
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suggested to facilitate PABP1 nuclear export (Woods et al., 2005), and the two 
characterised paxillin binding sites in PABP1 appear to be highly conserved in 
PABP5.  Demonstration of a PABP5-paxillin interaction could imply a conserved 
mechanism of nuclear-cytoplasmic transport.    
 
PABP5 Translational Activity 
Based on the function of other PABP proteins PABP5 was hypothesised to have a 
role in translational activation.  The association of ectopically expressed PABP5 with 
actively translating mRNAs would seemingly corroborate this.  While the co-
sedimentation of factors with polysomes can be indicative of an association with 
actively translating mRNAs great care must be taken in interpreting the results of 
these experiments, as other large molecular weight complexes also sediment within 
these gradient fractions.  Moreover mRNA binding factors with no intrinsic 
translational stimulatory activity have been isolated from the polysomal fractions of 
sucrose gradients, such as the decapping enzyme Dcp2 (Wang et al., 2002).  
 
A tethered function assay was employed to determine whether PABP5 had 
translational stimulatory activity.  Surprisingly, mouse and human PABP5 were 
found to have only limited translational stimulatory activity relative to PABP1 which 
has been described as a canonical translation factor (Kahvejian et al., 2005).  The 
activity of mouse and human PABP1 proteins in this assay indicate that the result is 
unlikely to be an artefact of assaying mammalian proteins in Xenopus cells.  
 
While the translational activity of many of the mammalian PABP proteins has not 
been established, other vertebrate PABPs such as Xenopus ePABP (Wilkie et al., 
2005), Xenopus PABP4 (B. Gorgoni, submitted) and mouse tPABP (Kimura et al., 
2009), all stimulated translation to a similar degree as PABP1 in translation assays.  
Thus the lack of translational activity appears unique to PABP5.  Nonetheless, 
PABP5 consistently stimulated translation of the reporter approximately 2-fold over 
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the U1A control protein.  The physiological relevance of this residual stimulatory 
activity remains unclear, although it could be an artefact of the high affinity 
MS2/MS2-binding site interaction given that the mRNA binding activity of PABP5 
has never been experimentally determined.  Two important questions therefore 
require addressing.  Firstly, is the relative inactivity of PABP5 reproducible in 
translational assays utilising reporters containing endogenous PABP5 binding sites, 
and secondly, what is the mRNA substrate preference of PABP5.      
 
PABP5 mRNA Binding 
The mRNA-binding activity of characterised PABP proteins is critical to their 
function.  The binding affinity of PABP1, tPABP, PABP4 and ePABP for poly(A) 
mRNAs has been established using electrophoretic mobility shift assay (EMSA) 
(Kim and Richter, 2007; Sladic et al., 2004) or via poly(A)-sepharose columns 
(Houng et al., 1997; Kimura et al., 2009).  In contrast the mRNA-binding activity of 
PABP5 remains to be addressed and if determined would allow formulation of a 
more informed hypotheses regarding PABP5 molecular function.  In yeast, and 
human PABP1 proteins poly(A) recognition activity was determined to be largely 
mediated by RRMs 1-2 (Burd et al., 1991; Deardorff and Sachs, 1997; Sladic et al., 
2004).   
 
In the molecular modelling study described in chapter 4 (section 4.15), the poly(A)-
binding potential of PABP5 RRMs 1-2 was investigated in relation to the structure of 
PABP1 RRMs 1-2 bound to poly(A).  Some 22 amino-acid residues in PABP1 
RRMs 1-2 are involved in mediating contacts with poly(A) RNA (Deo et al., 1999).  
Of these residues, there are 4 substitutions in the PABP5 protein: S12A, M46P, R89P 
and F142Y (PABP1 numbering) of which the first 3 are non-conservative.  Of these 
3 non-conservative substitutions, residues  S12 and M46 have been suggested to be 
important in adenine recognition (Deo et al., 1999) leading to speculation that base 
preference of PABP5 may be more flexible or that poly(A)-binding affinity may be 
reduced.  Highlighting the importance of the substitutions, in yeast Pab1p a single 
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mutation in RRM2, F170V, was capable of almost completely ablating binding to 
poly(A) (Deardorff and Sachs, 1997).  Furthermore, PABP5 also lacks the proline-
rich C-terminal domain that functions in PABP1 oligomerisation to mediate ordered 
binding to poly(A) (Melo et al., 2003).  Several PABP proteins have been 
demonstrated to have an affinity for AU-rich sequences (Sladic et al., 2004; Voeltz et 
al., 2001), with PABP4 having only a two-fold lower affinity for poly(AU) than for 
poly(A) (Sladic et al., 2004), suggesting that PABP5 may also bind AU sequences.     
 
To directly test the affinity of PABP5 for poly(A) RNA binding assays must be 
utilised.  To this end I have undertaken preliminary EMSA experiments using 
poly(A) and poly(AU) fluorescently labelled RNA probes.  These experiments are 
detailed in appendix 3.  Intriguingly, whilst highly preliminary, these assays suggest 
that PABP5 displays a strong preference for poly(AU) compared to poly(A).  This 
finding warrants further investigation as, if verified, it would describe the first PABP 
protein with an affinity for an mRNA substrate higher than poly(A) and would have 
interesting implications for the function of PABP5.  Indeed, if PABP5 proves to have 
a negligible affinity for poly(A) and instead binds specific target mRNAs through 
AU-rich sequences or other motifs, it may be possible to perform meaningful RNA-
IP experiments without isolating unmanageable numbers of polyadenylated mRNAs. 
 
Translation Assays 
One approach to validating the results of the tethered function assay is the utilisation 
of in vitro cell-free translation extracts.  Recently, cell-free translation extracts have 
been described that display cap-poly(A) synergy (Michel et al., 2000; Thoma et al., 
2004), overcoming the problem with many of the previous in-vitro translation 
systems with respect to assaying for PABP activity.  To this end active HeLa cell-
free translation extracts were prepared and demonstrated to display cap-poly(A) 
synergy (see appendix 4).  These extracts could be programmed with reporter 
mRNAs, and identification of the mRNA substrates of PABP5 would facilitate the 
use of reporter mRNAs containing endogenous PABP5 binding sites.   
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To investigate the function of PABP5 these assays would ideally be performed in 
both the presence and absence of competing PABP proteins (see chapter 5 for 
discussion of models).  Cell-free translation extracts depleted of PABP proteins have 
been described (Thoma et al., 2004).  Active cell-free HeLa extracts depleted of 
PABP1 were prepared (see appendix 4).  HeLa cells are also known to contain 
PABP4 (H. Burgess, unpublished) which would also require depletion.  Interestingly 
depletion of PABP1 by passing the extracts over PAIP-2 columns similarly depleted 
PABP4 (see appendix 4), suggesting that PAIP-1 and PABP4 may also interact.  
Thus these extracts would be suitable for undertaking experiments in the absence of 
other cytoplasmic PABPs.  As HeLa cells do not express PABP5 mRNA, purified 
recombinant PABP5 protein would have to be added to these extracts.  While 
purified PABP1 was generated in significant quantities, PABP5 was not.  
 
PABP5 Protein Interactions 
A molecular explanation for the relative inactivity of PABP5 in the tethered function 
assay could be its reduced affinity for the factors that are known to promote PABP1 
mediated translational stimulation.  The Y2H and in vitro binding assays undertaken 
with PABP5 and the initiation factors eIF4G and PAIP-1 show clearly reduced 
affinity.  However, if the interactions are particularly RNase sensitive or reliant on 
post-translational modifications they may not be detectable in the assays undertaken.  
It is known that the phosphorylation status of wheat germ PABP1 affects its ability to 
interact with both eIF4B and eIF4G for example (Le et al., 2000).  Therefore, the 
inability to interact with PABP5 must be confirmed by Co-IP of endogenous 
proteins. 
   
Furthermore the absence of the C-terminus which interacts with eIF4B and eRF3 
precludes a role for these proteins (Bushell et al., 2001; Cosson et al., 2002a), and 
indeed an interaction between PABP5 and eIF4B was not observed by Y2H.  It is 
therefore tempting to speculate that the functional differences between PABP1 and 
PABP5 may be linked to its inability to circularise and therefore promote the 
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translation of mRNAs.  In support of this hypothesis PABP5 could not be isolated by 
m7G-cap chromatography indicating that PABP5 does not interact with the cap 
complex.   
 
The closed loop model of translational stimulation is suggested to be mediated 
primarily through an interaction between eIF4G and PABP1.  To determine whether 
the low translational stimulatory activity of PABP5 was indeed through a reduced 
affinity for eIF4G, attempts were made to create a mutant PABP5 protein that bound 
eIF4G but were unsuccessful.  Molecular modelling suggested the failure of the 
PABP5 RRM2 mutant to interact with eIF4G may not have had a structural basis but 
rather reflected additionally required eIF4G contact sites that are present within full-
length wild-type PABP1 protein.  Although mammalian PABP1 RRM2 contains 
residues deemed critical for eIF4G interaction (Groft and Burley, 2002), and this 
region is solely responsible for the yeast PABP1-eIF4G interaction (Kessler and 
Sachs, 1998; Otero et al., 1999) it is possible that RRM1 may also influence binding.  
In support of this the ability of RRM2 to interact with eIF4G was significantly 
enhanced by the presence of RRM1 in-vitro despite RRM1 containing no intrinsic 
eIF4G binding activity (Imataka et al., 1998).  Similarly the ITC binding assay that 
determined the critical eIF4G binding residues in RRM2 was performed using a 
PABP1 RRMs 1-2 fragment (Groft and Burley, 2002).  Hence, the RRM2 domain 
alone may not be sufficient to promote robust binding of eIF4G.  The results of the 
Y2H assay utilising the mutant proteins would appear to be supportive of a larger 
eIF4G binding site.   
 
Intriguingly, despite stimulating translation to a lesser degree than PABP1, PABP5 
clearly has some low level stimulatory activity in the tethered function assay.  This 
activity of PABP5 may be the result of a residual affinity for these factors, or reflect 
a high affinity interaction with a yet to be described factor that contributes to PABP1 
activity.  Indeed, RRMs 3-4 of PABP1 and ePABP have been demonstrated to 
stimulate translation of a reporter mRNA (Gray et al., 2000; Wilkie et al., 2005), 
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implying that factors other than eIF4G and PAIP-1 can contribute to PABP1 
mediated translational activation.   
 
Interestingly PABP5 failed to interact with PAIP-1 but was positive for an 
interaction with PAIP-2 by Y2H thus representing the first example of a PABP 
protein differentially interacting with the PAIP proteins.  The interaction of PABP5 
with PAIP-2 was verified by pulldown assay but requires confirmation with 
endogenous proteins, possibly through Co-IP.  This interaction could be taken as 
further evidence that PABP5 has no role in translational stimulation given that it fails 
to interact with PAIP-1 yet binds PAIP-2 which is a characterised negative regulator 
of translation.  Conversely, it could be argued that if PABP5 had no intrinsic 
translational stimulatory activity it would not need repressed in a PAIP-2 mediated 
mechanism.  To this end it would be interesting to test PABP5 in a translational 
assay in which the PAIP-2 binding was ablated by mutation or depleted by siRNA. 
 
In conclusion, within this chapter I have demonstrated that PABP5 does not appear 
to act as a translation factor, at least not in a manner analogous to the prototypical 
PABP1.  PABP5 has limited ability to stimulate translation in a well characterised 
translational assay, and has not maintained protein interactions conserved by other 
PABPs, integral to their function.  Indeed the only interaction preserved would 
appear to be with the negative regulator of translation, PAIP-2.  Further experimental 
work will be required to elucidate the significance of this interaction and models for 





























5.1  Summary of Findings 
The role of mammalian PABP1 as a translation factor is well established.  While the 
mechanism of PABP1 mediated translational stimulation is still a subject of 
investigation it is apparent that several other mammalian cytoplasmic PABP proteins 
may also share a similar role in translational regulation through conserved protein-
protein interactions (Cosson et al., 2002a; Kimura et al., 2009; Okochi et al., 2005) 
and the ability to bind poly(A) (Sladic et al., 2004).  PABP5 represents a largely 
uncharacterised member of the PABP family.  Within this thesis I have examined the 
expression pattern of PABP5 mRNA showing that PABP5 has both a tissue and cell-
type restricted expression pattern within mice.  In particular PABP5 was found to be 
co-expressed with PABP1 and PABP4 in granulosa cells.  Furthermore I have 
demonstrated that PABP5 represents the first PABP protein to display an inability to 
bind the translation factors eIF4G and PAIP-1 and that PABP5 has little translational 
stimulatory activity.  These data strongly suggest that the function of PABP5 is 
distinct from that of other PABP proteins, performing a different molecular role 
within granulosa and other cell types.  Possible models for the function are presented 
below.   
 
5.2  PABP5 as a Translational Activator 
Although PABP5 has little translational stimulatory activity relative to PABP1 in the 
tethered function assay it clearly has a weak but positive stimulatory effect on 
luciferase reporter expression and may function as a weak translational activator.  
Consistent with this PABP5 co-sediments with the polysomes in HeLa cell lysates 
and was partially released upon treatment with puromycin.  While the latter does not 
identify a direct role in translational stimulation, it is potentially indicative of an 
association with actively translating mRNAs.     
 
If PABP5 is a potent translational stimulatory protein, it is unclear why such a low 
level of activity in the tethered function assay was observed.  One drawback of the 
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tethered function assay is that PABP5 is interacting with the mRNA via the 
MS2/MS2-binding site interaction.  PABP5 may undergo conformational 
rearrangements in response to mRNA binding that would not occur upon tethering.  
It could be speculated that this may affect PABP5-protein interactions and 
subsequent translational activity.  Indeed the interaction of yeast Pab-1 with eIF4G is 
RNA-dependent, requiring Pab-1 to be complexed with poly(A) (Tarun and Sachs, 
1996).  As PABP5 is mammalian specific it is also possible that PABP5 cap-
dependent translation requires an unidentified mammalian specific bridging protein 
to contact the cap-complex (see figure 5.1).  Undertaking translational assays in 
mammalian cell free extracts (described in chapter 4, section 4.18), could validate 
this theory.  The development of a functional antibody to PABP5 could allow IP of 
endogenous PABP5 interacting proteins.  A more comprehensive understanding of 
the PABP5 interactome would be highly informative with respect to the putative 
translational activity of PABP5. 
 
 
Figure 5.1  PABP5 may be a translational stimulatory protein.  Possible mechanisms of 
PABP5 mediated translational stimulation include the formation of alternative closed-loop 
conformations.  The mRNA binding activity and mRNA substrate of PABP5 remain to be 
experimentally determined and PABP5 may bind poly(A) or other elements such as AU-rich 
sequences within the 3’-UTR.  Arrow number 1 depicts a cap-dependent mechanism of 
translational stimulation whereby PABP5 interacts with the cap-complex via an unknown 
interacting protein thus forming the closed-loop.  Arrow number 2 depicts a cap-independent 
mechanism of translational stimulation whereby PABP5 interacts with mRNA sequences in 
the 3’-UTR of target mRNAs and simultaneously binds an element within the 5’-UTR thereby 
forming an alternative closed-loop.  The 5’ element may be an IRES.  It is possible that the 
interaction is not direct and may be facilitated by an unknown bridging protein.   
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It remains to be determined whether any ability of PABP5 to stimulate translation is 
specific to IRES dependent translation.  PABP1 has been shown to directly interact 
with the IRES of platelet-derived growth factor-2 (PDGF2) to stimulate the 
translation of this mRNA (Koloteva-Levine et al., 2004) suggesting that this 
alternative mechanism of closed-loop formation can be used to regulate the 
translation of cellular mRNAs.  PABP1 has also been shown to stimulate viral IRESs 
via interaction with other initiation factors such as eIF4G (Burgui et al., 2003; 
Svitkin et al., 2001a).  Thus, mechanisms exist for the direct and indirect associations 
of PABP proteins with IRES elements facilitating translational stimulation (see 
figure 5.1).  Fascinatingly the viral HIV-1 and HIV-2 proteases are known to cleave 
PABP1 liberating the C-terminus from the RRM domains producing a truncated 
PABP protein with resemblance to PABP5 (Alvarez et al., 2006).  It has been 
postulated that the viral mRNAs may recruit the PABP1 cleavage product to promote 
translation of the viral transcripts in a cap-independent mechanism (Collier and Gray, 
2006).   
 
5.3  PABP5 as an Indirect Translational Activator 
PAIP-2 regulates the activity of PABP1 by reducing the affinity of PABP1 for 
poly(A) (Khaleghpour et al., 2001b) and competing with eIF4G and PAIP-1 for 
binding to PABP1 (Karim et al., 2006).  The functional consequences of the 
interaction between PAIP-2 and PABP5 remain to be examined.  It could be 
envisaged to function in a manner analogous to its regulation of PABP1 activity, 
promoting a reduction in PABP5 mRNA binding affinity although testing this 
requires knowledge of the mRNA substrate preference of PABP5.   
 
Alternatively the interaction between PAIP-2 and PABP5 may affect the availability 
of PAIP-2 for other PABP proteins.  PABP1 is a known target of PAIP-2 and my 
data suggests that PABP4 could also be a PAIP-2 interacting protein (appendix 
figure 4).  Mouse tPABP and Xenopus laevis ePABP similarly interact with PAIP-2 
suggesting that this interaction is highly conserved within the PABP family.  Thus 
199 
 
the interaction between PABP5 and PAIP-2 could represent a plausible mechanism 
by which PAIP-2 is sequestered promoting the translational activity of other PABP 
proteins (see figure 5.2A) such as PABP1 and PABP4 which are expressed within 
granulosa cells alongside PABP5.  Certainly the predicted low affinity for poly(A) 
and an inability to bind eIF4G and PAIP-1 would support a model of this nature.  
The ability to isolate PABP1 and PAIP-2 by Co-IP in the presence versus absence of 
PABP5 would inform whether the PABP proteins are directly competing for PAIP-2 
binding.  An assumption of the sequestration model would be that the presence of 
PABP5 should result in a relative increase in PABP1/PABP4 activity.  Again this 
could be directly tested within the cell-free translation extracts subject to the 
production of recombinant PABP5 protein.  This model is an example of PABP5 
acting as an indirect activator of translation and therefore the cell-free translation 
assay would have to be performed in the presence of PABP1, as a polyadenylated 
reporter mRNA would not be stimulated in the presence of PABP5 alone.  
 
While this mechanism seems plausible there are certain pieces of evidence that 
would appear contradictory.  Firstly, overexpression of PABP5 fails to result in a 
simultaneous increase in the amount of PABP1 isolated with the cap complex.  
Secondly, PAIP-2 levels are already known to be regulated in response to PABP1 
levels by ubiquitination and proteasomal degradation therefore why a further 
mechanism of regulation would be required is unclear.  It is also feasible that the 
PABP5 interaction with PAIP-2 could act as a form of ‘failsafe’.  Finally, the cell-
type specific expression of PABP5 would imply that this is not a general mechanism 
of regulation, and it is unclear why this additional tier of regulation is only required 







Figure 5.2  PABP5 may stimulate translation via an indirect mechanism.  A.  PABP5 
binding to PAIP-2 could indirectly stimulate the translation of mRNAs by sequestering PAIP-
2, allowing PABP1 to bind poly(A) and interact with the translation initiation factors eIF4G 
and PAIP-1 supporting closed loop formation.  B.  PABP5 binds to an unidentified sequence 
element and inhibits the binding of a negative regulator of translation supporting PABP1 
mediated translational activation.  
 
 
There are also examples of PABP proteins having positive roles in translation 
independent of their interactions with poly(A).  Y-box binding protein-1 (YB-1) 
autoregulates the translation of its own mRNA through binding an A-rich element 
within the 3’-UTR and inhibiting translation initiation.  PABP1 relieves this 
repression by competing with YB-1 for binding to this element (Skabkina et al., 
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2005; Skabkina et al., 2003).  The possibility that PABP5 could bind 3’-UTR 
elements and promote translation by preventing the association of negative 
regulatory factors is intriguing (see figure 5.2B).    For this postulated mechanism 
poly(A) binding could potentially be redundant, as would an interaction with eIF4G.  
It would also explain the presence of PABP5 only polysomes despite having little 
intrinsic translational activity, and reconciles with a lack of interaction with the cap 
complex.  Furthermore, regulation of transcripts via binding to 3’-UTR elements 
could explain the restricted expression pattern of PABP5 if the target mRNAs are 
cell specific. 
 
5.4  PABP5 as a Stability Factor 
It is possible that the primary role of PABP5 is not in mRNA translation but in 
mRNA stability.  Consistent with this hypothesis PABP5 has little translational 
stimulatory activity but is found in the polysomal fractions of a sucrose gradient.  
Given the results of the bioinformatic modelling and the very preliminary EMSA 
binding experiments it would be tempting to speculate that PABP5 could potentially 
bind ARE sequences and affect mRNA stability in a manner independent of poly(A) 
binding (see figure 5.3).  In support ARE-BPs are known to associate with 
polysomes (Nguyen Chi et al., 2009).  The ARE-BP HuR has been demonstrated to 
co-localise with polysomes and competes for binding to the AREs of cyclin D1 and 
p21 with the destabilising ARE-BP AUF1 (Lal et al., 2004).  Thus a similar model to 
that of figure 5.2B could be conceived.  In this model, PABP5 might bind mRNA 
ARE sequences precluding the binding of destabilising factors, therefore allowing 
stabilisation of these transcripts (see figure 5.3).  The purpose of its interaction with 
PAIP-2 in the models 5.2B and 5.3 are unclear but may regulate PABP5 mRNA 





Figure 5.3  PABP5 may be an mRNA stabilising factor.  PABP5 may bind to mRNA 
stability elements, possibly AREs, and prevent association of destabilising factors such as 
ARE-BPs to these elements.  The stabilised messages can then be translated via PABP1. 
 
Determination of the mRNA targets of PABP5 would allow investigation into the 
ability of PABP5 to promote translation/stabilisation of a specific reporter mRNA in 
a mammalian cell background in addition to validating the very preliminary data 
documenting the AU-rich sequence binding ability of PABP5 noted in appendix 3.   
 
5.5  PABP Family Functional Redundancy 
While there are a number of putative models for PABP5 function the physiological 
purpose of expressing multiple PABPs in the same cell types remains enigmatic.  I 
have established that both PABP1 and PABP4 proteins are expressed within 
granulosa cells alongside PABP5.  From the data presented in this thesis it would 
appear unlikely that PABP5 is capable of promoting translation activity of mRNAs 
in a manner similar to that of PABP1 and PABP4.  Indeed PABP5 is the first 
example of a PABP protein that displays differential binding to certain translation 
factors.  PABP1 has a large interactome and in a number of cases these interacting 
proteins have been tested for binding against other PABPs.  Of the tested proteins 
none appear to be PABP1 specific.  This is clearly not the case for PABP5 which 
lacks the PABP C-terminus, the major platform for the binding of a number of 
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PABP1 proteins including eRF3 (Cosson et al., 2002a) and eIF4B (Bushell et al., 
2001).  If PABP5 truly has an altered mRNA substrate affinity as postulated by the 
bioinformatic modelling and preliminary EMSA experiments, it is conceivable that 
PABP5 not only has an alternative function from that of other PABPs but might 
additionally be specific to a particular subset or group of mRNA targets expressed 
within the granulosa cells.  Limited mRNA-specific roles for PABP1 have been 
described (reviewed H. Burgess and N. Gray, In press). 
 
Mammalian PABP phenotypes have not yet been described.  Understanding of the 
physiological role of PABP5 would benefit from the product of a knockout mouse 
model, allowing the characterisation of phenotypes.  Generation of a PABP5 
knockout mouse is complicated by its location in an X-specific subinterval of the 
Xq21.3/Yp11.2 homology block (Blanco et al., 2001), therefore lethality or sterility 
in males would prevent the generation of homozygous mice.  Given the expression 
pattern of PABP5 within the ovary, pituitary, and testis, the risk of sterility is 
relatively high.  Therefore a more prudent approach might be the generation of 
conditional knockout mice to allow the knockout of PABP5 in a temporal and spatial 
specific manner.  As a further tool for analysing the physiological role of PABP5 in 
granulosa cells mouse oocyte-granulosa complexes can be cultured in-vitro, from 
primary through to pre-ovulatory stages of follicle development (Qvist et al., 1990).  
Viral transduction can be utilised to deliver small hairpin mRNAs to knockdown the 
expression of PABP5 in these cells (P. Brown, personal communication) to establish 
effects on folliculogenesis.   
 
It is interesting to note that while PABP5 is found within a subinterval of the X-
chromosome that is known to be gene poor, this subinterval is found within a larger 
X-Y homology block that has been linked to normal ovarian function and to 
premature ovarian failure by mapping translocations (Sala et al., 1997).  Premature 
ovarian failure is the cessation of ovulation in women below the average menopausal 
age.  Symptoms vary but can include amenorrhea, hypoestrogenism and elevated 
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gonadotrophin levels (Shelling, 2010).  In most cases the loss of fertility directly 
correlates with a severe reduction or loss of the follicles available for recruitment 
into folliculogenesis therefore factors regulating follicular recruitment and 
development have been investigated (Shelling, 2010).  Establishing the causes of 
premature ovarian failure are difficult due to the heterogeneity of the condition and 
as a result it is usually idiopathic, but has been suggested in certain cases to be 
genetic in origin (Shelling, 2010).  Intriguingly, several candidate genes regulate 
folliculogenesis through directly targeting the granulosa and thecal cell function 
(reviewed in Goswami and Conway, 2005).  Thus although the link to PABP5 
expression is tenuous it warrants further investigation, utilising the mouse model and 
oocyte-granulosa complexes mentioned above. 
 
5.6  Final Summary 
In conclusion, while much is known regarding the function of PABP1 in eukaryotes 
there are clearly large gaps in our knowledge regarding the additional PABP family 
members.  Functional redundancy between PABP proteins and the necessity of 
expressing multiple PABPs within a single cell is a largely unanswered question.  
Recently submitted work from within my laboratory implies that PABP1 and PABP4 
have overlapping but also distinct functions within Xenopus laevis, as determined by 
morpholino knockdown and cross-rescue experiments within embryos, possibly 
explaining the requirement for multiple PABPs of similar domain organisation 
within a single cell.  In contrast, the work outlined in this thesis suggests that the 
function of PABP5 is highly distinct from the other PABP proteins.  It appears 
unique with regard to both its roles as a basal translation factor and in its molecular 
interactions.  These results highlight the importance of future work aimed at a more 
complete understanding of the molecular and physiological roles of PABP5 in human 























Appendix 1.  PABP1 mRNA localisation in the mouse ovary.  7µm tissue sections were subjected to in-situ hybridisation. A,B.  Adult mouse ovary 
sections incubated with PABP1 antisense probe.  A robust signal could be seen in mural granulosa cells (white arrow), and cumulus granulosa cells 
(blue arrow).  The corpus luteal cells also had staining (black star).  No signal could be observed in stromal tissue (black arrow).  The germ cells 
appeared negative for PABP5 staining (red arrow).  C.  Adult mouse ovary section incubated with PABP1 sense probe.  The probes were used                     






Appendix 2.  Quantification of GST proteins.  GST-proteins were eluted from various volumes of the beads and subjected to SDS-PAGE alongside 
BSA standards.  The protein gel was then stained with SYPRO Ruby (Invitrogen) and the proteins imaged and quantified using a Typhoon Variable 






Appendix 3.  Electrophoretic mobility shift assays.  A.  Oligonucleotide RNA probes (A25 and AUUU6) were 5’-labelled with Cy5 (Eurogentec) and 
subjected to PAGE with a non-denaturing gel.  B.  Increasing concentrations of purified recombinant PABP1 (0-20pmol) were incubated with 10pmol 
poly(A) or poly(AU) RNA probes and subjected to PAGE with a non-denaturing gel.  C.  2pmol of recombinant PABP5 protein was incubated with either 
20pmol poly(A) or poly(AU) RNA probes and subjected to PAGE with a non-denaturing gel. Images were scanned with a Typhoon Variable Mode 





Appendix 4.  Cell-free translation extracts.  A.  HeLa cell-free translation extracts were 
programmed with luciferase reporter mRNAs containing an ApG or m7G cap and/or poly(A) 
tail.  Luciferase units were normalised to the ApG capped poly(A) – mRNA which was set to 
1.  B.  HeLa cell-free translation extracts could be successfully depleted of PABP1 and 
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